https://crcwarriors.org/ 2026-08-08 daily 1.0 https://crcwarriors.org/ensayos-clinicos 2026-08-08 daily 0.9 https://crcwarriors.org/medicamentos 2026-08-08 weekly 0.9 https://crcwarriors.org/noticias-cientificas 2026-08-08 daily 0.8 https://crcwarriors.org/noticias 2026-08-08 daily 0.8 https://crcwarriors.org/combinaciones 2026-08-01 weekly 0.8 https://crcwarriors.org/eficacia 2026-08-01 weekly 0.8 https://crcwarriors.org/eficacia/kras 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/braf 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/msi 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/biomarker-unselected 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/her2 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/msi-h 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/mmr 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/mss 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/ras 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/egfr 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/pik3ca 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/nras 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/tp53 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/all 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/ras%2Fbraf 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/ntrk 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/apc 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/met 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/tmb 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/ddr 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/alk 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/atm 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/smad4 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/pten 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/ret 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/vegf 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/erbb2 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/arid1a 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/mlh1 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/pd-l1 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/fbxw7 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/rad51 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/ros1 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/tie2 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/blm 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/ccnd1 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/pole 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/ccne1 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/fgfr2 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/brca2 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/egfr+pathway 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/ntrk3 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/ctnnb1 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/msh2 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/msi-h%2Fdmmr 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/nf1 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/palb2 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/erbb3 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/ntrk1 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/prex2 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/rb1 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/brca1 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/cdh17 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/mutyh 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/ntrk2 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/pms2 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/arid1b 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/cdk4 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/cna 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/igf1r 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/line-1 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/myc 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/nthl1 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/pi3k+pathway 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/pold1 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/sox9 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/vegfa 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/arid2 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/cdk6 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/fgfr1 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/hpv 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/jag1 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/map2k1 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/rad51c 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/ras%2Fbraf%2Fegfr%2Fpik3ca%2Fmap2k1%2Fmet%2Fret%2Falk%2Fros1%2Fntrk%2F 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/smad2 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/stk11 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/vegfr 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/actl6b 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/cdkn2a 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/idh1 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/keap1 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/msh6 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/notch1 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/pathogenic+variants 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/pik3r1 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/rad51d 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/tcf7l2 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/wild-type 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/bcl2 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/chek2 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/erbb4 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/fgfr3 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/idh2 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/smarca4 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/tgfbr2 2026-08-01 monthly 0.7 https://crcwarriors.org/nuestra-historia 2026-08-01 monthly 0.7 https://crcwarriors.org/contacto 2026-08-01 monthly 0.6 https://crcwarriors.org/ayuda 2026-08-01 monthly 0.6 https://crcwarriors.org/colabora 2026-08-01 monthly 0.6 https://crcwarriors.org/ensayo/NCT07751783/desarrollo-y-difusion-de-programas-de-prescripcion-y-aplicacion-de-ejercicio-fisico-para-pacientes-con-cancer 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT07751783/development-and-dissemination-of-exercise-prescription-and-intervention-for-cancer-populations 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT04708470/un-estudio-de-fase-i-ii-sobre-inmunoterapia-combinada-para-canceres-avanzados-incluidos-los-tumores-asociados-al-vph-los-canceres-de-intestino-delgado-y-los-canceres-de-colon 2026-08-08 weekly 0.6 https://crcwarriors.org/ensayo/NCT04708470/a-phase-i-ii-study-of-combination-immunotherapy-for-advanced-cancers-including-hpv-associated-malignancies-small-bowel-and-colon-cancers 2026-08-08 weekly 0.6 https://crcwarriors.org/ensayo/NCT06679673/shr-1701-en-combinacion-con-shr2554-y-bp102-para-el-cmmr 2026-08-08 weekly 0.6 https://crcwarriors.org/ensayo/NCT06679673/shr-1701-combined-with-shr2554-and-bp102-for-mcrc 2026-08-08 weekly 0.6 https://crcwarriors.org/ensayo/NCT03828227/calidad-de-vida-en-pacientes-ancianos-con-cancer-colorrectal-metastasico-que-reciben-terapia-de-primera-linea-basada-en-parametros-geriatricos-simplificados 2026-08-08 weekly 0.6 https://crcwarriors.org/ensayo/NCT03828227/qol-in-mcrc-elderly-patients-receiving-first-line-therapy-based-on-simplified-geriatric-parameters 2026-08-08 weekly 0.6 https://crcwarriors.org/ensayo/NCT07713472/masaje-abdominal-despues-de-la-cirugia-de-colon-por-cancer 2026-08-08 weekly 0.6 https://crcwarriors.org/ensayo/NCT07713472/abdominal-massage-after-colon-surgery-for-cancer 2026-08-08 weekly 0.6 https://crcwarriors.org/ensayo/NCT07078656/efecto-de-la-formacion-en-video-sobre-la-autoeficacia-de-los-pacientes-tras-la-cirugia-de-cancer-colorrectal 2026-08-08 weekly 0.6 https://crcwarriors.org/ensayo/NCT07078656/effect-of-video-training-on-patients-self-efficacy-after-colorectal-surgery 2026-08-08 weekly 0.6 https://crcwarriors.org/ensayo/NCT07248020/un-estudio-de-fase-ii-de-un-solo-brazo-sobre-la-administracion-de-curcumina-de-alta-biodisponibilidad-como-quimiorradioterapia-neoadyuvante-en-el-cancer-de-recto-medio-a-bajo-analisis-clinico-y 2026-08-08 weekly 0.6 https://crcwarriors.org/ensayo/NCT07248020/a-phase-ii-single-arm-study-of-high-bioavailability-curcumin-as-neoadjuvant-chemoradiotherapy-in-mid-to-low-rectal-cancer-integrated-clinical-and-translational-analysis-of-tumor-tissue 2026-08-08 weekly 0.6 https://crcwarriors.org/ensayo/NCT04084249/vigilancia-guiada-por-ctdna-en-pacientes-con-cancer-colorrectal-en-estadio-iii-un-ensayo-clinico-aleatorizado 2026-08-08 weekly 0.6 https://crcwarriors.org/ensayo/NCT04084249/ctdna-guided-surveillance-for-stage-iii-crc-a-randomized-intervention-trial 2026-08-08 weekly 0.6 https://crcwarriors.org/ensayo/NCT04898504/hai-floxuridina-o-liver-tx-en-combinacion-con-quimioterapia-de-segunda-linea-frente-a-quimioterapia-de-segunda-linea-en-monoterapia-para-pacientes-con-metastasis-hepaticas-de-cancer-colorrectal-y-una 2026-08-08 weekly 0.6 https://crcwarriors.org/ensayo/NCT04898504/hai-floxuridine-or-liver-tx-combined-with-2nd-line-chemotherapy-versus-2nd-line-chemotherapy-alone-for-patients-with-colorectal-liver-metastases-and-heavy-tumour-burden 2026-08-08 weekly 0.6 https://crcwarriors.org/ensayo/NCT03093116/un-estudio-de-repotrectinib-tpx-0005-en-pacientes-con-tumores-solidos-avanzados-que-presentan-reordenamientos-de-alk-ros1-o-ntrk1-3 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT03093116/a-study-of-repotrectinib-tpx-0005-in-patients-with-advanced-solid-tumors-harboring-alk-ros1-or-ntrk1-3-rearrangements 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT07737600/un-estudio-de-la-terapia-combinada-con-mrg007-para-el-cancer-colorrectal-avanzado 2026-08-08 weekly 0.6 https://crcwarriors.org/ensayo/NCT07737600/a-study-of-mrg007-combination-therapy-for-advanced-colorectal-cancer 2026-08-08 weekly 0.6 https://crcwarriors.org/ensayo/NCT06944548/evaluacion-del-efecto-de-la-actividad-fisica-adaptada-sobre-la-modificacion-del-metabolismo-lipidico-durante-la-quimioterapia-para-el-cancer-colorrectal-metastasico 2026-08-08 weekly 0.6 https://crcwarriors.org/ensayo/NCT06944548/evaluation-of-the-effect-of-adapted-physical-activity-on-the-modification-of-lipid-metabolism-during-chemotherapy-for-metastatic-colorectal-cancer 2026-08-08 weekly 0.6 https://crcwarriors.org/ensayo/NCT07732894/ejercicio-aerobico-e-imagenes-guiadas-en-el-sindrome-de-la-reseccion-anterior-baja 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT07732894/aerobic-exercise-and-guided-imagery-in-low-anterior-resection-syndrome 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT07738042/para-evaluar-un-estudio-de-fase-ii-en-un-unico-brazo-sobre-el-trasplante-de-microbiota-intestinal-combinado-con-inmunoterapia-neoadyuvante-y-quimiorradioterapia-para-el-cancer-colorrectal-localmente 2026-08-08 weekly 0.6 https://crcwarriors.org/ensayo/NCT07738042/to-explore-a-single-arm-phase-ii-study-on-intestinal-microbiota-transplantation-combined-with-neoadjuvant-immunotherapy-and-chemoradiotherapy-for-locally-advanced-rectal-cancer-under-mss-pmmr 2026-08-08 weekly 0.6 https://crcwarriors.org/ensayo/NCT06135571/estudio-sobre-los-patrones-de-metastasis-en-el-ganglio-linfatico-numero-253-en-el-cancer-de-colon-y-recto-izquierdo 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT06135571/study-on-the-no-253-lymph-node-metastasis-patterns-in-left-sided-colon-and-rectal-cancer 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT04095299/dosis-estandar-frente-a-dosis-alta-de-radioterapia-en-la-preservacion-del-recto-con-quimiorradioterapia-en-pacientes-con-cancer-de-recto 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT04095299/standard-dose-versus-high-dose-of-radiotherapy-in-rectal-preservation-with-chemo-radiotherapy-in-rectal-cancer-patients 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT07315412/sabores-de-chicle-para-reducir-las-nauseas-y-los-vomitos-postoperatorios-tras-la-administracion-de-pipac 2026-08-08 weekly 0.6 https://crcwarriors.org/ensayo/NCT07315412/chewing-gum-flavors-to-reduce-postoperative-nausea-and-vomiting-after-pipac 2026-08-08 weekly 0.6 https://crcwarriors.org/ensayo/NCT07145255/estudio-de-fase-i-ii-para-determinar-la-dosis-evaluar-la-seguridad-y-la-farmacocinetica-en-tumores-solidos-avanzados-y-refractarios 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT07145255/phase-1-2-dose-finding-safety-and-pk-study-in-advanced-refractory-solid-tumors 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT04008797/un-estudio-de-e7386-en-combinacion-con-otros-farmacos-antineoplasicos-en-participantes-con-tumores-solidos 2026-08-08 weekly 0.6 https://crcwarriors.org/ensayo/NCT04008797/a-study-of-e7386-in-combination-with-other-anticancer-drug-s-in-participants-with-solid-tumor 2026-08-08 weekly 0.6 https://crcwarriors.org/ensayo/NCT07515963/fuliri-mas-terapia-dirigida-como-tratamiento-de-primera-linea-para-la-terapia-de-conversion-de-metastasis-hepaticas-del-cancer-colorrectal 2026-08-08 weekly 0.6 https://crcwarriors.org/ensayo/NCT07515963/fuliri-plus-targeted-therapy-for-first-line-conversion-therapy-of-colorectal-cancer-liver-metastases 2026-08-08 weekly 0.6 https://crcwarriors.org/ensayo/NCT07515729/concienciacion-sobre-la-deteccion-del-cancer-colorrectal-en-las-comunidades-de-nativos-americanos 2026-08-08 weekly 0.6 https://crcwarriors.org/ensayo/NCT07515729/raising-awareness-of-colorectal-screening-in-american-indian-communities 2026-08-08 weekly 0.6 https://crcwarriors.org/ensayo/NCT07630961/estudio-de-fase-i-de-jfi447-68ga-ga-dfc413-y-comparacion-con-ffg233-68ga-ga-nns309-en-pacientes-con-tumores-solidos 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT07630961/phase-i-study-of-jfi447-68ga-ga-dfc413-and-comparison-to-ffg233-68ga-ga-nns309-in-patients-with-solid-tumors 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT07141901/deteccion-de-cancer-colorrectal-basada-en-la-esperanza-de-vida 2026-08-08 weekly 0.6 https://crcwarriors.org/ensayo/NCT07141901/life-expectancy-informed-colorectal-cancer-screening 2026-08-08 weekly 0.6 https://crcwarriors.org/ensayo/NCT05919264/fog-001-en-tumores-solidos-localmente-avanzados-o-metastasicos 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT05919264/fog-001-in-locally-advanced-or-metastatic-solid-tumors 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT06582914/sindrome-de-lynch-epidemiologia-e-investigacion-genetica-integradas 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT06582914/lynch-syndrome-integrative-epidemiology-and-genetics 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT05726864/un-estudio-de-eli-002-7p-en-sujetos-con-tumores-solidos-con-mutaciones-en-kras-nras 2026-08-08 weekly 0.6 https://crcwarriors.org/ensayo/NCT05726864/a-study-of-eli-002-7p-in-subjects-with-kras-nras-mutated-solid-tumors 2026-08-08 weekly 0.6 https://crcwarriors.org/ensayo/NCT07337876/preservacion-de-organos-en-el-cancer-de-recto-mediante-radioterapia-adaptativa-guiada-por-resonancia-magnetica-con-dosis-escaladas 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT07337876/organ-preservation-in-rectal-cancer-by-dose-escalated-mr-guided-adaptive-radiotherapy 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT07642323/seguridad-y-eficacia-de-la-quimioterapia-neoadyuvante-y-la-observacion-frente-a-la-cirugia-para-los-canceres-gastrointestinales-con-dmmr-msi-h-o-mutacion-en-el-gen-pole 2026-08-08 weekly 0.6 https://crcwarriors.org/ensayo/NCT07642323/safety-and-efficacy-of-nom-and-opfs-versus-ro-for-dmmr-msi-h-or-pole-mutated-gastrointestinal-cancers 2026-08-08 weekly 0.6 https://crcwarriors.org/ensayo/NCT07341217/proyecto-de-rehabilitacion-preoperatoria-para-mitigar-los-efectos-de-la-quimioterapia-en-el-cerebro 2026-08-08 weekly 0.6 https://crcwarriors.org/ensayo/NCT07341217/chemo-brain-prehab-project 2026-08-08 weekly 0.6 https://crcwarriors.org/ensayo/NCT04854213/prelude-1-evaluacion-prospectiva-de-los-efectos-biologicos-inducidos-por-la-radioterapia-en-pacientes-con-enfermedad-oligo-metastasica-de-cancer-colorrectal-y-enfermedad-limitada-a-los-pulmones 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT04854213/prelude-1-prospective-evaluation-of-radiotherapy-induced-biologic-effects-in-colorectal-cancer-oligometastatic-patients-with-lung-limited-disease-evolution-of-cancer-genetics-and-regulatory-immune 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT06882746/un-estudio-para-evaluar-diferentes-dosis-de-bi-765049-en-pacientes-con-cancer-avanzado-de-colon-recto-estomago-o-pancreas 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT06882746/a-study-to-test-different-doses-of-bi-765049-in-people-with-advanced-cancer-of-the-colon-rectum-stomach-or-pancreas 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT02359565/pembrolizumab-en-el-tratamiento-de-pacientes-jovenes-con-gliomas-de-alto-grado-recurrentes-progresivos-o-refractarios-gliomas-intrinsecos-del-tronco-encefalico-difusos-tumores-cerebrales-hipermutados 2026-08-08 weekly 0.6 https://crcwarriors.org/ensayo/NCT02359565/pembrolizumab-in-treating-younger-patients-with-recurrent-progressive-or-refractory-high-grade-gliomas-diffuse-intrinsic-pontine-gliomas-hypermutated-brain-tumors-ependymoma-or-medulloblastoma 2026-08-08 weekly 0.6 https://crcwarriors.org/ensayo/NCT06848842/ivonescimab-mas-quimioterapia-en-pacientes-con-metastasis-hepaticas-de-cancer-colorrectal-inicialmente-irresecable 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT06848842/ivonescimab-plus-chemotherapy-in-patients-with-initially-unresectable-colorectal-cancer-liver-metastases 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT05860322/el-efecto-de-la-suplementacion-con-inulina-en-los-resultados-de-la-cirugia-de-cancer-colorrectal 2026-08-08 weekly 0.6 https://crcwarriors.org/ensayo/NCT05860322/the-effect-of-inulin-supplementation-on-colorectal-surgery-outcomes 2026-08-08 weekly 0.6 https://crcwarriors.org/ensayo/NCT04117100/estudio-observacional-basado-en-un-registro-de-un-procedimiento-endoscopico-avanzado 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT04117100/advanced-endo-therapeutic-procedure-registry-based-observational-study 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT05517811/indices-de-la-teg-preoperatorios-y-postoperatorios-en-pacientes-con-o-sin-adenocarcinoma-que-se-someten-a-reseccion-quirurgica 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT05517811/pre-and-post-operative-teg-indices-in-patients-with-or-without-adenocarcinoma-undergoing-surgical-resection 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT05846867/un-estudio-clinico-de-fase-ib-ii-sobre-ak112-administrado-solo-o-en-combinacion-con-ak119-en-pacientes-con-cancer-colorrectal-pmmr-mss 2026-08-08 weekly 0.6 https://crcwarriors.org/ensayo/NCT05846867/a-phase-ib-ii-clinical-study-on-ak112-combined-or-not-combined-with-ak119-in-pmmr-mss-colorectal-cancer 2026-08-08 weekly 0.6 https://crcwarriors.org/ensayo/NCT06076811/danish-mrd-evaluacion-danesa-de-la-enfermedad-residual-minima-mediante-biopsias-liquidas 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT06076811/danish-mrd-danish-assessment-of-minimal-residual-disease-by-liquid-biopsies 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT07088393/diagnostico-mediante-inteligencia-artificial-de-los-diferentes-patrones-de-crecimiento-histopatologico-de-las-metastasis-hepaticas-del-cancer-colorrectal 2026-08-08 weekly 0.6 https://crcwarriors.org/ensayo/NCT07088393/artificial-intelligence-diagnosis-of-different-histopathological-growth-patterns-of-colorectal-cancer-liver-metastasis 2026-08-08 weekly 0.6 https://crcwarriors.org/ensayo/NCT06881563/morfina-intratecal-frente-a-analgesia-epidural-para-la-cirugia-laparoscopica-de-colon 2026-08-08 weekly 0.6 https://crcwarriors.org/ensayo/NCT06881563/intrathecal-morphine-versus-epidural-analgesia-for-laparoscopic-colon-surgery 2026-08-08 weekly 0.6 https://crcwarriors.org/ensayo/NCT05492682/seguridad-y-actividad-antitumoral-de-pepticrad-1-en-el-tratamiento-del-cancer 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT05492682/start-safety-and-anti-tumor-activity-of-pepticrad-1-in-treatment-of-cancer 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT07371832/evaluacion-en-un-solo-centro-del-sistema-de-grapado-robotico-sureform-habilitado-con-inteligencia-artificial-sureformtm-en-comparacion-con-el-sistema-de-grapado-convencional-para-procedimientos-de 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT07371832/a-single-center-evaluation-of-ai-enabled-sureform-robotic-stapler-sureformtm-compared-to-conventional-stapler-for-colorectal-cancer-procedures 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT05776381/el-impacto-de-una-herramienta-de-apoyo-a-la-toma-de-decisiones-en-las-elecciones-de-tratamiento-para-pacientes-con-un-polipo-colorrectal-maligno-inesperado 2026-08-08 weekly 0.6 https://crcwarriors.org/ensayo/NCT05776381/the-impact-of-a-patient-decision-aid-on-treatment-choices-for-patients-with-an-unexpected-malignant-colorectal-polyp 2026-08-08 weekly 0.6 https://crcwarriors.org/ensayo/NCT07099924/cateteres-en-la-vaina-del-musculo-recto-tras-una-laparotomia-media 2026-08-08 weekly 0.6 https://crcwarriors.org/ensayo/NCT07099924/rectus-sheath-catheters-following-midline-laparotomy 2026-08-08 weekly 0.6 https://crcwarriors.org/ensayo/NCT06868095/protocolo-de-estudio-multicentrico-impacto-de-la-sarcopenia-en-el-cancer-colorrectal-de-inicio-temprano 2026-08-08 weekly 0.6 https://crcwarriors.org/ensayo/NCT06868095/multi-center-study-protocol-impact-of-sarcopenia-in-early-onset-colorectal-cancer 2026-08-08 weekly 0.6 https://crcwarriors.org/ensayo/NCT03923335/el-valor-predictivo-del-panel-de-guangzhou-para-la-recurrencia-en-el-cancer-colorrectal-en-estadio-temprano 2026-08-08 weekly 0.6 https://crcwarriors.org/ensayo/NCT03923335/the-predictive-value-of-guangzhou-panel-for-recurrence-in-early-stage-colorectal-cancer 2026-08-08 weekly 0.6 https://crcwarriors.org/ensayo/NCT05513716/caracterizacion-molecular-de-las-metastasis-peritoneales-del-cancer-colorrectal 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT05513716/molecular-characterisation-of-colorectal-cancer-peritoneal-metastases 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT06245356/seguridad-de-trifluridina-tipiracil-en-pacientes-con-deficiencia-de-dihidropirimidina-deshidrogenasa-diagnosticados-con-cancer-colorrectal-metastasico-o-cancer-gastroesofagico 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT06245356/safety-of-trifluridine-tipiracil-in-patients-with-dihydropyrimidine-dehydrogenase-deficiency-diagnosed-with-metastatic-colorectal-or-gastroesophageal-cancer 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT04087421/comparacion-de-la-irrigacion-transanal-y-los-supositorios-de-glicerol-en-el-tratamiento-del-sindrome-de-reseccion-anterior-baja 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT04087421/comparison-of-transanal-irrigation-and-glycerol-suppositories-in-treatment-of-low-anterior-resection-syndrome 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT04282044/estudio-de-crx100-como-monoterapia-y-en-combinacion-con-pembrolizumab-en-pacientes-con-tumores-solidos-avanzados 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT04282044/study-of-crx100-as-monotherapy-and-in-combination-with-pembrolizumab-in-patients-with-advanced-solid-malignancies 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT06902701/diseccion-endoscopica-submucosa-frente-a-cirugia-endoscopica-transanal-para-neoplasias-rectales 2026-08-08 weekly 0.6 https://crcwarriors.org/ensayo/NCT06902701/endoscopic-submucosal-dissection-vs-transanal-endoscopic-surgery-for-rectal-neoplasia 2026-08-08 weekly 0.6 https://crcwarriors.org/ensayo/NCT06154538/inhibidores-de-los-puntos-de-control-inmunitario-quimioterapia-frente-a-quimioterapia-en-el-tratamiento-neoadyuvante-del-cancer-colorrectal-localmente-avanzado 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT06154538/immune-checkpoint-inhibitors-chemotherapy-versus-chemotherapy-in-the-neoadjuvant-treatment-of-locally-advanced-colorectal-cancer 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT06962293/guia-magnetica-para-la-contraccion-durante-la-diseccion-submucosa-endoscopica 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT06962293/magnetic-guided-counetrtraction-during-endoscopic-submucosal-dissection 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT07391956/atencion-paliativa-de-nivel-superior-para-pacientes-con-insuficiencia-cardiaca-avanzada-o-cancer 2026-08-08 weekly 0.6 https://crcwarriors.org/ensayo/NCT07391956/tier-palliative-care-for-patients-with-advanced-heart-failure-or-cancer 2026-08-08 weekly 0.6 https://crcwarriors.org/ensayo/NCT06956976/preservacion-frente-a-diseccion-de-los-ganglios-linfaticos-n-o-253-en-la-reseccion-robotica-para-el-cancer-de-recto-medio-inferior 2026-08-08 weekly 0.6 https://crcwarriors.org/ensayo/NCT06956976/preservation-vs-dissection-of-no-253-lymph-nodes-of-robotic-resection-for-mid-low-rectal-cancer 2026-08-08 weekly 0.6 https://crcwarriors.org/ensayo/NCT04808323/radioterapia-adaptativa-guiada-por-resonancia-magnetica-para-la-preservacion-de-organos-en-el-cancer-de-recto 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT04808323/mri-guided-adaptive-radiation-therapy-for-organ-preservation-in-rectal-cancer 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT07113275/un-ensayo-clinico-que-compara-la-radioterapia-de-ciclo-largo-frente-a-la-radioterapia-de-ciclo-corto-seguida-de-inmunoterapia-combinada-con-terapia-neoadyuvante-total-tnt-frente-a-la-radioterapia-de 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT07113275/a-clinical-trial-comparing-long-course-versus-short-course-radiotherapy-followed-by-immunotherapy-combined-with-total-neoadjuvant-therapy-tnt-to-long-course-radiotherapy-followed-by-tnt-in-locally 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT06682650/implementacion-de-una-herramienta-de-deteccion-del-cancer-colorrectal-en-centros-de-atencion-primaria-de-los-estados-unidos-mejora-de-la-calidad-habitual-10-centros-frente-al-proceso-de-normalizacion 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT06682650/implementation-of-a-colorectal-cancer-screening-tool-in-us-primary-care-practices-usual-quality-improvement-10-clinics-vs-normalization-process-theory-participatory-learning-in-action-10-clinics 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT06778863/un-estudio-de-clsp-1025-en-pacientes-adultos-con-tumores-solidos-que-presentan-la-mutacion-p53-r175h 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT06778863/a-study-of-clsp-1025-in-adult-patients-with-solid-tumors-that-harbor-the-p53-r175h-mutation 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT05844514/analisis-del-aliento-en-pacientes-con-cancer-colorrectal-cobra2 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT05844514/colorectal-breath-analysis-cobra2 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT05030493/un-analisis-adicional-de-los-datos-del-estudio-exploratorio-paradigm-nct02394834-en-pacientes-con-cancer-colorrectal-avanzado-o-recurrente 2026-08-08 weekly 0.6 https://crcwarriors.org/ensayo/NCT05030493/an-additional-analysis-of-data-from-the-paradigm-exploratory-study-nct02394834-in-patients-with-advanced-recurrent-colorectal-cancer 2026-08-08 weekly 0.6 https://crcwarriors.org/ensayo/NCT06118762/estudio-clinico-de-fruquintinib-en-combinacion-con-raltitrexed-para-el-tratamiento-del-cancer-colorrectal-metastasico 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT06118762/clinical-study-of-fruquintinib-combined-with-raltitrexed-in-the-treatment-of-metastatic-colorectal-cancer 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT06096688/descubriendo-nuevos-objetivos-para-la-reduccion-del-riesgo-de-cancer-colorrectal-y-de-endometrio 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT06096688/discovering-new-targets-for-colorectal-and-endometrial-cancer-risk-reduction 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT06853769/terapia-neoadyuvante-para-el-cancer-colorrectal-localmente-avanzado 2026-08-08 weekly 0.6 https://crcwarriors.org/ensayo/NCT06853769/neoadjuvant-therapy-for-locally-advanced-rectal-cancer 2026-08-08 weekly 0.6 https://crcwarriors.org/ensayo/NCT01941641/estudio-de-folfoxiri-neoadyuvante-en-cancer-colorrectal 2026-08-08 weekly 0.6 https://crcwarriors.org/ensayo/NCT01941641/colon-neoadjuvant-folfoxiri-study 2026-08-08 weekly 0.6 https://crcwarriors.org/ensayo/NCT06218810/cadonilimab-en-combinacion-con-bevacizumab-y-el-regimen-folfox-para-el-tratamiento-de-primera-linea-del-cancer-colorrectal-metastasico-avanzado-irresecable-y-de-tipo-mss-con-mutacion-en-los-genes-ras 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT06218810/cadonilimab-in-combination-with-bevacizumab-and-folfox-regimen-for-the-first-line-treatment-of-advanced-unresectable-mss-type-ras-mutated-metastatic-colorectal-cancer 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT06226857/otras-mutaciones-en-oncogenes-que-podrian-influir-en-la-eficacia-de-los-tratamientos-anti-egfr-en-pacientes-con-cancer-colorrectal-metastasico-de-lado-izquierdo-y-con-ras-de-tipo-salvaje 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT06226857/other-oncogene-mutations-for-anti-egfr-efficacy-in-patients-with-left-sided-ras-wild-type-metastatic-colorectal-cancer 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT05450029/quimiorradioterapia-neoadyuvante-mas-sintilimab-para-el-cancer-colorrectal-localmente-avanzado-de-riesgo-intermedio-alto-segun-el-indice-de-inmunidad 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT05450029/neoadjuvant-chemoradiotherapy-plus-sintilimab-for-intermediate-high-immunoscore-locally-advanced-rectal-cancer 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT06263088/equity-gi-un-estudio-prospectivo-para-mejorar-la-calidad-la-inclusion-y-la-participacion-en-ensayos-clinicos-en-pacientes-negros-con-cancer-gastrointestinal 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT06263088/equity-gi-a-prospective-study-to-enhance-quality-inclusivity-and-trial-participation-in-black-patients-with-gastrointestinal-cancer 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT06542588/radioterapia-de-corta-duracion-seguida-de-quimioterapia-neoadyuvante-hlx07-y-serplulimab-en-el-cancer-colorrectal-localmente-avanzado-larc 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT06542588/short-course-radiotherapy-followed-by-neoadjuvant-chemotherapy-hlx07and-serplulimab-in-larc 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT04929223/un-estudio-que-evalua-la-seguridad-y-la-eficacia-de-las-terapias-dirigidas-en-subpoblaciones-de-pacientes-con-cancer-colorrectal-metastasico-intrinsic 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT04929223/a-study-evaluating-the-safety-and-efficacy-of-targeted-therapies-in-subpopulations-of-patients-with-metastatic-colorectal-cancer-intrinsic 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT07669298/vigilancia-activa-frente-a-quimiorradioterapia-adyuvante-en-cancer-de-recto-t1-de-riesgo-intermedio-tras-reseccion-local 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT07669298/active-surveillance-vs-adjuvant-chemoradiotherapy-for-locally-resected-intermediate-risk-t1-rectal-cancer 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT06212817/fibra-dietetica-antes-de-la-cirugia-para-el-cancer-colorrectal 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT06212817/dietary-fiber-before-colorectal-cancer-surgery 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT05939661/un-estudio-multicentrico-de-un-solo-brazo-de-fase-ii-para-evaluar-la-seguridad-y-la-eficacia-de-la-terapia-neoadyuvante-total-en-pacientes-con-cancer-de-recto-ct2 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT05939661/a-multicenter-single-arm-p2-to-evaluate-safety-and-efficacy-of-the-total-neoadjuvant-therapy-for-ct2-rectal-cancer 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT04815525/el-riesgo-a-largo-plazo-de-neoplasia-colorrectal-avanzada-despues-de-la-colonoscopia-un-estudio-de-cohorte-basado-en-la-poblacion-en-hong-kong 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT04815525/the-longterm-risk-of-advanced-colorectal-neoplasia-after-colonoscopy-a-population-based-cohort-study-in-hong-kong 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT07148297/analisis-de-cancer-colorrectal-para-la-evaluacion-mediante-la-prueba-delta-hld 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT07148297/colorectal-analysis-for-signature-cancer-assessment-using-delta-hld 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT07259304/salud-social-habitos-de-actividad-y-calidad-de-vida-en-jovenes-adultos-supervivientes-de-cancer 2026-08-08 weekly 0.6 https://crcwarriors.org/ensayo/NCT07259304/social-health-activity-behaviors-and-quality-of-life-among-young-adult-cancer-survivors 2026-08-08 weekly 0.6 https://crcwarriors.org/ensayo/NCT05649072/identificacion-de-individuos-desatendidos-en-texas-con-riesgo-hereditario-de-cancer-mediante-unidades-moviles-de-mamografia-y-telegenetica 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT05649072/identifying-underserved-individuals-intexas-with-hereditary-cancer-risk-using-mobile-mammography-units-and-telegenetics 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT06885034/un-estudio-para-evaluar-la-seguridad-y-eficacia-de-gsk5764227-solo-o-en-combinacion-con-otros-tratamientos-en-participantes-con-canceres-gastrointestinales-avanzados-que-no-pueden-ser-tratados 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT06885034/a-study-to-test-the-safety-and-effectiveness-of-gsk5764227-alone-or-with-other-treatments-in-participants-with-advanced-gastrointestinal-cancers-that-cannot-be-surgically-removed-embold-pangi-201 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT05780684/escalada-de-dosis-individualizada-de-5-fu-para-el-cancer-gastrointestinal 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT05780684/individualized-dose-escalation-of-5-fu-for-gastrointestinal-cancer 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT07186842/un-ensayo-clinico-para-evaluar-si-el-farmaco-en-investigacion-bnt329-es-seguro-y-potencialmente-beneficioso-para-pacientes-con-tumores-solidos-avanzados-que-expresan-el-marcador-tumoral-ca19-9 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT07186842/a-clinical-trial-to-test-if-the-investigational-drug-bnt329-is-safe-and-potentially-beneficial-for-people-with-advanced-solid-tumors-known-to-express-the-tumor-marker-ca19-9 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT07689812/un-ensayo-aleatorizado-multicentrico-y-de-etiqueta-abierta-que-evalua-la-interrupcion-guiada-por-la-enfermedad-residual-minima-erm-frente-al-tratamiento-estandar-con-inhibidores-de-puntos-de-control 2026-08-08 weekly 0.6 https://crcwarriors.org/ensayo/NCT07689812/a-multicenter-randomized-open-label-trial-evaluating-ctdna-guided-interruption-versus-standard-of-care-immune-checkpoint-inhibitor-ici-therapy-in-patients-with-advanced-metastatic-solid-tumors 2026-08-08 weekly 0.6 https://crcwarriors.org/ensayo/NCT06856837/ikf-aio-quintis-evaluacion-de-fruquintinib-en-combinacion-con-tislelizumab-en-cancer-colorrectal-metastasico-con-microsatelites-estables-reparacion-deficiente-de-errores-de-apareamiento-mss-pmmr-sin 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT06856837/ikf-aio-quintis-evaluating-fruquintinib-in-combination-with-tislelizumab-in-microsatellite-stable-proficient-mismatch-repair-mss-pmmr-metastatic-colorectal-cancer-without-active-liver-metastases 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT06949111/radioterapia-terapia-sistemica-como-terapia-de-conversion-para-cancer-de-colon-pmmr-mss-t4m0-neo-color 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT06949111/radiotherapy-systemic-therapy-as-conversion-therapy-for-pmmr-mss-t4m0-colon-cancer-neo-color 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT05286814/pds01adc-en-combinacion-con-una-bomba-de-infusion-en-la-arteria-hepatica-haip-y-terapia-sistemica-para-sujetos-con-cancer-colorrectal-metastasico-colangiocarcinoma-intrahepatico-o-carcinoma 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT05286814/pds01adc-in-combination-with-hepatic-artery-infusion-pump-haip-and-systemic-therapy-for-subjects-with-metastatic-colorectal-cancer-intrahepatic-cholangiocarcinoma-or-metastatic-adrenocortical 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT05867303/estudio-rc198-en-pacientes-con-tumores-solidos-metastasicos-o-localmente-avanzados-irresecables 2026-08-08 weekly 0.6 https://crcwarriors.org/ensayo/NCT05867303/a-rc198-study-in-subjects-with-locally-advanced-unresectable-or-metastatic-solid-tumors 2026-08-08 weekly 0.6 https://crcwarriors.org/ensayo/NCT07705139/la-importancia-de-los-ruidos-intestinales-en-la-evaluacion-de-la-recuperacion-de-la-funcion-intestinal-postoperatoria-en-pacientes-con-cancer-colorrectal 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT07705139/the-value-of-bowel-sounds-in-evaluating-postoperative-intestinal-function-recovery-in-colorectal-cancer-patients 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT04907643/realidad-virtual-para-el-manejo-del-dolor-en-pacientes-con-cancer-gastrointestinal-con-el-fin-de-mejorar-los-resultados-informados-por-los-pacientes 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT04907643/virtual-reality-for-gi-cancer-pain-to-improve-patient-reported-outcomes 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT06722183/futibatinib-en-combinacion-con-quimio-inmunoterapia-en-el-cancer-colorrectal-y-otras-entidades-tumorales-solidas 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT06722183/futibatinib-in-combination-with-chemo-immunotherapy-in-colorectal-cancer-and-other-solid-tumor-entities 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT07285356/estudio-para-evaluar-el-uso-de-guantes-quirurgicos-en-la-prevencion-de-la-neuropatia-periferica-inducida-por-oxaliplatino 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT07285356/study-to-evaluate-the-use-of-surgical-gloves-for-the-prevention-of-oxaliplatin-induced-peripheral-neuropathy 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT05693649/enfoques-de-economia-conductual-para-la-deteccion-del-cancer-colorrectal-a-nivel-poblacional 2026-08-08 weekly 0.6 https://crcwarriors.org/ensayo/NCT05693649/behavioral-economic-approaches-for-population-based-colorectal-cancer-screening 2026-08-08 weekly 0.6 https://crcwarriors.org/ensayo/NCT07264556/efecto-de-la-analgesia-con-opioides-la-analgesia-con-opioides-y-antiinflamatorios-no-esteroideos-aine-frente-a-la-analgesia-basada-en-opioides-en-los-tumores-neuroendocrinos-tne-y-la-malignidad-de 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT07264556/effect-of-ofa-osa-versus-opioid-based-anesthesia-on-nets-and-cancer-cell-malignancy-after-colorectal-cancer-surgery 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT05343013/tas-102-con-o-sin-celecoxib-en-pacientes-con-enfermedad-residual-minima-definida-por-ctdna-tras-la-finalizacion-de-la-quimioterapia-adyuvante-para-el-cancer-colorrectal 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT05343013/tas-102-with-or-without-celecoxib-in-ctdna-defined-minimal-residual-disease-in-colorectal-cancer-after-completion-of-adjuvant-chemotherapy 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT06207656/estudio-para-evaluar-la-eficacia-y-la-seguridad-del-cetuximab-en-combinacion-con-encorafenib-mas-binimetinib-como-tratamiento-de-induccion-en-pacientes-con-cancer-colorrectal-avanzado-con-mutacion 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT06207656/study-to-evaluate-the-efficacy-and-safety-of-cetuximab-in-combination-with-encorafenib-plus-binimetinib-as-induction-treatment-in-braf-v600e-mutated-mss-initially-resectable-or-potentially-resectable 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT07228832/estudio-de-fase-iii-con-ivonescimab-o-bevacizumab-en-combinacion-con-folfox-en-pacientes-con-cancer-colorrectal-metastasico 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT07228832/phase-iii-study-of-ivonescimab-or-bevacizumab-combined-with-folfox-in-patients-with-metastatic-colorectal-cancer 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT06645015/el-ensayo-clinico-aidpro-crc 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT06645015/the-aidpro-crc-trial 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT07740343/remimazolam-para-el-sueno-postoperatorio-en-pacientes-ancianos 2026-08-08 weekly 0.6 https://crcwarriors.org/ensayo/NCT07740343/remimazolam-for-postoperative-sleep-in-elderly-patients 2026-08-08 weekly 0.6 https://crcwarriors.org/ensayo/NCT07224724/deteccion-de-metastasis-extrahepaticas-derivadas-de-exosomas-mediante-biopsia-liquida-en-metastasis-hepaticas-del-cancer-colorrectal 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT07224724/exosome-derived-extrahepatic-metastasis-detection-by-liquid-biopsy-in-colorectal-cancer-liver-metastases 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT07454642/ava6103-en-pacientes-con-tumores-solidos-avanzados-localmente-o-metastasicos-seleccionados 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT07454642/ava6103-in-subjects-with-locally-advanced-or-metastatic-selected-solid-tumors 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT07509424/radioterapia-neoadyuvante-de-corta-duracion-seguida-de-una-combinacion-de-disitamab-vedotina-sintilimab-y-capecitabina-en-el-cancer-colorrectal-localmente-avanzado-con-expresion-de-her2 2026-08-08 weekly 0.6 https://crcwarriors.org/ensayo/NCT07509424/neoadjuvant-short-course-radiotherapy-followed-by-a-combination-of-disitamab-vedotin-sintilimab-and-capecitabine-in-locally-advanced-her2-expressing-rectal-cance 2026-08-08 weekly 0.6 https://crcwarriors.org/ensayo/NCT06827366/intervencion-sobre-el-estilo-de-vida-en-participantes-del-programa-frances-de-deteccion-del-cancer-colorrectal-life-screen 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT06827366/lifestyle-intervention-among-participants-of-the-french-colorectal-cancer-screening-program-life-screen 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT04141449/una-intervencion-multidimensional-para-mejorar-la-deteccion-oportuna-del-cancer-y-el-inicio-del-tratamiento 2026-08-08 weekly 0.6 https://crcwarriors.org/ensayo/NCT04141449/a-multilevel-intervention-to-improve-timely-cancer-detection-and-treatment-initiation 2026-08-08 weekly 0.6 https://crcwarriors.org/ensayo/NCT07321106/un-estudio-para-investigar-la-seguridad-la-tolerabilidad-la-farmacocinetica-y-la-actividad-antitumoral-de-cbi-1214-un-activador-de-celulas-t-en-participantes-con-cancer-colorrectal-avanzado-o 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT07321106/a-study-to-investigate-the-safety-tolerability-pharmacokinetics-and-anti-tumor-activity-of-cbi-1214-t-cell-engager-in-participants-with-advanced-or-metastatic-mss-msi-l-colorectal-cancer 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT07750041/un-estudio-de-fase-ib-ii-sobre-la-terapia-combinada-con-sys6090-en-el-cancer-colorrectal-avanzado 2026-08-08 weekly 0.6 https://crcwarriors.org/ensayo/NCT07750041/a-phase-ib-ii-study-of-sys6090-combination-therapy-in-advanced-colorectal-cancer 2026-08-08 weekly 0.6 https://crcwarriors.org/ensayo/NCT05990543/combinacion-de-nelmastobart-y-capecitabina-en-el-tratamiento-del-cancer-colorrectal-metastasico 2026-08-08 weekly 0.6 https://crcwarriors.org/ensayo/NCT05990543/combination-of-nelmastobart-and-capecitabine-therapy-in-metastatic-colorectal-cancer 2026-08-08 weekly 0.6 https://crcwarriors.org/ensayo/NCT07318389/ascend-crc-perfilado-y-abordaje-de-la-resistencia-tumoral-dinamica-en-pacientes-con-cancer-colorrectal-metastasico 2026-08-08 weekly 0.6 https://crcwarriors.org/ensayo/NCT07318389/ascend-crc-profiling-and-targeting-dynamic-tumor-resistance-in-patients-with-metastatic-colorectal-cancer 2026-08-08 weekly 0.6 https://crcwarriors.org/ensayo/NCT06470178/un-estudio-en-el-mundo-real-sobre-la-terapia-neoadyuvante-de-conversion-para-el-cancer-colorrectal-con-quimioterapia-y-agentes-dirigidos-antiangiogenicos 2026-08-08 weekly 0.6 https://crcwarriors.org/ensayo/NCT06470178/a-real-world-study-of-neoadjuvant-conversion-therapy-for-colorectal-cancer-with-chemotherapy-and-anti-angiogenic-targeted-agents 2026-08-08 weekly 0.6 https://crcwarriors.org/ensayo/NCT06895031/estudio-de-jyp0015-en-pacientes-con-tumores-solidos-avanzados-que-presentan-mutaciones-especificas-en-ras 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT06895031/study-of-jyp0015-in-patients-with-advanced-solid-tumors-harboring-specific-mutations-in-ras 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT05623787/valor-diagnostico-de-la-resonancia-magnetica-con-ponderacion-en-difusion-en-neoplasias-colorrectales-y-apendiculares-de-alto-riesgo 2026-08-08 weekly 0.6 https://crcwarriors.org/ensayo/NCT05623787/diagnostic-value-of-diffusion-weighted-magnetic-resonance-in-high-risk-colorectal-and-appendiceal-neoplasms 2026-08-08 weekly 0.6 https://crcwarriors.org/ensayo/NCT07035886/un-estudio-para-monitorizar-el-tratamiento-con-fruzaqla-en-adultos-con-cancer-colorrectal-metastasico-mcrc-en-corea-del-sur 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT07035886/a-study-to-monitor-the-fruzaqla-treatment-of-adults-with-metastatic-colorectal-cancer-mcrc-in-south-korea 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT07337551/acetato-de-gossipol-folfiri-bevacizumab-en-pacientes-con-cancer-colorrectal-metastasico-mcrc-con-mutacion-en-tp53-y-expresion-positiva-de-lrpprc 2026-08-08 weekly 0.6 https://crcwarriors.org/ensayo/NCT07337551/gossypol-acetate-folfiri-bev-in-mcrc-with-tp53-mutant-and-lrpprc-positive 2026-08-08 weekly 0.6 https://crcwarriors.org/ensayo/NCT07152886/los-efectos-de-clostridium-butyricum-sobre-los-eventos-adversos-durante-la-quimioterapia-adyuvante-para-el-cancer-colorrectal 2026-08-08 weekly 0.6 https://crcwarriors.org/ensayo/NCT07152886/the-effects-of-clostridium-butyricum-on-adverse-events-during-adjuvant-chemotherapy-for-colorectal-cancer 2026-08-08 weekly 0.6 https://crcwarriors.org/ensayo/NCT05672524/un-estudio-de-tucatinib-y-trastuzumab-en-pacientes-con-cancer-de-recto 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT05672524/a-study-of-tucatinib-and-trastuzumab-in-people-with-rectal-cancer 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT02568267/estudio-basket-de-entrectinib-rxdx-101-para-el-tratamiento-de-pacientes-con-tumores-solidos-que-presentan-reordenamientos-fusiones-en-los-genes-ntrk-1-2-3-trk-a-b-c-ros1-o-alk 2026-08-08 weekly 0.6 https://crcwarriors.org/ensayo/NCT02568267/basket-study-of-entrectinib-rxdx-101-for-the-treatment-of-patients-with-solid-tumors-harboring-ntrk-1-2-3-trk-a-b-c-ros1-or-alk-gene-rearrangements-fusions 2026-08-08 weekly 0.6 https://crcwarriors.org/ensayo/NCT07638956/icg-en-el-cancer-de-colon 2026-08-08 weekly 0.6 https://crcwarriors.org/ensayo/NCT07638956/icg-in-colon-cancer 2026-08-08 weekly 0.6 https://crcwarriors.org/ensayo/NCT06973083/eficacia-y-seguridad-de-la-diseccion-endoscopica-submucosa-asistida-por-robot-para-neoplasias-colorrectales 2026-08-08 weekly 0.6 https://crcwarriors.org/ensayo/NCT06973083/efficacy-and-safety-of-robot-assisted-endoscopic-submucosal-dissection-for-colorectal-neoplasm 2026-08-08 weekly 0.6 https://crcwarriors.org/ensayo/NCT06043947/seguimiento-de-la-supervivencia-en-los-registros-de-cancer-de-rusia 2026-08-08 weekly 0.6 https://crcwarriors.org/ensayo/NCT06043947/survival-monitoring-in-russian-cancer-registries 2026-08-08 weekly 0.6 https://crcwarriors.org/ensayo/NCT06218914/estudio-de-fase-i-para-investigar-las-terapias-con-celulas-t-receptoras-quimericas-tcrt-dirigidas-a-la-mutacion-kras-en-tumores-solidos-avanzados-irresecables-y-o-metastasicos 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT06218914/phase-1-study-to-investigate-tcrts-kras-mutation-in-unresectable-advanced-and-or-metastatic-solid-tumors 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT03191110/el-estudio-colon-cohorte-de-cancer-colorrectal 2026-08-08 weekly 0.6 https://crcwarriors.org/ensayo/NCT03191110/the-colon-study-colorectal-cancer-cohort 2026-08-08 weekly 0.6 https://crcwarriors.org/ensayo/NCT07544589/un-estudio-de-fase-i-que-evalua-disp-10-en-participantes-con-canceres-gastrointestinales-avanzados 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT07544589/a-phase-1-study-evaluating-disp-10-in-participants-with-advanced-gastrointestinal-cancers 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT06841159/radioterapia-estereotactica-adaptativa-ultrafraccionada-y-personalizada-pulsar-combinada-con-terapia-anti-pd1-quimioterapia-y-terapia-dirigida-para-el-cancer-colorrectal-metastasico 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT06841159/personalized-ultrafractionated-stereotactic-adaptive-radiotherapy-pulsar-combined-with-anti-pd1-chemotherapy-and-target-therapy-for-metastatic-colorectal-cancer 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT07128355/botensilimab-balstilimab-y-radioterapia-estereotactica-ablativa-sbrt-en-el-cancer-colorrectal 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT07128355/botensilimab-balstilimab-and-sbrt-in-colorectal-cancer 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT05428735/el-ensayo-dragon-2 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT05428735/the-dragon-2-trial 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT07543848/un-estudio-exploratorio-prospectivo-multicentrico-de-un-solo-brazo-de-fase-ii-para-evaluar-la-combinacion-de-serplulimab-con-el-virus-oncolitico-h101-radioterapia-de-corta-duracion-y-quimioterapia 2026-08-08 weekly 0.6 https://crcwarriors.org/ensayo/NCT07543848/a-prospective-multicenter-single-arm-phase-ii-exploratory-study-of-serplulimab-combined-with-oncolytic-virus-h101-short-course-radiotherapy-and-xelox-chemotherapy-as-total-neoadjuvant-treatment-for 2026-08-08 weekly 0.6 https://crcwarriors.org/ensayo/NCT06708429/sindrome-de-lynch-interaccion-entre-la-mucosa-enteral-y-el-sistema-inmunitario 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT06708429/lynch-syndrome-x-talk-of-enteral-mucosa-with-immune-system 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT06662643/un-ensayo-clinico-que-compara-la-anastomosis-de-turnbull-cutait-escalonada-con-la-anastomosis-directa-mas-ileostomia-profilactica-en-el-tratamiento-del-cancer-rectal-bajo-despues-de-la-reseccion-del 2026-08-08 weekly 0.6 https://crcwarriors.org/ensayo/NCT06662643/a-clinical-trial-comparing-staged-turnbull-cutait-pull-through-anastomosis-with-direct-anastomosis-plus-prophylactic-ileostomy-in-the-treatment-of-low-rectal-cancer-after-internal-sphincter-resection 2026-08-08 weekly 0.6 https://crcwarriors.org/ensayo/NCT06922383/un-estudio-clinico-de-arfolitixorina-en-pacientes-con-mcrc 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT06922383/a-clinical-study-of-arfolitixorin-in-patients-with-mcrc 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT03018418/terapia-con-protones-para-reducir-la-toxicidad-en-el-cancer-anal 2026-08-08 weekly 0.6 https://crcwarriors.org/ensayo/NCT03018418/proton-therapy-in-reducing-toxicity-in-anal-cancer 2026-08-08 weekly 0.6 https://crcwarriors.org/ensayo/NCT07012954/cetuximab-o-bevacizumab-guiados-por-ctdna-mas-trifluridina-tipiracil-en-pacientes-con-mcrc-con-ras-braf-de-tipo-salvaje 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT07012954/ctdna-guided-cetuximab-or-bevacizumab-plus-trifluridine-tipiracil-in-ras-braf-wild-type-mcrc 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT06183736/cvl237-en-comprimidos-para-el-tratamiento-de-tumores-solidos-avanzados-con-deficiencia-de-pten 2026-08-08 weekly 0.6 https://crcwarriors.org/ensayo/NCT06183736/cvl237-tablets-in-the-treatment-of-advanced-solid-tumors-with-pten-deficiency 2026-08-08 weekly 0.6 https://crcwarriors.org/ensayo/NCT05706129/un-estudio-para-evaluar-la-seguridad-la-tolerabilidad-y-las-caracteristicas-de-imagen-de-68ga-ga-dpi-4452-y-para-evaluar-la-seguridad-la-tolerabilidad-y-la-eficacia-de-177lu-lu-dpi-4452-en 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT05706129/a-study-to-assess-safety-tolerability-and-imaging-characteristics-of-68ga-ga-dpi-4452-and-to-assess-safety-tolerability-and-efficacy-of-177lu-lu-dpi-4452-in-participants-with-unresectable-locally 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT05228431/regimen-terapeutico-sandwich-modificado-para-el-cancer-colorrectal-localmente-avanzado 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT05228431/modified-sandwich-therapeutic-regimen-for-locally-advanced-rectal-cancer 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT05576480/scrt-penpulimab-en-combinacion-con-capeox-en-el-tratamiento-neoadyuvante-del-cancer-colorrectal-localmente-avanzado-mss 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT05576480/scrt-sequential-penpulimab-in-combination-with-capeox-in-the-neoadjuvant-treatment-of-mss-locally-advanced-rectal-cancer 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT06195670/estudio-clinico-de-radioterapia-de-corta-duracion-seguida-de-fruquintinib-mas-sintilimab-frente-a-bevacizumab-mas-capecitabina-como-tratamiento-de-primera-linea-en-pacientes-con-mcrc-avanzado 2026-08-08 weekly 0.6 https://crcwarriors.org/ensayo/NCT06195670/clinical-study-of-short-course-radiotherapy-followed-by-fruquintinib-plus-sintilimab-vs-bevacizumab-plus-capecitabine-as-first-line-treatment-in-advanced-mcrc 2026-08-08 weekly 0.6 https://crcwarriors.org/ensayo/NCT03485209/estudio-de-eficacia-y-seguridad-de-tisotumab-vedotina-en-pacientes-con-tumores-solidos 2026-08-08 weekly 0.6 https://crcwarriors.org/ensayo/NCT03485209/efficacy-and-safety-study-of-tisotumab-vedotin-for-patients-with-solid-tumors 2026-08-08 weekly 0.6 https://crcwarriors.org/ensayo/NCT06521866/estudio-de-fase-ii-de-serplulimab-en-combinacion-con-terapia-dirigida-de-primera-linea-quimioterapia-y-radioterapia-en-cancer-colorrectal-avanzado 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT06521866/phase-ii-study-of-serplulimab-combined-with-first-line-targeted-therapy-chemotherapy-and-radiation-in-advanced-colorectal-cancer 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT06425133/regorafenib-en-combinacion-con-quimioterapia-metronomica-multimodal-para-cancer-colorrectal-metastasico-resistente-a-la-quimioterapia 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT06425133/regorafenib-in-combination-with-multimodal-metronomic-chemotherapy-for-chemo-resistant-metastatic-colorectal-cancers 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT05663502/recopilacion-de-donaciones-de-muestras-de-sangre-y-tejido-para-la-investigacion-de-canceres-relacionados-con-el-vih-sida 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT05663502/collecting-blood-and-tissue-sample-donations-for-research-for-hiv-aids-related-cancers 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT04592003/cohorte-francesa-de-pacientes-con-cancer-colorrectal-sometidos-a-reseccion-endoscopica-con-dispositivo-de-corte-esd-en-centros-especializados 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT04592003/french-colorectal-esd-cohort-in-experts-centers 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT06369259/estudio-de-fase-2-abierto-con-avutometinib-inhibidor-de-raf-mek-en-combinacion-con-defactinib-inhibidor-de-fak-y-cetuximab-en-pacientes-con-cancer-colorrectal-avanzado-irresecable-y-resistente-a-los 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT06369259/open-label-phase-2-study-of-avutometinib-raf-mek-clamp-in-combination-with-defactinib-fak-inhibitor-and-cetuximab-in-patients-with-unresectable-anti-egfr-refractory-advanced-colorectal-cancer 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT04288999/cirugia-combinada-con-quimioterapia-frente-a-quimiorradioterapia-seguida-de-cirugia-combinada-con-quimioterapia-para-el-cancer-de-recto-localmente-recurrente 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT04288999/surgery-plus-chemo-versus-chemoradiotherapy-followed-by-surgery-plus-chemo-for-locally-recurrent-rectal-cancer 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT06136026/cohorte-especializada-en-medicina-china-y-occidental-integrada-para-el-cancer-colorrectal 2026-08-08 weekly 0.6 https://crcwarriors.org/ensayo/NCT06136026/integrated-chinese-and-western-medicine-specialized-disease-cohort-for-colorectal-cancer 2026-08-08 weekly 0.6 https://crcwarriors.org/ensayo/NCT05129605/estudio-de-evaluacion-y-cribado-del-riesgo-genetico-del-cancer-de-prostata 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT05129605/prostate-cancer-genetic-risk-evaluation-and-screening-study 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT07063550/microplasticos-en-tejidos-paraneoplasicos-e-intratumorales-del-cancer-colorrectal 2026-08-08 weekly 0.6 https://crcwarriors.org/ensayo/NCT07063550/microplastics-in-paraneoplastic-and-intratumoral-for-colorectal-cancer 2026-08-08 weekly 0.6 https://crcwarriors.org/ensayo/NCT06685497/colorectum-sistema-digital-para-la-mejora-de-la-calidad-en-el-seguimiento-postoperatorio-del-cancer-colorrectal 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT06685497/colorectum-digital-system-for-postoperative-quality-improvement-in-colorectal-cancer 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT07397338/estudio-de-inhibidores-de-ras-on-en-combinacion-con-ivonescimab-en-pacientes-con-tumores-solidos 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT07397338/study-of-ras-on-inhibitors-in-combination-with-ivonescimab-in-patients-with-solid-tumors 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT07399236/prediccion-basada-en-inteligencia-artificial-de-la-metastasis-hepatica-en-el-cancer-colorrectal-un-estudio-retrospectivo 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT07399236/ai-based-prediction-of-liver-metastasis-in-colorectal-cancer-a-retrospective-study 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT06940388/tratamiento-neoadyuvante-total-con-o-sin-tislelizumab-para-el-cancer-colorrectal-localmente-avanzado 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT06940388/total-neoadjuvant-treatment-with-or-without-tislelizumab-for-locally-advanced-rectal-cancer 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT07398456/identificacion-hibrida-mediante-telefono-inteligente-del-cancer-colorrectal-en-etapas-tempranas-utilizando-pruebas-de-deteccion-basadas-en-sangre-en-todo-el-estado-de-texas 2026-08-08 weekly 0.6 https://crcwarriors.org/ensayo/NCT07398456/smartphone-enabled-hybrid-identification-of-early-colorectal-disease-using-blood-based-cancer-testing-across-texas 2026-08-08 weekly 0.6 https://crcwarriors.org/ensayo/NCT06384417/utilizacion-de-un-juego-de-conversacion-sobre-el-final-de-la-vida-para-involucrar-a-los-pacientes-con-cancer-en-la-planificacion-anticipada-de-la-atencion-fase-ii 2026-08-08 weekly 0.6 https://crcwarriors.org/ensayo/NCT06384417/using-an-end-of-life-conversation-game-to-engage-patients-with-cancer-in-advance-care-planning-phase-2 2026-08-08 weekly 0.6 https://crcwarriors.org/ensayo/NCT06574087/determinar-la-frecuencia-de-aparicion-y-definir-la-prueba-de-deteccion-mas-adecuada-para-la-neoplasia-intraepitelial-anal-nia-en-pacientes-con-enfermedades-ginecologicas-relacionadas-con-el-virus-del 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT06574087/determining-the-frequency-of-occurrence-and-defining-the-most-appropriate-screening-test-for-anal-intraepithelial-neoplasia-ain-in-patients-with-human-papillomavirus-hpv-related-gynecological-diseases 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT06589388/monitorizacion-del-ctdna-para-predecir-la-eficacia-de-tnt-en-el-cancer-de-recto 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT06589388/ctdna-monitoring-to-predict-the-efficacy-of-tnt-for-rectal-cancer 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT05570279/plan-a-recopilacion-de-datos-bio-y-de-planes-para-el-scca-en-dinamarca 2026-08-08 weekly 0.6 https://crcwarriors.org/ensayo/NCT05570279/plan-a-data-bio-and-plan-bank-collection-for-scca-in-denmark 2026-08-08 weekly 0.6 https://crcwarriors.org/ensayo/NCT04767984/evaluacion-de-atorvastatina-para-reducir-el-riesgo-de-cancer-de-colon-en-pacientes-con-colitis-ulcerosa-cronica 2026-08-08 weekly 0.6 https://crcwarriors.org/ensayo/NCT04767984/testing-atorvastatin-to-lower-colon-cancer-risk-in-longstanding-ulcerative-colitis 2026-08-08 weekly 0.6 https://crcwarriors.org/ensayo/NCT05195710/radioembolizacion-preoperatoria-con-y-90-para-el-control-tumoral-y-la-hipertrofia-del-futuro-remanente-hepatico-en-pacientes-con-metastasis-hepaticas-de-cancer-colorrectal 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT05195710/preoperative-y-90-radioembolization-for-tumor-control-and-future-liver-remnant-hypertrophy-in-patients-with-colorectal-liver-metastases 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT05914389/quimioterapia-de-induccion-combinada-con-inmunoterapia-neoadyuvante-para-cancer-de-colon-mss 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT05914389/induction-chemotherapy-combined-with-neoadjuvant-immunotherapy-for-mss-colon-cancer 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT06824623/prevencion-de-las-reingresos-y-la-deshidratacion-en-pacientes-sometidos-a-ileostomia-electiva 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT06824623/readmission-and-dehydration-prevention-in-patients-with-elective-ileostomy 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT04739696/desarrollo-de-una-intervencion-virtual-para-el-manejo-del-estres-dirigida-a-los-cuidadores-de-pacientes-con-cancer-de-tumores-solidos-que-tienen-pareja-o-conyuge 2026-08-08 weekly 0.6 https://crcwarriors.org/ensayo/NCT04739696/developing-a-virtual-stress-management-intervention-for-spousal-partnered-caregivers-of-solid-tumor-cancer-patients 2026-08-08 weekly 0.6 https://crcwarriors.org/ensayo/NCT06983743/un-estudio-de-eras-0015-en-pacientes-con-tumores-solidos-avanzados-o-metastasicos 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT06983743/a-study-of-eras-0015-in-patients-with-advanced-or-metastatic-solid-tumors 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT06082648/estudio-de-la-reconstruccion-de-la-funcion-cerebro-intestinal-tras-la-reseccion-interesfinter-para-tumores-rectales-ultra-bajos 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT06082648/study-of-brain-gut-function-reconstruction-after-intersphincteric-resection-for-ultra-low-rectal-tumors 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT07137000/el-efecto-de-la-terapia-artistica-en-pacientes-sometidos-a-tratamiento-para-el-cancer-colorrectal 2026-08-08 weekly 0.6 https://crcwarriors.org/ensayo/NCT07137000/the-effect-of-art-therapy-in-patients-undergoing-colorectal-cancer 2026-08-08 weekly 0.6 https://crcwarriors.org/ensayo/NCT06374173/un-estudio-de-fase-i-para-evaluar-tgi-6-en-sujetos-con-tumores-solidos-localmente-avanzados-o-metastasicos 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT06374173/a-phase-1-study-to-evaluate-tgi-6-in-subjects-with-locally-advanced-metastatic-solid-tumors 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT07192627/reseccion-endoscopica-con-dispositivo-de-corte-esd-en-el-cancer-colorrectal-localmente-avanzado-tras-quimiorradioterapia-qrt 2026-08-08 weekly 0.6 https://crcwarriors.org/ensayo/NCT07192627/esd-in-locally-advanced-rectal-cancer-following-crt 2026-08-08 weekly 0.6 https://crcwarriors.org/ensayo/NCT07433283/nanoparticulas-de-carbono-cargadas-con-hierro-en-el-tratamiento-de-tumores-solidos-avanzados 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT07433283/carbon-nanoparticle-loaded-iron-in-the-treatment-of-advanced-solid-tumor 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT06280495/serplulimab-y-bevacizumab-como-tratamiento-neoadyuvante-en-combinacion-con-folfox-frente-a-folfox-solo-en-pacientes-con-cancer-colorrectal-ccr-ras-braf-wt-y-pmmr-mss 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT06280495/neoadjuvant-serplulimab-bevacizumab-with-folfox-vs-folfox-alone-in-ras-braf-wt-pmmr-mss-crc-patients 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT04938986/interes-del-immunoscore-r-como-herramienta-complementaria-postoperatoria-para-la-deteccion-del-riesgo-de-recurrencia-en-pacientes-con-cancer-colorrectal-no-metastasico 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT04938986/interest-of-the-immunoscore-r-as-a-post-operative-complementary-tool-for-the-detection-of-the-risk-of-recurrence-in-patients-with-nonmetastatic-colorectal-cancer 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT06146946/seguridad-de-la-cirugia-para-el-cancer-de-recto-medio-e-inferior-sin-diseccion-del-ganglio-linfatico-numero-253-s-m-o-o-t-h 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT06146946/safety-of-mid-and-low-rectal-cancer-surgery-without-dissection-of-the-no-253-lymph-node-s-m-o-o-t-h 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT04751448/colon-md-estudio-longitudinal-del-cancer-de-colon 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT04751448/colon-md-colon-cancer-longitudinal-study 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT06328738/elvn-002-trastuzumab-quimioterapia-en-tumores-solidos-her2-cancer-colorrectal-y-cancer-de-mama 2026-08-08 weekly 0.6 https://crcwarriors.org/ensayo/NCT06328738/elvn-002-with-trastuzumab-chemotherapy-in-her2-solid-tumors-colorectal-and-breast-cancer 2026-08-08 weekly 0.6 https://crcwarriors.org/ensayo/NCT07260617/asociacion-entre-la-composicion-de-la-microbiota-intestinal-y-el-estado-nutricional-en-pacientes-con-cancer-digestivo 2026-08-08 weekly 0.6 https://crcwarriors.org/ensayo/NCT07260617/association-between-composition-of-the-gut-microbiota-and-nutritional-status-in-digestive-oncology 2026-08-08 weekly 0.6 https://crcwarriors.org/ensayo/NCT03841799/colon-im-microbiota-e-infiltrado-inmunitario-en-tejido-colorrectal-normal-displasico-y-neoplasico 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT03841799/colon-im-microbiota-and-immune-infiltrate-in-normal-dysplastic-and-neoplastic-colorectal-tissue 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT05954429/un-estudio-para-evaluar-el-tratamiento-de-tercera-linea-con-fruquintinib-en-combinacion-con-serplulimab-en-pacientes-con-cancer-colorrectal-metastasico-avanzado-no-limitado-al-higado-un-estudio-de 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT05954429/a-study-to-explore-the-third-line-treatment-of-fruquintinib-combined-with-serplulimab-in-advanced-non-liver-limited-metastatic-colorectal-cancer-a-single-center-phase-2-study 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT04631692/evaluacion-de-una-intervencion-para-mejorar-la-alfabetizacion-en-salud-con-el-fin-de-optimizar-la-deteccion-del-cancer-colorrectal-en-zonas-desfavorecidas 2026-08-08 weekly 0.6 https://crcwarriors.org/ensayo/NCT04631692/evaluating-a-health-literacy-intervention-to-improve-colorectal-cancer-screening-in-underserved-areas 2026-08-08 weekly 0.6 https://crcwarriors.org/ensayo/NCT06633133/ileoestomia-virtual-frente-a-ileostomia-de-derivacion-en-pacientes-sometidos-a-reseccion-total-del-mesorrecto 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT06633133/virtual-ileostomy-versus-diverting-ileostomy-in-patients-undergoing-total-mesorectal-excision 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT05187338/terapia-con-triple-inhibidor-de-puntos-de-control-para-tumores-solidos-avanzados 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT05187338/triplex-checkpoint-inhibitors-therapy-for-advanced-solid-tumors 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT06783569/un-estudio-de-escalada-y-expansion-en-humanos-el-primero-de-su-tipo-en-pacientes-con-tumores-solidos-avanzados 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT06783569/a-first-in-human-escalation-and-expansion-study-of-patients-with-advanced-solid-tumors 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT05722288/alimentacion-con-horarios-restringidos-frente-a-asesoramiento-nutricional-para-la-reduccion-de-los-efectos-secundarios-del-tratamiento-con-radioterapia-o-quimiorradioterapia-en-pacientes-con-cancer 2026-08-08 weekly 0.6 https://crcwarriors.org/ensayo/NCT05722288/time-restricted-eating-versus-nutritional-counseling-for-the-reduction-of-radiation-or-chemoradiation-tx-side-effects-in-patients-with-prostate-cervical-or-rectal-cancers 2026-08-08 weekly 0.6 https://crcwarriors.org/ensayo/NCT06307548/cirugia-guiada-por-imagen-de-fluorescencia-seguida-de-terapia-fotodinamica-intraoperatoria-para-mejorar-el-control-tumoral-local-en-pacientes-con-cancer-colorrectal-localmente-avanzado-o-recurrente 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT06307548/fluorescence-image-guided-surgery-followed-by-intraoperative-photodynamic-therapy-for-improving-local-tumor-control-in-patients-with-locally-advanced-or-recurrent-colorectal-cancer 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT04677413/radioterapia-ultrafraccionada-para-el-cancer-de-recto 2026-08-08 weekly 0.6 https://crcwarriors.org/ensayo/NCT04677413/ultra-fractionated-radiotherapy-for-rectal-cancer 2026-08-08 weekly 0.6 https://crcwarriors.org/ensayo/NCT06079242/estudio-observacional-sobre-la-terapia-con-sir-spheres-para-el-tratamiento-de-tumores-hepaticos-metastasicos-irresecables-procedentes-de-cancer-colorrectal-primario 2026-08-08 weekly 0.6 https://crcwarriors.org/ensayo/NCT06079242/observational-study-for-sir-spheres-therapy-for-the-treatment-of-unresectable-metastatic-liver-tumors-from-primary-colorectal-cancer 2026-08-08 weekly 0.6 https://crcwarriors.org/ensayo/NCT07130903/campos-electromagneticos-de-radiofrecuencia-de-amplitud-modulada-am-rf-emf-en-combinacion-con-fruquintinib-en-el-cancer-colorrectal-metastasico-refractario 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT07130903/amplitude-modulated-radiofrequency-electromagnetic-fields-am-rf-emf-in-combination-with-fruquintinib-in-refractory-metastatic-colorectal-cancer 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT05358249/estudio-de-plataforma-de-jdq443-en-combinacion-con-otros-farmacos-en-pacientes-con-tumores-solidos-avanzados-que-presentan-la-mutacion-kras-g12c 2026-08-08 weekly 0.6 https://crcwarriors.org/ensayo/NCT05358249/platform-study-of-jdq443-in-combinations-in-patients-with-advanced-solid-tumors-harboring-the-kras-g12c-mutation 2026-08-08 weekly 0.6 https://crcwarriors.org/ensayo/NCT04449874/un-estudio-para-evaluar-la-seguridad-la-farmacocinetica-y-la-actividad-de-gdc-6036-en-monoterapia-o-en-combinacion-en-participantes-con-tumores-solidos-avanzados-o-metastasicos-con-una-mutacion-kras 2026-08-08 weekly 0.6 https://crcwarriors.org/ensayo/NCT04449874/a-study-to-evaluate-the-safety-pharmacokinetics-and-activity-of-gdc-6036-alone-or-in-combination-in-participants-with-advanced-or-metastatic-solid-tumors-with-a-kras-g12c-mutation 2026-08-08 weekly 0.6 https://crcwarriors.org/ensayo/NCT00867464/seguimiento-a-largo-plazo-de-mujeres-jovenes-en-costa-rica-que-recibieron-la-vacuna-contra-los-tipos-16-y-18-del-virus-del-papiloma-humano-y-de-un-grupo-de-control-no-vacunado 2026-08-08 weekly 0.6 https://crcwarriors.org/ensayo/NCT00867464/extended-follow-up-of-young-women-in-costa-rica-who-received-vaccine-for-human-papillomavirus-types-16-and-18-and-unvaccinated-controls 2026-08-08 weekly 0.6 https://crcwarriors.org/ensayo/NCT06115733/estudio-de-fuquinitinib-en-combinacion-con-capecitabina-como-tratamiento-de-mantenimiento-de-primera-linea-en-el-tratamiento-del-cancer-colorrectal-metastasico 2026-08-08 weekly 0.6 https://crcwarriors.org/ensayo/NCT06115733/study-of-fuquinitinib-combined-with-capecitabine-first-line-maintenance-in-the-treatment-of-metastatic-colorectal-cancer 2026-08-08 weekly 0.6 https://crcwarriors.org/ensayo/NCT04246684/radioterapia-de-corta-duracion-frente-a-radioterapia-convencional-seguida-de-quimioterapia-y-tratamiento-conservador-de-organos-en-pacientes-con-cancer-de-recto-de-riesgo-intermedio-y-alto 2026-08-08 weekly 0.6 https://crcwarriors.org/ensayo/NCT04246684/short-rt-versus-rct-followed-by-chemo-and-organ-preservation-for-interm-and-high-risk-rectal-cancer-patients 2026-08-08 weekly 0.6 https://crcwarriors.org/ensayo/NCT06697964/estudio-de-anoscopia-de-alta-resolucion 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT06697964/high-resolution-anuscopy-study 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT04185779/estudio-colo-cohort-cohorte-de-cancer-colorrectal 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT04185779/colo-cohort-colorectal-cancer-cohort-study 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT07229872/un-estudio-clinico-de-fase-ii-de-aipalolitovorelizumab-ql1706-en-combinacion-con-fruquintinib-para-el-tratamiento-del-cancer-colorrectal-metastasico-pmmr-mss-inmunodominante-que-ha-mostrado-falta-de 2026-08-08 weekly 0.6 https://crcwarriors.org/ensayo/NCT07229872/a-phase-ii-clinical-study-of-aipalolitovorelizumab-ql1706-combined-with-fruquintinib-in-the-treatment-of-immunodominant-pmmr-mss-metastatic-colorectal-cancer-that-has-failed-second-line-or-above 2026-08-08 weekly 0.6 https://crcwarriors.org/ensayo/NCT04680260/optimizacion-de-la-seleccion-del-tratamiento-y-el-seguimiento-en-el-cancer-colorrectal-oligo-metastasico 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT04680260/optimization-of-treatment-selection-and-follow-up-in-oligometastatic-colorectal-cancer 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT07234968/ensayo-clinico-para-evaluar-los-resultados-postoperatorios-de-la-colocacion-de-un-cateter-ureteral-frente-a-la-cistectomia-radical-sin-cateter-ureteral 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT07234968/clinical-trial-to-evaluate-post-operative-outcomes-of-ureteral-stent-vs-ureteral-stent-free-radical-cystectomy 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT05194995/jab-21822-en-combinacion-con-cetuximab-en-pacientes-con-crc-avanzado-y-otros-tumores-solidos-con-mutacion-kras-g12c 2026-08-08 weekly 0.6 https://crcwarriors.org/ensayo/NCT05194995/jab-21822-in-combination-with-cetuximab-in-patients-with-advanced-crc-and-other-solid-tumors-with-kras-g12c-mutation 2026-08-08 weekly 0.6 https://crcwarriors.org/ensayo/NCT06631443/base-de-datos-asiatica-de-seguimiento-y-observacion-awwd 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT06631443/asian-watch-and-wait-database-awwd 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT06666166/shr-a1811-en-combinacion-con-apatinib-en-el-tratamiento-del-adenocarcinoma-gastrico-o-de-la-union-gastroesofagica-avanzado-y-del-cancer-colorrectal 2026-08-08 weekly 0.6 https://crcwarriors.org/ensayo/NCT06666166/shr-a1811-combined-with-apatinib-in-the-treatment-of-advanced-gastric-or-gastroesophageal-junction-adenocarcinoma-and-colorectal-cancer 2026-08-08 weekly 0.6 https://crcwarriors.org/ensayo/NCT06857773/tratamiento-de-induccion-para-metastasis-hepaticas-de-cancer-colorrectal-inicialmente-irresecables-terapia-combinada-con-bomba-de-infusion-intraarterial-hepatica-y-terapia-sistemica 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT06857773/induction-treatment-for-initially-unresectable-colorectal-liver-metastases-combined-hepatic-arterial-infusion-pump-therapy-with-systemic-therapy 2026-08-08 weekly 0.7 https://crcwarriors.org/ensayo/NCT07605702/protocolo-del-registro-clinico-del-canopy-cancer-collective 2026-08-08 weekly 0.6 https://crcwarriors.org/ensayo/NCT07605702/the-canopy-cancer-collective-clinical-registry-protocol 2026-08-08 weekly 0.6 https://crcwarriors.org/ensayo/NCT07750951/estudio-clinico-de-fase-ii-de-un-solo-brazo-para-evaluar-la-seguridad-y-la-eficacia-de-sintilimab-en-combinacion-con-ibi-310-y-quimioterapia-como-terapia-neoadyuvante-para-el-cancer-colorrectal 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07750951/single-arm-phase-ii-clinical-study-evaluating-the-safety-and-efficacy-of-sintilimab-combined-with-ibi-310-and-chemotherapy-as-neoadjuvant-therapy-for-locally-advanced-rectal-cancer 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07745023/intervenciones-mente-cuerpo-para-mejorar-la-calidad-de-vida-el-estres-y-la-calidad-del-sueno-en-supervivientes-de-cancer-de-mama-prostata-endometrio-o-colon-y-recto 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07745023/mind-body-interventions-for-the-improvement-of-quality-of-life-stress-and-sleep-quality-among-survivors-of-breast-prostate-endometrial-or-colorectal-cancer 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07748377/aumento-de-la-deteccion-de-cancer-de-mama-y-cancer-colorrectal-en-la-comunidad 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07748377/increasing-breast-and-colorectal-cancer-screening-in-the-community 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT05378919/terapia-neoadyuvante-frente-a-terapia-estandar-en-el-cancer-colorrectal-localmente-avanzado 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT05378919/neoadjuvant-therapy-vs-standard-therapy-in-locally-advanced-rectal-cancer 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06405139/irinotecano-nanoliposomal-oxaliplatino-mas-capecitabina-como-terapia-de-conversion-en-el-cancer-colorrectal-localmente-avanzado 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06405139/nanoliposomal-irinotecan-oxaliplatin-plus-capecitabine-as-conversion-therapy-of-locally-advanced-colorectal-cancer 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06301386/everolimus-en-combinacion-con-un-inhibidor-de-pd-1-en-pacientes-con-cancer-colorrectal-avanzado 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06301386/everolimus-combined-with-pd-1-in-advanced-colorectal-cancer-patients 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06055439/un-estudio-de-fase-1-2-para-evaluar-chm-2101-una-terapia-celular-t-con-receptor-quimerico-de-antigeno-17-car-autologa 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06055439/a-phase-1-2-study-to-evaluate-chm-2101-an-autologous-cadherin-17-chimeric-antigen-receptor-car-t-cell-therapy 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT05856305/terapia-de-radiacion-estereotactica-en-tumores-del-tracto-nervioso-con-o-sin-clorofilina 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT05856305/scrt-in-tnt-with-or-without-chlorophyllin 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06098560/el-adn-tumoral-circulante-ctdna-como-biomarcador-predictivo-para-la-inmunoterapia-en-pacientes-con-cancer-colorrectal-avanzado-o-localmente-avanzado-con-dmmr-msi-h 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06098560/circulating-tumor-dna-ctdna-as-a-predictive-biomarker-for-immunotherapy-in-advanced-or-locally-advanced-dmmr-msi-h-colorectal-patients 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07523763/inmunoterapia-neoadyuvante-a-dosis-bajas-en-el-cancer-colorrectal-localmente-avanzado-con-deficiencia-de-mmr 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07523763/neoadjuvant-low-dose-immunotherapy-in-locally-advanced-mmr-deficient-colorectal-cancer 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT04928807/radioterapia-de-corta-duracion-seguida-de-quimioterapia-neoadyuvante-y-camrelizumab-en-el-cancer-colorrectal-localmente-avanzado-union 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT04928807/short-course-radiotherapy-followed-by-neoadjuvant-chemotherapy-and-camrelizumab-in-locally-advanced-rectal-cancer-union 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07359989/leucina-mas-quimiorradioterapia-para-el-tratamiento-neoadyuvante-del-cancer-colorrectal-localmente-avanzado 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07359989/leucine-plus-radiochemotherapy-for-neoadjuvant-treatment-of-locally-advanced-rectal-cancer 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06831669/metabolomica-para-predecir-la-respuesta-al-tratamiento-y-las-toxicidades-en-el-cancer-de-recto 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06831669/metabolomics-to-predict-treatment-response-and-toxicities-in-rectal-cancer 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07549906/iparomlimab-tuvonralimab-neoadyuvante-mas-capeox-frente-a-iparomlimab-tuvonralimab-mas-capeox-y-propranolol-para-el-cancer-colorrectal-localmente-avanzado-pmmr-un-estudio-prospectivo-unicentrico-y 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07549906/neoadjuvant-iparomlimab-tuvonralimab-plus-capeox-versus-iparomlimab-tuvonralimab-plus-capeox-and-propranolol-for-locally-advanced-pmmr-colon-cancer-a-prospective-single-center-multi-cohort-study 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT05426005/cadonilimab-para-el-cancer-colorrectal-avanzado-msi-h-dmmr-que-no-responde-al-bloqueo-de-pd-1-pd-l1 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT05426005/cadonilimab-for-pd-1-pd-l1-blockade-refractory-msi-h-dmmr-advanced-colorectal-cancer 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT02572141/quimioterapia-perioperatoria-con-folfox-o-capox-frente-a-quimioterapia-postoperatoria-para-el-cancer-colorrectal-localmente-avanzado-optical 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT02572141/folfox-or-capox-perioperative-chemotherapy-versus-postoperative-chemotherapy-for-locally-advanced-colon-cancer-optical 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT03466424/radioterapia-de-corta-duracion-5-x-6-gy-7-gy-8-gy-seguida-de-quimioterapia-neoadyuvante-para-el-cancer-de-recto-localmente-avanzado 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT03466424/short-course-radiotherapy-5x6gy-7gy-8gy-followed-by-neo-adjuvant-chemotherapy-for-locally-advanced-rectal-cancer 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07394192/radioterapia-de-corta-duracion-con-preservacion-de-los-ganglios-linfaticos-que-drenan-el-tumor-seguida-de-inhibidores-de-pd-1-en-el-cancer-de-recto-en-estadio-ii-iii-con-pmmr-mss 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07394192/short-course-radiotherapy-with-tumor-draining-lymph-node-preservation-followed-by-pd-1-inhibitors-in-pmmr-mss-stage-ii-iii-rectal-cancer 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07393048/aplicacion-y-exploracion-de-la-tecnologia-de-deteccion-personalizada-de-ctdna-mrd-para-predecir-la-eficacia-de-la-terapia-neoadyuvante-en-el-cancer-de-recto 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07393048/application-and-exploration-of-personalized-ctdna-mrd-detection-technology-in-predicting-the-efficacy-of-neoadjuvant-therapy-for-rectal-cancer 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT05212012/d-l-metadona-y-mfolfox6-en-el-tratamiento-del-cancer-colorrectal-avanzado 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT05212012/d-l-methadone-and-mfolfox6-in-treatment-of-advanced-colorectal-cancer 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT05136326/quimiorradioterapia-preoperatoria-con-capecitabina-y-temozolomida-en-cancer-colorrectal-localmente-avanzado-con-expresion-de-mgmt-silenciada-y-mss 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT05136326/preoperative-chemoradiotherapy-with-capecitabine-and-temozolomide-in-mgmt-silenced-mss-locally-advanced-rectal-cancer 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06229340/leflunomida-o-combinacion-de-un-inhibidor-de-mek-e-hidroxicloroquina-para-pacientes-con-mutaciones-en-ras-que-no-responden-al-tratamiento 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06229340/leflunomide-or-combination-of-mek-inhibitor-and-hydroxychloroquine-for-refractory-patients-with-ras-mutations 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT05999812/ensayo-clinico-de-acido-al-trans-retinoico-bevacizumab-y-atezolizumab-en-cancer-colorrectal 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT05999812/clinical-trial-of-all-trans-retinoic-acid-bevacizumab-and-atezolizumab-in-colorectal-cancer 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06373133/shr-8068-en-combinacion-con-adbelizumab-y-bp102-en-el-tratamiento-del-cancer-colorrectal-avanzado 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06373133/shr-8068-combined-with-adbelizumab-and-bp102-in-the-treatment-of-advanced-colorectal-cancer 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT05984485/la-eficacia-de-la-cirugia-primaria-de-reseccion-total-del-mesorrecto-tme-frente-a-la-quimioterapia-neoadyuvante-combinada-con-la-cirugia-tme-en-el-cancer-colorrectal-localmente-avanzado-de-bajo-riesgo 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT05984485/the-efficacy-of-primary-total-mesorectal-excision-tme-surgery-versus-neoadjuvant-chemotherapy-combined-with-tme-surgery-in-low-risk-locally-advanced-rectal-cancer 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06812728/quimioterapia-neoadyuvante-con-folfirinox-y-quimiorradioterapia-preoperatoria-para-pacientes-con-cancer-colorrectal-localmente-avanzado 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06812728/neoadjuvant-folfirinox-and-preoperative-chemoradiotherapy-for-locally-advanced-rectal-cancer-patients 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07080411/la-eficacia-de-la-radioterapia-adaptativa-en-linea-guiada-por-resonancia-magnetica-para-el-cancer-de-recto-localmente-avanzado 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07080411/the-efficacy-of-mr-guided-online-adaptive-radiotherapy-for-locally-advanced-rectal-cancer 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT05201430/quimioterapia-neoadyuvante-con-folfoxiri-frente-a-capeox-en-el-cancer-colorrectal-localmente-avanzado 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT05201430/neoadjuvant-folfoxiri-versus-capeox-chemotherapy-for-local-advanced-rectal-cancer 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT05009069/un-estudio-de-atezolizumab-con-o-sin-tiragolumab-tras-la-quimiorradioterapia-neoadyuvante-en-participantes-con-cancer-colorrectal-localmente-avanzado 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT05009069/a-study-of-atezolizumab-with-or-without-tiragolumab-following-neoadjuvant-chemoradiotherapy-in-participants-with-locally-advanced-rectal-cancer 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07279077/radioterapia-de-baja-dosis-con-conservacion-de-los-ganglios-linfaticos-administrada-de-forma-concurrente-con-quimioterapia-e-inhibidor-de-pd-1-en-pacientes-con-cancer-colorrectal-localmente-avanzado 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07279077/node-sparing-low-dose-radiotherapy-concurrent-with-chemotherapy-and-pd-1-inhibitor-in-pmmr-mss-high-risk-locally-advanced-colon-cancer-a-prospective-single-arm-phase-ii-trial 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06890624/mfolfoxiri-mas-inhibidor-de-pd-1-frente-a-mfolfox6-como-terapia-neoadyuvante-para-el-cancer-colorrectal-localmente-avanzado 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06890624/mfolfoxiri-plus-pd-1-inhibitor-vs-mfolfox6-as-neoadjuvant-therapy-for-locally-advanced-colon-cancer 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07487168/seguridad-y-eficacia-de-la-administracion-intraperitoneal-de-quimioterapia-pipac-con-mitomicina-como-agente-unico-en-tumores-solidos 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07487168/safety-and-efficacy-of-pipac-using-single-agent-mitomycin-in-solid-tumors 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07201259/analisis-de-las-diferencias-en-el-microbioma-intestinal-de-pacientes-con-cancer-y-diferentes-niveles-de-funcion-ovarica-y-resultados-de-fertilidad-tras-la-terapia-con-inhibidores-de-puntos-de-control 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07201259/exploring-gut-microbiome-differences-in-female-cancer-patients-with-varied-ovarian-function-and-fertility-outcomes-following-immune-checkpoint-inhibitor-therapy 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07260058/terapia-con-celulas-inmunitarias-para-tumores-solidos-avanzados 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07260058/immune-cell-therapy-for-advanced-solid-tumors 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07406633/kqb198-en-combinacion-con-imatinib-en-participantes-con-gist-avanzado-metastasico-en-primera-linea-de-tratamiento 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07406633/kqb198-in-combination-with-imatinib-in-participants-with-advanced-metastatic-gist-in-1st-line-setting-synergist-1st-line 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT05636085/rendimiento-clinico-del-test-de-deteccion-de-cancer-colorrectal-de-mainz-biomed-para-el-cancer-colorrectal-y-el-adenoma-avanzado 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT05636085/clinical-performance-of-the-mainz-biomed-colorectal-cancer-screening-test-for-colorectal-cancer-and-advanced-adenoma 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07236983/biodiversidad-de-la-microbiota-intestinal-en-pacientes-con-tumores-solidos-tratados-con-inhibidores-de-puntos-de-control-inmunitario-icpi-un-estudio-prospectivo-monocentrico-para-identificar-las 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07236983/gut-microbiota-gm-biodiversity-in-patients-with-solid-tumors-treated-with-immune-checkpoint-inhibitors-icis-a-monocenter-prospective-study-to-identify-the-interactions-between-gm-and-icis 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT04443543/un-estudio-de-cohorte-prospectivo-con-diseno-adaptativo-sobre-la-estrategia-de-observacion-y-espera-en-pacientes-con-cancer-colorrectal-localmente-avanzado 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT04443543/an-adaptive-design-prospective-cohort-study-of-watch-and-wait-strategy-in-patients-with-locally-advanced-rectal-cancer 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06337552/intervencion-con-alimentos-altamente-fermentados-en-pacientes-con-cancer-colorrectal-localmente-avanzado-el-estudio-feed 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06337552/high-fermented-food-intervention-among-locally-advanced-rectal-cancer-patients-the-feed-trial 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT05484024/radioterapia-de-corta-duracion-seguida-de-quimioterapia-e-inhibidor-de-pd-1-para-el-cancer-colorrectal-localmente-avanzado 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT05484024/short-course-radiotherapy-followed-by-chemotherapy-and-pd-1-inhibitor-for-locally-advanced-rectal-cancer 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT05608044/un-estudio-de-botensilimab-y-balstilimab-para-el-tratamiento-del-cancer-colorrectal 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT05608044/a-study-of-botensilimab-and-balstilimab-for-the-treatment-of-colorectal-cancer 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT05719558/un-estudio-de-asp1002-en-adultos-para-el-tratamiento-de-tumores-solidos 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT05719558/a-study-of-asp1002-in-adults-for-treatment-of-solid-tumors 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT05694936/combinacion-de-valproato-sodico-con-el-tratamiento-estandar-con-anticuerpos-monoclonales-dirigidos-al-egfr-receptor-del-factor-de-crecimiento-epidermico-en-pacientes-con-cancer-colorrectal-metastasico 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT05694936/combining-sodium-valproate-with-standard-of-care-egfr-epidermal-growth-factor-receptor-monoclonal-antibody-treatment-in-patients-with-metastatic-colorectal-cancer 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06293625/personalizacion-y-optimizacion-de-la-quimioterapia-neoadyuvante-en-el-cancer-colorrectal-localmente-avanzado-pero-resecable-en-pacientes-de-edad-avanzada-de-70-anos-o-mas 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06293625/personalising-and-refining-neo-adjuvant-chemotherapy-in-locally-advanced-but-resecable-colon-cancer-in-the-elderly-of-70-years-old-or-more 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT04130971/prediccion-del-cancer-colorrectal-analisis-de-muestras-de-tejido-para-evaluar-las-caracteristicas-del-tumor-y-la-respuesta-al-tratamiento 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT04130971/predicting-colorectal-cancer-tissue-samples-to-evaluate-tumour-characteristics-and-treatment-response 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06368141/quimioterapia-neoadyuvante-combinada-con-terapia-secuencial-con-inhibidores-de-puntos-de-control-inmunitario-ici-en-el-cancer-colorrectal-localmente-avanzado 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06368141/neoadjuvant-chemotherapy-plus-sequential-immune-checkpoint-inhibitor-ici-therapy-in-locally-advanced-colon-cancer 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06011772/terapia-antigeno-egf-cimavax-egf-en-combinacion-con-la-terapia-estandar-para-el-cancer-colorrectal-metastasico-con-mutaciones-ras-y-braf-no-detectables 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06011772/egf-depleting-therapy-cimavax-egf-in-combination-with-standard-therapy-for-ras-and-braf-wild-type-metastatic-colorectal-cancer 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT01762813/evaluacion-de-los-resultados-clinicamente-relevantes-y-analisis-de-biomarcadores-para-su-integracion-traslacional-en-el-cancer-colorrectal 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT01762813/assessment-of-clinically-related-outcomes-and-biomarker-analysis-for-translational-integration-in-colorectal-cancer 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07503808/un-estudio-de-ide034-en-participantes-adultos-con-tumores-solidos-avanzados-localmente-o-metastasicos 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07503808/a-study-of-ide034-in-adult-participants-with-locally-advanced-metastatic-solid-tumors-types 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07503756/js212-terapias-combinadas-en-el-cancer-colorrectal-metastasico 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07503756/js212-combination-therapies-in-metastatic-colorectal-cancer 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07735624/rectify-1-botensilimab-balstilimab-como-tratamiento-neoadyuvante-en-el-cancer-colorrectal-en-estadio-temprano-mss-pmmr 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07735624/rectify-1-neoadjuvant-botensilimab-balstilimab-in-mss-pmmr-early-rectal-cancer 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07503639/ensayo-clinico-umbrella-de-terapia-neoadyuvante-para-el-cancer-colorrectal-localmente-avanzado 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07503639/umbrella-trial-of-neoadjuvant-therapy-for-locally-advanced-colorectal-cancer 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07497789/reorganizacion-metabolica-impulsada-por-smyd3-en-metastasis-hepaticas-de-cancer-colorrectal 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07497789/smyd3-driven-metabolic-rewiring-in-colorectal-liver-metastases 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06790212/quimioterapia-neoadyuvante-con-capox-mas-ivonescimab-frente-a-capox-en-el-cancer-colorrectal-localmente-avanzado 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06790212/neoadjuvant-capox-plus-ivonescimab-versus-capox-for-locally-advanced-colon-cancer 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06625775/estudio-abierto-con-bbo-10203-en-pacientes-con-tumores-solidos-avanzados 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06625775/open-label-study-of-bbo-10203-in-subjects-with-advanced-solid-tumors 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07730970/bloqueo-neuromuscular-profundo-y-una-dieta-baja-en-residuos-para-optimizar-el-campo-quirurgico-en-la-histerectomia-vnotes 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07730970/deep-neuromuscular-blockade-and-a-low-residue-diet-for-the-surgical-field-in-vnotes-hysterectomy 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT04556253/ak104-en-el-carcinoma-gastrico-y-el-cancer-colorrectal-localmente-avanzado-msi-h-dmmr 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT04556253/ak104-in-locally-advanced-msi-h-dmmr-gastric-carcinoma-and-colorectal-cancer 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06863038/valor-predictivo-de-premm5-mmrpredict-y-el-cribado-universal-de-tumores-para-el-sindrome-de-lynch-en-vietnam 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06863038/predictive-value-of-premm5-mmrpredict-and-universal-tumor-screening-for-lynch-syndrome-in-vietnam 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07314294/estudio-de-fase-ii-de-emb-01-en-pacientes-con-cancer-colorrectal-recurrente-o-metastasico 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07314294/phase-ii-study-of-emb-01-in-recurrent-metastatic-colorectal-cancer-patients 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07622017/kortuc-krc-01-mas-radioterapia-para-la-preservacion-de-organos-en-el-cancer-de-recto 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07622017/kortuc-krc-01-plus-radiotherapy-for-organ-preservation-in-rectal-cancer 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT04798898/mejora-de-la-supervivencia-en-metastasis-hepaticas-de-cancer-colorrectal-mediante-la-inmunostimulacion-inducida-por-ablacion-por-radiofrecuencia 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT04798898/improving-survival-of-colorectal-liver-metastases-by-rfa-mediated-immunostimulation 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07740720/un-estudio-sobre-la-duracion-del-tratamiento-con-dostarlimab-en-pacientes-no-tratados-con-cancer-colorrectal-localmente-avanzado-con-deficiencia-en-la-reparacion-de-desajustes-dmmr-y-alta 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07740720/a-study-of-the-duration-of-dostarlimab-in-untreated-mismatch-repair-deficient-dmmr-microsatellite-instability-high-msi-h-locally-advanced-rectal-cancer 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06204094/radioterapia-que-preserva-los-ganglios-linfaticos-combinada-con-quimioterapia-neoadyuvante-total-con-capox-y-sintilimab-para-el-cancer-colorrectal-medio-y-bajo-con-mss 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06204094/node-sparing-radiotherapy-combined-with-total-neoadjuvant-capox-and-sintilimab-for-mss-middle-and-low-rectal-cancer 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT01060371/estudio-de-la-historia-natural-y-de-los-modificadores-geneticos-en-las-ataxias-espinocerebelosas 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT01060371/natural-history-study-of-and-genetic-modifiers-in-spinocerebellar-ataxias 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT05854498/irinotecan-liposomal-en-combinacion-con-tas102-y-bevacizumab-para-pacientes-con-cancer-colorrectal-metastasico 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT05854498/liposomal-irinotecan-with-tas102-and-bevacizumab-for-patients-with-metastatic-colorectal-cancer 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT03874026/estudio-de-folfiri-cetuximab-en-pacientes-con-cancer-colorrectal-en-estadio-iv-y-genotipo-v-v-del-receptor-fcgammariiia 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT03874026/study-of-folfiri-cetuximab-in-fcgammariiia-v-v-stage-iv-colorectal-cancer-patients 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT02008656/ensayo-que-evalua-la-supervivencia-libre-de-enfermedad-a-3-anos-en-pacientes-con-cancer-colorrectal-localmente-avanzado-tratados-con-quimiorradiacion-mas-quimioterapia-de-induccion-o-consolidacion-y 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT02008656/trial-evaluating-3-year-disease-free-survival-in-patients-with-locally-advanced-rectal-cancer-treated-with-chemoradiation-plus-induction-or-consolidation-chemotherapy-and-total-mesorectal-excision-or 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06770270/pucotenlimab-mas-radioterapia-y-quimioterapia-para-el-tratamiento-neoadyuvante-del-cancer-de-recto-localmente-avanzado-pucrt 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06770270/pucotenlimab-plus-radiotherapy-and-chemotherapy-for-neoadjuvant-treatment-of-locally-advanced-rectal-cance-pucrt 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06923345/radioterapia-de-larga-duracion-modificada-seguida-de-quimioterapia-e-inhibidor-de-pd-1-para-pacientes-con-cancer-colorrectal-localmente-avanzado-de-riesgo-alto-y-con-msi-pmmr-estudio-modifi-rc-i 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06923345/modified-long-course-radiotherapy-followed-by-chemotherapy-and-pd-1-inhibitor-for-mss-pmmr-high-risk-mid-low-larc-modifi-rc-i 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT04046445/estudio-de-fase-1b-para-evaluar-atp128-vsv-gp128-y-bi-754091-en-pacientes-con-cancer-colorrectal-en-estadio-iv 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT04046445/phase-1b-study-to-evaluate-atp128-vsv-gp128-and-bi-754091-in-patients-with-stage-iv-colorectal-cancer 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07138859/errores-tecnicos-intraoperatorios-en-la-hemicolectomia-radical-derecha-realizada-con-cirugia-robotica-frente-a-la-laparoscopica 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07138859/the-intraoperative-technical-errors-of-robotic-vs-laparoscopic-radical-right-hemiclectomy 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07369219/el-impacto-de-una-intervencion-de-asistencia-de-enfermeria-basada-en-inteligencia-artificial-dentro-del-programa-de-recuperacion-mejorada-en-los-resultados-de-los-pacientes-sometidos-a-cirugia-de 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07369219/the-impact-of-ai-assisted-nursing-care-intervention-within-the-enhanced-recovery-framework-on-outcomes-of-colorectal-surgery-patients 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT05093907/un-estudio-para-evaluar-la-seguridad-y-la-eficacia-de-bey1107-en-combinacion-con-capecitabina-en-pacientes-con-cancer-colorrectal-metastasico 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT05093907/a-study-to-evaluate-safety-and-efficacy-of-bey1107-in-combination-with-capecitabine-in-patients-with-metastatic-colorectal-cancer 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07528937/aplicacion-de-la-reconstruccion-tridimensional-para-la-planificacion-preoperatoria-del-cancer-colorrectal-localmente-avanzado 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07528937/application-of-3d-reconstruction-for-preoperative-strategy-of-locally-advanced-colon-cancer 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07200141/aumento-simultaneo-de-la-dosis-en-la-radioterapia-neoadyuvante-para-el-cancer-de-recto 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07200141/simultaneous-boost-in-neoadjuvant-radiotherapy-for-rectal-cancer 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07071844/between-bevacizumab-y-trifluridina-tipiracil-administrados-cada-dos-semanas-para-reducir-la-neutropenia-de-grado-3-4-en-pacientes-con-mcrc 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07071844/between-biweekly-bevacizumab-trifluridine-tipiracil-to-reduce-grade-3-4-neutropenia-in-mcrc-patients 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT05057052/crioablacion-combinada-con-sintilimab-mas-regorafenib-en-metastasis-hepaticas-de-cancer-colorrectal-previamente-tratadas 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT05057052/cryoablation-combined-with-sintilimab-plus-regorafenib-in-previously-treated-colorectal-cancer-liver-metastasis 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT04833387/anticuerpo-anti-pd-1-tras-quimiorradioterapia-neoadyuvante-en-cancer-colorrectal-localmente-avanzado-pmmr-mss 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT04833387/pd-1-antibody-following-preoperative-chemoradiotherapy-for-locally-advanced-pmmr-mss-rectal-cancer 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07153458/identificacion-de-nuevos-biomarcadores-no-invasivos-predictivos-y-diagnosticos-para-el-cancer-colorrectal 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07153458/identification-of-new-non-invasive-predictive-and-diagnostic-biomarkers-for-colorectal-cancer 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT05765214/impacto-de-un-programa-de-educacion-sobre-el-cancer-colorrectal-y-la-nutricion-en-pacientes-de-minorias-con-diabetes-tipo-2 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT05765214/impact-of-colorectal-cancer-and-nutrition-education-program-among-minority-patients-with-type-2-diabetes 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT05523245/prediccion-de-la-eficacia-de-la-terapia-neoadyuvante-en-pacientes-con-cancer-colorrectal-localmente-avanzado-mediante-una-plataforma-de-inteligencia-artificial-basada-en-la-resonancia-magnetica 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT05523245/predicting-the-efficacy-of-neoadjuvant-therapy-in-patients-with-locally-advanced-rectal-cancer-using-an-ai-platform-based-on-multi-parametric-mri 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06549907/un-estudio-exploratorio-de-biomarcadores-sobre-el-bloqueo-dual-de-pd1-pdl1-y-ctla4-y-la-terapia-antiangiogenica 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06549907/a-biomarker-exploratory-study-of-dual-blockade-of-pd1-pdl1-and-ctla4-and-anti-angiogenic-therapy 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06647680/quimioterapia-neoadyuvante-e-inhibidor-de-pd-1-para-el-cancer-colorrectal-localmente-avanzado-control-01 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06647680/neoadjuvant-chemotherapy-and-pd-1-inhibitor-for-locally-advanced-rectal-cancer-control-01 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06276686/ejercicio-para-mejorar-la-eficacia-de-la-quimiorradioterapia-prolongada-en-pacientes-con-cancer-colorrectal-localmente-avanzado 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06276686/exercise-for-improving-long-course-chemoradiotherapy-efficacy-in-people-with-locally-advanced-rectal-cancer 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06440902/exploracion-de-estrategias-terapeuticas-para-el-cancer-colorrectal-metastasico-con-mutacion-nras-de-tipo-salvaje-basada-en-el-adn-tumoral-circulante 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06440902/exploration-of-therapeutic-strategies-for-neoras-wild-type-metastatic-colorectal-cancer-based-on-circulating-tumor-dna 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT04024917/impacto-de-la-coherencia-cardiaca-en-la-ansiedad-de-pacientes-sometidos-a-cirugia-por-carcinomatosis-peritoneal 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT04024917/impact-of-cardiac-coherence-on-anxiety-in-patients-operated-on-for-a-peritoneal-carcinosis 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT03981497/ablacion-por-microondas-para-el-tratamiento-de-tumores-renales-pequenos-y-neoplasias-hepaticas-primarias-y-secundarias 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT03981497/microwave-ablation-for-treatment-of-small-renal-tumors-and-primary-and-secondary-liver-neoplasms 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT05601505/estrategia-de-tratamiento-neoadyuvante-guiada-por-el-adn-tumoral-circulante-para-el-cancer-colorrectal-localmente-avanzado 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT05601505/circulating-tumor-dna-guided-neoadjuvant-treatment-strategy-for-locally-advanced-rectal-cancer 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07353645/nanovacuna-neoantigenica-contra-kras-como-terapia-adyuvante-para-el-cancer-colorrectal-cancer-de-pancreas 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07353645/kras-neoantigen-nanovaccine-as-adjuvant-therapy-for-colorectal-cancer-pancreatic-cancer 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06601075/el-papel-del-pet-tc-con-18f-fdg-y-68ga-fapi-en-el-diagnostico-y-la-evaluacion-de-la-eficacia-del-cancer-colorrectal-avanzado-metastasis-peritoneal-con-o-sin-otras-metastasis 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06601075/the-role-of-18f-fdg-and-68ga-fapi-pet-ct-in-the-diagnosis-and-the-efficacy-evaluation-of-advanced-colorectal-cancer-peritoneal-metastasis-with-without-other-metastases 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT03526835/un-estudio-del-anticuerpo-bispecifico-mcla-158-en-pacientes-con-tumores-solidos-avanzados 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT03526835/a-study-of-bispecific-antibody-mcla-158-in-patients-with-advanced-solid-tumors 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07543744/un-estudio-comparativo-de-la-farmacocinetica-la-seguridad-y-la-inmunogenicidad-de-rph-030-y-vectibix-r-en-pacientes-con-cancer-colorrectal-metastasico-con-ras-de-tipo-salvaje-como-terapia-de-primera 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07543744/a-comparative-study-of-pharmacokinetics-safety-and-immunogenicity-of-rph-030-and-vectibix-r-in-patients-with-metastatic-colorectal-cancer-with-wild-type-ras-as-first-line-therapy-in-combination-with 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT02838836/deteccion-de-celulas-tumorales-y-adn-en-la-sangre-la-orina-y-la-medula-osea-de-pacientes-con-canceres-solidos 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT02838836/tumor-cell-and-dna-detection-in-the-blood-urine-and-bone-marrow-of-patients-with-solid-cancers 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07355764/ma-crc-ii-016-shr-1811 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06746012/diseno-de-una-intervencion-de-msalud-basada-en-diadas-para-mejorar-el-cumplimiento-de-las-recomendaciones-sobre-habitos-de-vida-en-pacientes-supervivientes-de-cancer-colorrectal-y-sus-cuidadores 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06746012/designing-a-dyad-based-mhealth-intervention-to-improve-adherence-to-lifestyle-recommendations-in-colorectal-cancer-survivors-and-their-family-caregivers 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT03089268/caracteristicas-moleculares-e-histologicas-de-las-lesiones-serradas-del-colon 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT03089268/molecular-and-histological-characteristics-of-serrated-lesions-of-the-colon 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT05772923/preservacion-de-organos-en-el-cancer-de-recto-braquiterapia-de-contacto-con-rayos-x-frente-a-la-prolongacion-del-intervalo-de-espera-y-la-escision-local 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT05772923/organ-preservation-in-rectal-cancer-contact-x-ray-brachytherapy-vs-extending-the-waiting-interval-and-local-excision 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07361003/un-estudio-de-fase-ib-iii-de-suvemcitug-mas-ftd-tpi-en-participantes-con-cancer-colorrectal-metastasico-refractario 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07361003/a-phase-ib-iii-study-of-suvemcitug-plus-ftd-tpi-in-participants-with-refractory-metastatic-colorectal-cancer 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06938971/ensayo-clinico-aleatorizado-y-controlado-para-evaluar-los-efectos-del-ejercicio-combinado-de-resistencia-y-aerobico-en-la-calidad-de-vida-relacionada-con-la-salud-en-pacientes-que-reciben 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06938971/randomized-controlled-trial-of-the-effects-of-combined-resistance-and-aerobic-exercise-on-health-related-quality-of-life-in-patients-undergoing-first-line-chemotherapy-for-metastatic-colorectal 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06052332/eficacia-y-seguridad-de-la-terapia-neoadyuvante-convencional-frente-a-la-terapia-neoadyuvante-total-en-pacientes-de-edad-avanzada-con-cancer-colorrectal-localmente-avanzado 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06052332/efficacy-and-safety-of-conventional-neoadjuvant-therapy-versus-total-neoadjuvant-therapy-in-older-patients-with-locally-advanced-rectal-cancer 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT05914766/una-intervencion-informativa-y-de-apoyo-para-pacientes-con-cancer-de-recto-localmente-avanzado 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT05914766/an-informational-and-supportive-care-intervention-for-patients-with-locally-advanced-rectal-cancer 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06846268/adg126-y-pembrolizumab-como-tratamiento-neoadyuvante-en-el-cancer-colorrectal-localmente-avanzado 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06846268/neoadjuvant-adg126-and-pembrolizumab-in-locally-advanced-colorectal-cancer 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07555639/un-enfoque-genomico-integrado-para-evaluar-el-riesgo-genetico-y-la-sensibilidad-a-los-farmacos 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07555639/an-integrated-genomic-approach-to-assess-genetic-risk-and-drug-sensitivity 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06202001/irinotecan-tas-102-mas-bevacizumab-como-terapia-de-segunda-linea-en-pacientes-con-mcrc 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06202001/irinotecan-tas-102-plus-bevacizumab-as-a-second-line-therapy-in-mcrc-patients 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07365527/sonoporacion-y-respuesta-del-microambiente-tumoral-en-metastasis-hepaticas-de-cancer-colorrectal 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07365527/sonoporation-and-tumor-microenvironment-response-in-colorectal-liver-metastases 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07555210/estudio-piloto-de-los-cambios-en-la-densidad-mineral-osea-durante-la-inmunoterapia-anti-pd-1 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07555210/pilot-study-of-bone-mineral-density-changes-during-anti-pd-1-immunotherapy 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07365592/quimioterapia-neoadyuvante-anticuerpo-anti-pd-1-y-sitagliptina-para-el-cancer-colorrectal-localmente-avanzado-con-pmmr 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07365592/neoadjuvant-chemotherapy-anti-pd-1-antibody-and-sitagliptin-for-locally-advanced-pmmr-crc 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06980454/comparacion-de-la-farmacocinetica-en-la-fase-i-de-hlx05-frente-a-erbitux-r-en-hombres-chinos-sanos-seguridad-inmunogenicidad-y-farmacocinetica 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06980454/phase-i-pk-comparison-of-hlx05-vs-erbitux-r-in-healthy-chinese-males-safety-immunogenicity-and-pharmacokinetics 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06698757/diferentes-ciclos-de-sintilimab-neoadyuvante-preoperatorio-en-cancer-colorrectal-localmente-avanzado-con-deficiencia-en-la-reparacion-de-errores-de-emparejamiento-alta-inestabilidad-de-microsatelites 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06698757/different-cycles-of-preoperative-neoadjuvant-sintilimab-in-mismatch-repair-deficient-microsatellite-instability-high-locally-advanced-colorectal-cancer 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06524245/un-modelo-predictivo-para-la-recurrencia-del-cancer-colorrectal-basado-en-el-analisis-multi-omico-de-la-sangre-de-la-vena-porta 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06524245/a-predictive-model-for-recurrence-of-colorectal-cancer-based-on-multi-omics-of-portal-vein-blood 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06784258/comparacion-de-los-factores-inflamatorios-la-escala-de-dolor-y-la-calidad-de-la-recuperacion-postoperatoria-qor-15-en-pacientes-sometidos-a-cirugia-de-cancer-colorrectal-con-tecnicas-de-anestesia 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06784258/comparison-of-inflammatory-factors-pain-scale-and-postoperative-recovery-quality-qor-15-in-patients-undergoing-colorectal-cancer-surgery-with-conventional-general-anesthesia-techniques-compared-to 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06234007/radioterapia-de-corta-duracion-seguida-de-fruquintinib-mas-adebrelimab-y-capox-en-el-tratamiento-neoadyuvante-completo-del-cancer-colorrectal-localmente-avanzado-un-estudio-multicentrico-de-un-solo 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06234007/short-course-radiotherapy-followed-by-fruquintinib-plus-adebrelimab-and-capox-in-the-full-course-neoadjuvant-treatment-of-locally-advanced-rectal-cancer-a-multicenter-single-arm-open-label-study 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06356584/fruquintinib-en-combinacion-con-sintilimab-radioterapia-para-el-tratamiento-en-tercera-linea-del-cancer-colorrectal-con-metastasis-hepaticas 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06356584/fruquintinib-combined-with-sintilimab-radiotherapy-for-third-line-treatment-of-colorectal-cancer-with-liver-metastases 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07183124/modelado-tridimensional-para-la-deteccion-del-cancer-colorrectal-localmente-avanzado-con-margenes-de-reseccion-circunferencial-positivos 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07183124/3d-modeling-for-detecting-locally-advanced-rectal-cancer-with-positive-circumferential-resection-margin 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT04304209/anticuerpo-anti-pd1-sintilimab-en-combinacion-con-quimiorradioterapia-para-el-cancer-colorrectal-localmente-avanzado 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT04304209/pd1-antibody-sintilimab-chemoradiotherapy-for-locally-advanced-rectal-cancer 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT04512937/cirugia-asistida-por-navegacion-computarizada-para-el-cancer-colorrectal-localmente-avanzado-y-recurrente 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT04512937/computer-navigation-assisted-surgery-for-locally-advanced-and-recurrent-rectal-cancer 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06903858/toripalimab-mas-celecoxib-como-tratamiento-neoadyuvante-para-el-cancer-colorrectal-localmente-avanzado-con-dmmr-msi-h 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06903858/toripalimab-plus-celecoxib-for-dmmr-msi-h-locally-advanced-colorectal-cancer 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06940921/sbrt-ldrt-cadonilimab-para-el-cancer-gastrico-colorrectal-y-ovarico-avanzado-con-metastasis-peritoneales 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06940921/sbrt-ldrt-cadonilimab-for-advanced-gastric-colorectal-and-ovarian-cancers-with-peritoneal-metastases 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06321081/estudio-ice-combinacion-de-irinotecan-mas-cetuximab-y-envafolimab-como-regimen-de-retreatment-en-mcrc 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06321081/ice-study-combination-of-irinotecan-plus-cetuximab-and-envafolimab-as-a-rechallenge-regimen-in-mcrc 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07215000/ensayo-coop-sit-opciones-de-limpieza-en-el-entorno-ambulatorio-para-mejorar-la-tolerancia 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07215000/cleansing-options-in-out-patient-setting-to-improve-tolerance-coop-sit-trial 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT05674526/un-estudio-de-fase-1b-de-wu-nk-101-en-combinacion-con-cetuximab 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT05674526/a-phase-1b-study-of-wu-nk-101-in-combination-with-cetuximab 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07123441/un-estudio-sobre-la-eficacia-y-la-seguridad-del-liposoma-de-irinotecan-ii-5-fu-lv-en-combinacion-con-bevacizumab-para-el-tratamiento-del-cancer-colorrectal-avanzado 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07123441/a-study-on-the-efficacy-and-safety-of-irinotecan-liposome-ii-5-fu-lv-in-combination-with-bevacizumab-for-the-treatment-of-advanced-colorectal-cancer 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06753136/electroquimioterapia-ect-en-pacientes-con-tumores-viscerales-primarios-y-o-localizaciones-viscerales-secundarias-de-cualquier-histotipo 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06753136/electrochemotherapy-ect-in-patients-with-primary-visceral-tumors-and-or-secondary-visceral-localizations-of-any-histotype 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07391566/lpm6690176-en-combinacion-con-quimioterapia-y-bevacizumab-en-pacientes-con-cancer-colorrectal-metastasico-con-mutacion-en-ras 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07391566/lpm6690176-in-combination-with-chemotherapy-and-bevacizumab-in-metastatic-colorectal-cancer-patients-with-ras-mutation 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07570914/infusion-intraarterial-hepatica-de-irinotecan-liposomal-mas-oxaliplatino-y-capecitabina-como-terapia-adyuvante-para-metastasis-hepaticas-del-cancer-colorrectal 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07570914/hepatic-arterial-infusion-of-liposomal-irinotecan-plus-oxaliplatin-and-capecitabine-as-adjuvant-therapy-for-colorectal-cancer-liver-metastases 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07395063/un-estudio-clinico-sobre-el-tratamiento-del-cancer-colorrectal-metastasico-en-segunda-linea-o-posterior 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07395063/a-clinical-study-on-the-treatment-of-metastatic-colorectal-cancer-at-the-second-line-or-beyond 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT02754115/una-auditoria-de-la-cirugia-citorreductora-y-la-quimioterapia-intraperitoneal-hipertermica 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT02754115/an-audit-of-cytoreductive-surgery-and-hyperthermic-intraperitoneal-chemotherapy 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07580339/combinacion-de-dcsz11-con-radioterapia-y-quimioterapia-como-tratamiento-neoadyuvante-para-el-cancer-colorrectal-localmente-avanzado-con-pmmr 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07580339/combining-dcsz11-with-radiation-and-chemotherapy-as-neoadjuvant-treatment-for-pmmr-locally-advanced-rectal-cancer 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06762405/prodige-90-ffcd-2204-dostarlimab-neoadyuvante-con-radioterapia-de-corta-duracion-en-una-estrategia-de-observacion-y-espera-para-pacientes-con-cancer-colorrectal-localmente-avanzado-inestable-en 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06762405/prodige-90-ffcd-2204-neoadjuvant-dostarlimab-with-short-course-radiotherapy-in-a-watch-and-wait-strategy-for-microsatellite-unstable-or-mismatch-repair-deficient-locally-advanced-rectal-cancer 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07106359/evaluacion-inicial-de-una-intervencion-conductual-sobre-los-servicios-de-asesoramiento-genetico-para-familias-con-riesgo-de-sindrome-de-lynch 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07106359/initial-testing-of-a-behavioral-intervention-about-genetic-services-for-families-at-risk-of-lynch-syndrome 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07403981/promocion-colaboracion-divulgacion-y-obtencion-de-resultados-optimos-en-la-atencion-de-pacientes-con-cancer 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07403981/advocacy-partnership-outreach-and-yielding-optimized-care-for-oncology-patients 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT05731726/serplulimab-en-combinacion-con-capeox-y-celecoxib-como-tratamiento-neoadyuvante-para-el-cancer-colorrectal-localmente-avanzado 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT05731726/serplulimab-combined-with-capeox-celecoxib-as-neoadjuvant-treatment-for-locally-advanced-rectal-cancer 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07580027/radioterapia-preoperatoria-adaptativa-concomitante-con-quimioterapia-para-el-adenocarcinoma-rectal-ensayo-adaptativo-de-cancer-rectal-02 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07580027/preoperative-adaptive-radiotherapy-concomitant-to-chemotherapy-for-rectal-adenocarcinoma-adaptive-rectal-cancer-trial-02 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT05444491/aplicacion-de-marcadores-de-metilacion-poligenica-en-el-seguimiento-postoperatorio-de-la-recurrencia-del-cancer-colorrectal 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT05444491/application-of-polygenic-methylation-markers-in-postoperative-recurrence-monitoring-of-colorectal-cancer 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT03926338/toripalimab-como-tratamiento-neoadyuvante-con-o-sin-celecoxib-en-cancer-colorrectal-con-dmmr-msi-h 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT03926338/neoadjuvant-toripalimab-with-or-without-celecoxib-in-dmmr-msi-h-colorectal-cancer 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT02917707/analisis-integrativo-de-la-metastasis-hepatica-del-ccrc 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT02917707/integrative-analysis-of-crc-liver-metastasis 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT03525262/terapia-oncologica-para-el-cancer-de-prostata-que-garantiza-la-preservacion-de-los-nervios-y-los-vasos-sanguineos-poten-c 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT03525262/prostate-oncologic-therapy-while-ensuring-neurovascular-conservation-poten-c 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06220617/estudio-multi-omico-para-la-deteccion-temprana-del-cancer-colorrectal-moed-crc 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06220617/multi-omics-study-for-early-detection-of-colorectal-cancer-moed-crc 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06547203/cetuximab-irinotecan-y-toripalimab-en-un-estudio-de-cancer-colorrectal-derecho-ultra-seleccionado-con-mutaciones-ras-braf-de-tipo-salvaje 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06547203/cetuximab-irinotecan-toripalimab-in-ras-braf-wild-type-ultraselected-right-sided-colorectal-cancer-study 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06259552/un-estudio-de-spx-303-un-anticuerpo-bispecifico-dirigido-contra-lilrb2-y-pd-l1-en-pacientes-con-tumores-solidos 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06259552/a-study-of-spx-303-a-bispecific-antibody-targeting-lilrb2-and-pd-l1-in-patients-with-solid-tumors 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07415031/un-estudio-de-tumores-solidos-para-el-tratamiento-a-largo-plazo-de-pacientes-con-cancer-que-participaron-en-estudios-con-adagrasib 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07415031/a-solid-tumor-study-for-long-term-treatment-of-cancer-patients-who-participated-in-adagrasib-studies 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT02521844/un-estudio-para-evaluar-la-seguridad-y-la-tolerabilidad-de-etc-1922159-como-agente-unico-y-en-combinacion-con-pembrolizumab-en-tumores-solidos-avanzados 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT02521844/a-study-to-evaluate-the-safety-and-tolerability-of-etc-1922159-as-a-single-agent-and-in-combination-with-pembrolizumab-in-advanced-solid-tumours 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06594692/radioterapia-de-curso-corto-con-preservacion-de-los-ganglios-junto-con-capox-y-sintilimab-para-el-cancer-colorrectal-localmente-avanzado-mss-un-estudio-aleatorizado-prospectivo-y-multicentrico 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06594692/node-sparing-short-course-radiation-with-capox-and-sintilimab-for-mss-locally-advanced-colon-cancer-a-randomized-prospective-multicenter-study 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06229041/tratamiento-neoadyuvante-total-inmunoterapia-para-cancer-colorrectal-localmente-avanzado-de-alto-riesgo-tnti 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06229041/total-neoadjuvant-treatment-immunotherapy-for-high-risk-locally-advanced-rectal-cancer-tnti 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT01696981/deteccion-del-cancer-colorrectal-en-pacientes-de-edad-avanzada-ensayo-de-deteccion-plco 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT01696981/screening-for-colorectal-cancer-in-older-patients-plco-screening-trial 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07054047/mejorando-el-diagnostico-y-el-tratamiento-de-los-pacientes-con-cancer-de-recto 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07054047/improving-diagnosis-and-treatment-for-patients-with-rectal-cancer 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07407647/dhea-vaginal-para-mejorar-la-salud-vaginal-despues-de-la-radioterapia-en-mujeres-con-cancer-ginecologico-anal-o-de-recto 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07407647/vaginal-dhea-to-improve-vaginal-health-after-radiation-for-women-with-gynecologic-anal-or-rectal-cancer 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT03975049/combinacion-triple-o-regimen-de-doble-farmaco-frente-a-quimiorradiacion-como-terapia-neoadyuvante-para-el-cancer-colorrectal-localmente-avanzado 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT03975049/triplet-combination-or-doublet-regimen-versus-chemoradiation-as-neoadjuvant-therapy-for-locally-advanced-rectal-cancer 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT05148767/terapia-con-irinotecan-basada-en-ugt1a1-para-el-cancer-colorrectal-localmente-avanzado 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT05148767/ugt1a1-based-irinotecan-therapy-for-locally-advanced-rectal-cancer 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06267378/evaluacion-de-la-fragilidad-y-sus-efectos-en-pacientes-que-se-someten-a-una-cirugia-mayor-del-tracto-gastrointestinal 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06267378/assessing-frailty-and-its-impacts-on-patients-facing-major-gi-surgery 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07076823/seguridad-y-eficacia-de-canagliflozina-en-pacientes-con-cancer-colorrectal-metastasico-con-alta-inestabilidad-de-microsatelites-msi-h 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07076823/safety-and-efficacy-of-canagliflozin-in-patients-with-metastatic-high-microsatellite-instability-msi-h-colorectal-cancer 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06998758/megestrol-acetato-para-mejorar-la-perdida-de-peso-relacionada-con-la-quimioterapia-neoadyuvante-en-el-cancer-colorrectal-localmente-avanzado 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06998758/megestrol-acetate-in-improving-neoadjuvant-chemotherapy-related-weight-loss-in-locally-advanced-crc 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07276048/especialistas-en-orientacion-genetica-comunitaria-para-aumentar-el-conocimiento-sobre-la-genetica-del-cancer-colorrectal-en-las-comunidades-hispanas-latinas 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07276048/community-genetic-navigation-engagement-specialists-to-increase-knowledge-about-colorectal-cancer-genetics-in-hispanic-latino-a-communities 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07553234/estudio-para-comprender-la-relacion-entre-la-salud-intestinal-y-las-toxicidades-del-tratamiento-hormonal-del-cancer-de-mama 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07553234/study-to-understand-relationship-between-gut-health-and-toxicities-of-hormonal-breast-cancer-treatment 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06690593/caracteristicas-y-relevancia-clinica-de-la-microbiota-intestinal-en-pacientes-con-gammapatia-monoclonal 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06690593/characteristics-and-clinical-significance-of-gut-microbiota-in-patients-with-monoclonal-gammopathy 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07656038/nelmastobart-en-combinacion-con-tas-102-y-bevacizumab-en-el-cancer-colorrectal-recurrente-metastasico 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07656038/nelmastobart-in-combination-with-tas-102-and-bevacizumab-in-recurrent-metastatic-colorectal-cancer 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06220058/comparacion-de-la-malla-de-polipropileno-y-la-tecnica-de-pequenos-fragmentos-en-el-cierre-de-la-laparotomia-media-en-la-cirugia-colorrectal-de-emergencia-estudio-para-la-prevencion-de-la-hernia 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06220058/comparing-polypropylene-mesh-and-small-bites-technique-in-emergency-colorectal-surgery-s-midline-laparotomy-closure-study-for-incisional-hernia-prevention 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07277842/pd-1-folfoxiri-frente-a-capox-como-terapia-neoadyuvante-total-para-cancer-de-recto-pmmr 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07277842/pd-1-folfoxiri-vs-capox-as-total-neoadjuvant-therapy-for-pmmr-low-rectal-cancer 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06380101/evaluacion-de-un-alimento-medico-con-restriccion-de-aminoacidos-no-esenciales-neaar-en-combinacion-con-terapia-neoadyuvante-total-para-el-cancer-colorrectal-localmente-avanzado-larc 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06380101/evaluating-a-nonessential-amino-acid-restriction-neaar-medical-food-with-total-neoadjuvant-therapy-for-locally-advanced-rectal-cancer-larc 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT05673772/radioterapia-secuencial-preoperatoria-de-corta-duracion-y-folfox-para-el-cancer-colorrectal-localmente-avanzado 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT05673772/preoperative-sequential-short-course-radiation-therapy-and-folfox-for-locally-advanced-rectal-cancer 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06843434/un-estudio-de-botensilimab-y-balstilimab-para-el-adenocarcinoma-rectal 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06843434/a-study-of-botensilimab-and-balstilimab-for-rectal-adenocarcinoma 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06443671/fruquintinib-neoadyuvante-mas-tislelizumab-en-combinacion-con-mcapeox-frente-a-capeox-para-el-cancer-colorrectal-localmente-avanzado-de-pmmr-mss-intermedio-alto 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06443671/neoadjuvant-fruquintinib-plus-tislelizumab-combined-with-mcapeox-versus-capeox-for-mid-high-pmmr-mss-locally-advanced-rectal-cancer 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06722534/celecoxib-para-la-prevencion-de-la-progresion-en-el-sindrome-de-peutz-jeghers 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06722534/celecoxib-for-prevention-of-progression-in-peutz-jeghers-syndrome 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07436078/adaptacion-cultural-de-una-intervencion-para-aumentar-la-realizacion-de-pruebas-geneticas-en-supervivientes-de-cancer-afroamericanos 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07436078/culturally-adapting-an-intervention-to-increase-genetic-testing-in-african-american-cancer-survivors 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT05572684/un-estudio-de-seguridad-tolerabilidad-y-eficacia-de-nc410-en-combinacion-con-pembrolizumab-en-participantes-con-tumores-solidos-avanzados-irresecables-o-metastasicos 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT05572684/a-safety-tolerability-and-efficacy-study-of-nc410-plus-pembrolizumab-in-participants-with-advanced-unresectable-or-metastatic-solid-tumors 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07067385/vacuna-de-arnm-personalizada-contra-el-cancer-para-el-tratamiento-de-tumores-solidos-gastrointestinales 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07067385/personalized-mrna-cancer-vaccine-for-gastrointestinal-solid-tumor-treatment 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07134101/terapia-neoadyuvante-para-el-cancer-colorrectal-localmente-avanzado-en-el-recto-inferior-smarti-rc01 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07134101/neoadjuvant-therapy-for-locally-advanced-low-rectal-cancer-smarti-rc01 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07433673/gemcitabina-cisplatino-nab-paclitaxel-gap-y-cemiplimab-para-el-cancer-de-las-vias-biliares-localmente-avanzado-btc 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07433673/gemcitabine-cisplatin-nab-paclitaxel-gap-and-cemiplimab-for-locally-advanced-biliary-tract-cancer-btc 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT05447923/abordando-las-disparidades-en-la-deteccion-del-cancer-colorrectal-en-las-comunidades-negras-y-desfavorecidas-de-phoenix 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT05447923/addressing-disparities-in-colorectal-cancer-screening-in-black-and-underserved-phoenix-communities 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT03694938/deteccion-de-metastasis-cerebrales-mediante-resonancia-magnetica-en-pacientes-con-cancer-colorrectal-metastasico 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT03694938/detection-of-brain-metastasis-by-mri-in-metastatic-colorectal-cancer-patients 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07441369/abemaciclib-en-combinacion-con-los-regimenes-folfox-folfiri-en-pacientes-con-metastasis-hepaticas-de-cancer-colorrectal-avanzado 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07441369/abemaciclib-combined-with-folfox-folfiri-regimen-in-patients-with-advanced-colorectal-liver-metastases-cancer 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT05167071/estudio-de-hbm4003-en-combinacion-con-toripalimab-en-pacientes-con-tumores-neuroendocrinos-avanzados-y-otros-tumores-solidos 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT05167071/hbm4003-combine-with-toripalimab-in-patients-with-advanced-nen-and-other-solid-tumors-study 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT04294264/tas-102-y-oxaliplatino-para-el-tratamiento-del-cancer-colorrectal-en-estadio-iv-refractario 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT04294264/tas-102-and-oxaliplatin-for-the-treatment-of-refractory-stage-iv-colon-cancer 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT05563922/estrategia-de-preservacion-organica-mediante-quimiorradioterapia-neoadyuvante-total-para-el-carcinoma-rectal-bajo 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT05563922/organ-preservation-strategy-of-total-neoadjuvant-chemoradiotherapy-for-low-rectal-carcinoma 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT03921684/ensayo-clinico-de-nivolumab-en-combinacion-con-folfox-tras-quimiorradioterapia-en-pacientes-con-cancer-de-recto 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT03921684/trial-of-nivolumab-with-folfox-after-chemoradiation-in-rectal-cancer-patients 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT01479608/trasplante-hepatico-y-cancer-colorrectal 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT01479608/liver-transplantation-and-colorectal-cancer 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT04230759/radioterapia-y-quimioterapia-con-o-sin-durvalumab-para-el-carcinoma-anal-localmente-avanzado-un-ensayo-multicentrico-aleatorizado-de-fase-ii-del-grupo-de-estudio-del-cancer-anal-aleman 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT04230759/radiochemotherapy-durvalumab-for-locally-advanced-anal-carcinoma-a-multicenter-randomized-phase-ii-trial-of-the-german-anal-cancer-study-group 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07239466/un-estudio-piloto-que-evalua-la-suplementacion-con-hidroxibutirato-en-combinacion-con-radioterapia-de-corta-duracion-seguida-de-inmunoterapia-combinada-con-terapia-neoadyuvante-con-capeox-en 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07239466/a-pilot-study-evaluating-hydroxybutyrate-supplementation-concomitant-to-short-course-radiotherapy-followed-by-immunotherapy-combined-with-capeox-neoadjuvant-therapy-in-patients-with-locally-advanced 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06613165/explorando-la-duracion-del-tratamiento-con-terapia-neoadyuvante-anti-pd-1-en-el-cancer-colorrectal-en-estadio-ii-iii-con-dmmr 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06613165/exploring-the-treatment-duration-of-pd-1-neoadjuvant-therapy-in-stage-ii-iii-dmmr-rectal-cancer 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06965166/tomografia-computarizada-con-detector-de-fotones-de-conteo-y-contraste-pcd-ct-para-la-estadificacion-local-del-cancer-de-recto 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06965166/contrast-enhanced-photon-counting-detector-ct-pcd-ct-for-the-local-staging-of-rectal-cancer 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT05674422/estudio-gemcad-reveal-el-adn-tumoral-circulante-como-predictor-de-recurrencia-en-pacientes-con-cancer-colorrectal-localmente-avanzado 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT05674422/gemcad-reveal-study-circulating-tumor-dna-as-a-predictor-of-relapse-in-patients-with-locally-advanced-rectal-cancer 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06718543/radioterapia-neoadyuvante-de-corta-duracion-con-o-sin-quimioterapia-y-ak112-en-el-cancer-colorrectal-localmente-avanzado 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06718543/neoadjuvant-short-course-radiotherapy-with-or-without-chemotherapy-and-ak112-in-locally-advanced-rectal-cancer 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT04713618/cambios-en-la-salud-pelvica-la-funcion-sexual-y-la-calidad-de-vida-en-mujeres-con-cancer-pelvico-que-se-someten-a-radioterapia 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT04713618/changes-in-pelvic-health-sexual-function-and-quality-of-life-in-women-with-pelvic-cancer-undergoing-radiation-therapy 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT04008030/un-estudio-de-nivolumab-nivolumab-mas-ipilimumab-o-quimioterapia-a-eleccion-del-investigador-para-el-tratamiento-de-participantes-con-cancer-colorrectal-metastasico-mcrc-con-deficiencia-en-la 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT04008030/a-study-of-nivolumab-nivolumab-plus-ipilimumab-or-investigator-s-choice-chemotherapy-for-the-treatment-of-participants-with-deficient-mismatch-repair-dmmr-microsatellite-instability-high-msi-h 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07166263/seguridad-y-eficacia-de-nk510-en-el-tratamiento-del-cancer-gastrico-y-del-cancer-colorrectal 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07166263/safety-and-efficacy-of-nk510-to-treat-gastric-cancer-and-colorectal-cancer 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06550453/seguridad-y-eficacia-de-pembrolizumab-en-combinacion-con-bevacizumab-y-capecitabina-mas-oxaliplatino-en-el-tratamiento-neoadyuvante-del-cancer-colorrectal-localmente-avanzado-con-mutacion-en-ras-braf 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06550453/safety-and-efficacy-of-pembrolizumab-in-combination-with-bevacizumab-capeox-in-the-neoadjuvant-treatment-of-ras-mutated-braf-wild-type-microsatellite-stabilized-locally-advanced-colorectal-cancer 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT04215731/mfolfoxiri-neoadyuvante-mas-bevacizumab-en-pacientes-con-cancer-colorrectal-localmente-avanzado-de-alto-riesgo 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT04215731/neoadjuvant-mfolfoxiri-plus-bevacizumab-in-patients-with-high-risk-locally-advanced-rectal-cancer 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT04749108/estudio-que-evalua-el-tratamiento-personalizado-del-carcinoma-rectal-localmente-avanzado 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT04749108/study-evaluating-the-tailored-management-of-locally-advanced-rectal-carcinoma 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT04430725/ablacion-por-microondas-o-reseccion-en-cuna-para-el-tratamiento-de-lesiones-pulmonares-de-sarcoma-y-colorrectales-estudio-allume 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT04430725/microwave-ablation-or-wedge-resection-for-the-treatment-of-lung-sarcoma-and-colorectal-lesions-allume-study 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT05903885/una-colaboracion-transversal-para-mejorar-la-prevencion-y-la-equidad-en-salud-entre-los-afroamericanos 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT05903885/a-cross-sectional-partnership-to-improve-prevention-and-health-equity-among-african-americans 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT05965531/tratamiento-del-cancer-colorrectal-localmente-avanzado-con-quimioterapia-con-tas-102-mas-radioterapia-neoadyuvante 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT05965531/treating-locally-advanced-rectal-cancer-with-tas-102-chemotherapy-plus-neoadjuvant-radiotherapy 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07176182/ensayo-clinico-de-mfolfox-neoadyuvante-mas-alvenor-en-pacientes-con-cancer-colorrectal-localmente-avanzado-larc-con-alta-expresion-de-ywhab 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07176182/clinical-trial-of-neoadjuvant-mfolfox-plus-alvenor-for-larc-patients-with-high-ywhab-expression 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06719206/reduccion-del-comportamiento-sedentario-durante-el-tratamiento-del-cancer-el-estudio-redsedcan 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06719206/reduce-sedentary-behavior-during-cancer-treatment-the-redsedcan-study 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07457541/imagenes-moleculares-de-la-expresion-de-la-proteina-de-activacion-de-fibroblastos-mediante-el-uso-de-fapi-marcado-con-tecnecio-99m-hynic 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07457541/molecular-imaging-of-fibroblast-activation-protein-expression-using-labeled-technetium-99m-hynic-fapi 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07594925/radioterapia-de-corta-duracion-seguida-de-inmunoterapia-combinada-con-quimioterapia-para-el-cancer-colorrectal-localmente-avanzado-con-estabilidad-de-microsatelites-un-ensayo-clinico-prospectivo 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07594925/short-course-radiotherapy-followed-by-immunotherapy-combined-with-chemotherapy-for-microsatellite-stable-locally-advanced-rectal-cancer-a-prospective-randomized-controlled-phase-ii-clinical-trial 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06252649/estudio-de-sotorasib-panitumumab-y-folfiri-frente-a-folfiri-con-o-sin-bevacizumab-en-participantes-con-cancer-colorrectal-metastasico-con-mutacion-kras-p-g12c-que-no-han-recibido-tratamiento-previo 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06252649/study-of-sotorasib-panitumumab-and-folfiri-versus-folfiri-with-or-without-bevacizumab-awwb-in-treatment-naive-participants-with-metastatic-colorectal-cancer-with-kras-p-g12c-mutation 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT05566249/un-estudio-para-validar-la-seguridad-y-la-viabilidad-de-artisential-en-la-cirugia-de-cancer-colorrectal-mediante-el-uso-de-un-registro-multicentrico-construido-de-forma-prospectiva 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT05566249/a-study-to-validate-the-safety-and-feasibility-of-artisential-in-colorectal-cancer-surgery-using-prospectively-constructed-multi-center-registry 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06254521/los-efectos-del-tratamiento-neoadyuvante-con-tislelizumab-en-combinacion-con-quimioterapia-en-el-cancer-colorrectal-localmente-avanzado-mss 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06254521/the-effects-of-neoadjuvant-tislelizumab-combined-with-chemotherapy-in-locally-advanced-mss-rectal-cancer 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07263178/un-estudio-sobre-la-quimioterapia-paliativa-en-segunda-linea-y-posteriores-en-pacientes-con-cancer-colorrectal-metastasico 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07263178/a-study-of-second-and-later-line-palliative-chemotherapy-in-patients-with-metastatic-colorectal-cancer 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06823323/estudio-sobre-la-eficacia-y-la-seguridad-de-lactobacillus-johnsonii-en-combinacion-con-capeox-y-pembrolizumab-para-el-tratamiento-del-cancer-colorrectal-metastasico-mss-pmmr 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06823323/the-study-on-the-efficacy-and-safety-of-lactobacillus-johnsonii-in-combination-with-capeox-and-pembrolizumab-for-the-treatment-of-mss-pmmr-metastatic-colorectal-cancer 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06931808/trasplante-de-microbiota-intestinal-radioterapia-combinada-con-quimioterapia-y-sintilimab-en-cancer-colorrectal-avanzado-localizado 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06931808/intestinal-microbiota-transplantation-radiochemotherapy-and-sintilimab-in-localized-advanced-colon-cancer 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07281716/inmunoterapia-combinada-para-el-tratamiento-del-cancer-colorrectal-metastasico-mss-resistente-a-la-quimioterapia 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07281716/combination-immunotherapy-for-the-treatment-of-chemotherapy-refractory-metastatic-mss-crc 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06575127/folfoxiri-modificado-mas-terapia-dirigida-como-tratamiento-de-primera-linea-para-el-cancer-colorrectal-avanzado-un-estudio-prospectivo-de-fase-ii 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06575127/modified-folfoxiri-plus-target-therapy-as-a-first-line-treatment-for-advanced-colorectal-cancer-a-prospective-phase-two-study 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07283939/estudio-del-algoritmo-pagoda-para-ajustar-las-dosis-de-quimioterapia-y-prevenir-retrasos-no-previstos-en-el-tratamiento 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07283939/studying-the-pagoda-algorithm-for-chemotherapy-dose-changes-to-prevent-unplanned-treatment-delays 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06402864/evaluacion-del-contacto-con-rayos-x-y-la-braquiterapia-para-la-preservacion-del-recto-en-el-adenocarcinoma-rectal-de-estadio-intermedio 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06402864/evaluation-contact-x-ray-brachytherapy-for-rectal-preservation-in-intermediate-substage-rectal-adenocarcinoma 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07125729/pruebas-de-enfermedad-residual-minima-para-la-deteccion-temprana-de-la-recurrencia-del-cancer-en-pacientes-con-cancer-colorrectal-en-estadio-ii-iv-que-puede-ser-extirpado-quirurgicamente 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07125729/minimal-residual-disease-testing-for-the-early-detection-of-cancer-recurrence-in-resectable-stage-ii-iv-colorectal-cancer-patients 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT05969847/preservacion-de-organos-tras-la-terapia-neoadyuvante-total-basada-en-enverolimab-para-el-cancer-colorrectal-localmente-avanzado-en-estadio-muy-temprano 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT05969847/organ-preservation-following-enverolimab-based-total-neoadjuvant-therapy-for-locally-advanced-very-low-rectal-cancer 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT03164486/primer-estudio-en-humanos-mediante-tomografia-por-emision-de-positrones-que-utiliza-el-peptido-18f-v6 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT03164486/first-in-human-positron-emission-tomography-study-using-the-18f-v6-binding-peptide 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07596290/yang-et-al-inmunoterapia-dual-anti-pd-1-ctla-4-para-el-cancer-colorrectal-localmente-avanzado-larc 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07596290/yang-et-al-anti-pd-1-ctla-4-dual-immunotherapy-for-larc 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06832917/radioterapia-de-corta-duracion-scrt-seguida-de-6-ciclos-de-cadonilimab-mas-mfolfox6-como-terapia-neoadyuvante-para-pacientes-con-cancer-colorrectal-localmente-avanzado-larc-un-ensayo-multicentrico-de 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06832917/short-course-radiation-scrt-followed-by-6-cycles-of-cadonilimab-plus-mfolfox6-as-neoadjuvant-therapy-for-patients-with-locally-advanced-rectal-cancer-larc-a-multicenter-two-arm-parallel-open-label 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06682247/un-estudio-en-el-mundo-real-de-chidamide-en-combinacion-con-anticuerpos-anti-pd-1-pd-l1-y-agentes-antiangiogenicos-en-el-cancer-colorrectal-avanzado-mss 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06682247/a-real-world-study-of-chidamide-in-combination-with-pd-1-pd-l1-antibodies-and-anti-angiogenic-agents-in-advanced-mss-colorectal-cancer 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06783491/eficacia-del-uso-de-la-quimioterapia-neoadyuvante-con-o-sin-hipertermia-intraabdominal-en-el-tratamiento-del-cancer-colorrectal-localmente-avanzado 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06783491/efficacy-of-the-use-of-neoadjuvant-with-without-hyperthermic-intraperitoneal-chemotherapy-in-the-treatment-of-locally-advanced-colon-cancer 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07478731/tratamiento-neoadyuvante-con-shr-1701-mas-quimiorradioterapia-para-el-cancer-colorrectal-localmente-avanzado 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07478731/neoadjuvant-shr-1701-plus-chemoradiotherapy-for-locally-advanced-rectal-cancer 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT03840239/tnt-para-aumentar-la-tasa-de-respuesta-completa-clinica-en-el-cancer-colorrectal-localizado-en-la-parte-distal 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT03840239/tnt-to-increase-the-clinical-complete-response-rate-for-distal-larc 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07290309/supervivientes-unidos-a-traves-de-ejercicios-guiados-a-distancia 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07290309/survivors-uniting-for-remote-guided-exercise 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT04166604/lonsurf-y-uso-de-g-csf-mantener-la-dosis-e-intensidad-adecuadas-para-optimizar-la-eficacia-del-tratamiento 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT04166604/lonsurf-and-g-csf-use-being-on-a-right-dose-intensity-to-optimize-treatment-efficacy 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT04701476/tate-y-pembrolizumab-mk3475-en-el-tratamiento-del-mcrc-y-el-nsclc 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT04701476/tate-and-pembrolizumab-mk3475-in-mcrc-and-nsclc 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT05806931/administracion-secuencial-de-tas-ox-en-combinacion-con-tas-iri-alternada-con-bevacizumab-para-el-tratamiento-de-pacientes-con-cancer-colorrectal-metastasico-en-lineas-de-tratamiento-avanzadas 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT05806931/sequential-tas-ox-alternating-with-tas-iri-plus-bevacizumab-for-late-line-metastatic-colorectal-cancer 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT05691491/evaluacion-de-la-combinacion-de-los-farmacos-antineoplasicos-temozolomida-y-m1774-para-determinar-su-seguridad-y-eficacia 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT05691491/testing-the-combination-of-the-anti-cancer-drugs-temozolomide-and-m1774-to-evaluate-their-safety-and-effectiveness 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07494578/estudio-observacional-sobre-la-combinacion-de-fluoropirimidina-y-bevacizumab-en-pacientes-con-mcrc 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07494578/observational-study-regarding-the-combination-of-fluoropyrimidine-and-bevacizumab-in-patients-with-mcrc 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07500298/estudio-de-fase-i-de-sar445877-en-combinacion-con-folfox6-y-bevacizumab-como-tratamiento-de-primera-linea-para-el-cancer-colorrectal-metastasico-con-estabilidad-de-microsatelites 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07500298/phase-1-study-of-sar445877-in-combination-with-folfox6-and-bevacizumab-as-first-line-treatment-for-microsatellite-stable-metastatic-colorectal-cancer 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06821048/estudio-de-la-terapia-car-t-dirigida-contra-el-cea-ptc13-en-el-tratamiento-de-tumores-solidos-malignos-avanzados-cea-positivos 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06821048/study-of-cea-targeting-car-t-ptc13-in-the-treatment-of-cea-positive-advanced-malignant-solid-tumors 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT04991948/estudio-del-tratamiento-con-pembrolizumab-tras-la-administracion-de-cyad-101-con-acondicionamiento-previo-con-folfox-en-el-cancer-colorrectal-metastasico 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT04991948/study-of-pembrolizumab-treatment-after-cyad-101-with-folfox-preconditioning-in-metastatic-colorectal-cancer 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07030257/estudio-de-cp-383-en-pacientes-con-tumores-solidos-avanzados-o-metastasicos 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07030257/study-of-cp-383-in-patients-with-advanced-or-metastatic-solid-tumors 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07306390/distribucion-y-analisis-de-los-ganglios-linfaticos-metastasicos-en-pacientes-con-cancer-colorrectal-diamond 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07306390/distribution-and-analysis-of-metastatic-lymph-nodes-in-colorectal-cancer-patients-diamond 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07621497/folfox8-frente-a-mfolfox6-con-bevacizumab-o-cetuximab-para-el-cancer-colorrectal-metastasico-irresecable-en-primera-linea-fase-ii 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07621497/folfox8-versus-mfolfox6-with-bevacizumab-or-cetuximab-for-first-line-unresectable-metastatic-colorectal-cancer-phase-ii 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT03493048/cetuximab-mas-folfoxiri-frente-a-cetuximab-mas-folfox-en-el-tratamiento-del-cancer-colorrectal-metastasico-crclm 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT03493048/cetuximab-plus-folfoxiri-vs-cetuximab-plus-folfox-for-crclm 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT05787197/ctdna-en-pacientes-con-crc-sometidos-a-cirugia-con-intencion-curativa-para-metastasis-hepaticas 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT05787197/ctdna-in-crc-patients-undergoing-curative-intent-surgery-for-liver-metastases 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07619859/impacto-de-fusobacterium-nucleatum-en-la-respuesta-al-tratamiento-anti-egfr-en-el-cancer-colorrectal-metastasico 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07619859/impact-of-fusobacterium-nucleatum-on-response-to-anti-egfr-therapy-in-metastatic-colorectal-cancer 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06202183/ejercicio-fisico-y-microbiota-intestinal-en-pacientes-con-cancer-colorrectal-de-inicio-temprano-que-reciben-quimioterapia-el-ensayo-courage 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06202183/exercise-for-gut-microbiome-in-patients-with-young-onset-colorectal-cancer-undergoing-chemotherapy-the-courage-trial 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT05524012/evaluacion-longitudinal-multimodal-de-la-respuesta-durante-el-tratamiento-neoadyuvante-del-cancer-de-recto 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT05524012/longitudinal-multimodal-response-assessment-during-neoadjuvant-treatment-of-rectal-cancer 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07744139/perfilado-radiogenomico-de-las-celulas-dendriticas-y-los-macrofagos-para-predecir-la-recurrencia-en-las-metastasis-hepaticas-del-cancer-colorrectal 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07744139/radiogenomic-profiling-of-dendritic-cells-and-macrophages-to-predict-recurrence-in-colorectal-liver-metastasis 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT05299840/impacto-del-uso-del-dispositivo-oncogramme-r-en-la-seleccion-del-tratamiento-de-primera-linea-para-pacientes-con-cancer-colorrectal-metastasico 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT05299840/impact-of-using-the-oncogramme-r-device-to-select-the-first-line-of-treatment-for-patients-with-metastatic-colorectal-cancer 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT04188145/un-estudio-aleatorizado-de-fase-iii-que-compara-el-tratamiento-de-mantenimiento-con-fluoropirimidina-bevacizumab-frente-a-fluoropirimidina-despues-de-la-quimioterapia-de-induccion-en-pacientes-con 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT04188145/a-randomized-phase-iii-study-comparing-maintenance-treatment-with-fluoropyrimidine-bevacizumab-versus-fluoropyrimidine-after-induction-chemotherapy-for-a-metastatic-colorectal-cancer 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06882915/eficacia-y-seguridad-de-trifluridina-tipiracil-tas-102-en-combinacion-con-bevacizumab-y-putalimab-en-el-tratamiento-de-pacientes-con-cmmr-despues-de-una-cirugia-citoreductora-un-estudio-clinico-de-un 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06882915/efficacy-and-safety-of-trifluridine-tipiracil-tas-102-combined-with-bevacizumab-and-serplulimab-in-patients-with-metastatic-colorectal-cancer-undergoing-cytoreductive-surgery-a-single-arm-single 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT03494946/trasplante-hepatico-en-comparacion-con-quimioterapia-en-pacientes-con-cancer-colorrectal 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT03494946/liver-transplantation-compared-to-chemotherapy-in-patients-with-colorectal-cancer 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06106308/estudio-de-onvansertib-en-combinacion-con-folfiri-y-bevacizumab-o-folfox-y-bevacizumab-en-comparacion-con-folfiri-y-bevacizumab-o-folfox-y-bevacizumab-para-el-tratamiento-de-primera-linea-del-cancer 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06106308/study-of-onvansertib-in-combination-with-folfiri-and-bevacizumab-or-folfox-and-bevacizumab-versus-folfiri-and-bevacizumab-or-folfox-and-bevacizumab-for-first-line-treatment-of-metastatic-colorectal 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06887218/5-fluorouracilo-leucovorina-5fu-lv-en-combinacion-con-regorafenib-en-pacientes-con-cancer-colorrectal-metastasico 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06887218/5-fluorouracil-leucovorin-5fu-lv-in-combination-with-regorafenib-in-patients-with-metastatic-colorectal-cancer 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT02804815/add-aspirin-un-ensayo-clinico-que-evalua-los-efectos-de-la-aspirina-sobre-la-recurrencia-de-la-enfermedad-y-la-supervivencia-tras-la-terapia-primaria-en-tumores-solidos-no-metastasicos-comunes 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT02804815/add-aspirin-a-trial-assessing-the-effects-of-aspirin-on-disease-recurrence-and-survival-after-primary-therapy-in-common-non-metastatic-solid-tumours 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06270017/evaluacion-de-la-enfermedad-metastasica-y-del-tratamiento-oncologico-en-pacientes-con-cancer-de-colon-mediante-el-uso-de-avatares-de-pez-cebra 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06270017/evaluation-of-metastatic-disease-and-oncological-treatment-in-patients-with-colon-cancer-using-zebra-fish-avatars 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07536113/evaluacion-de-la-eficacia-y-la-seguridad-de-la-seleccion-basada-en-el-adn-tumoral-circulante-ctdna-para-un-nuevo-tratamiento-con-anti-egfr-en-una-cohorte-de-pacientes-con-cancer-colorrectal 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07536113/assessing-the-efficacy-and-safety-of-ctdna-driven-selection-for-anti-egfr-retreatment-in-a-real-world-metastatic-colorectal-cancer-patients-cohort-the-realchallenge-study 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07649655/emb-01-en-combinacion-con-quimioterapia-para-el-cancer-colorrectal-irresecable-o-metastasico 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07649655/emb-01-in-combination-with-chemotherapy-for-unresectable-or-metastatic-colorectal-cancer 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06728072/adicion-de-antibioticos-al-regimen-de-tratamiento-inicial-para-el-cancer-colorrectal 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06728072/addition-of-antibiotics-to-upfront-treatment-regimen-for-colorectal-cancer 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT05462613/regorafenib-combinado-con-quimioterapias-a-dosis-bajas-y-aspirina-seguido-de-quimioterapias-estandar-en-el-cancer-colorrectal-metastasico 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT05462613/regorafenib-with-low-dose-chemotherapies-and-aspirin-followed-by-standard-chemotherapies-in-metastatic-colorectal-cancer 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07175636/ql1706-radioterapia-y-quimioterapia-a-corto-plazo-para-el-cancer-colorrectal-mss 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07175636/ql1706-with-short-course-radiotherapy-and-chemotherapy-for-mss-rectal-cancer 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT04894370/combinacion-de-spartalizumab-mdcf-y-radioterapia-en-pacientes-con-carcinoma-anal-de-celulas-escamosas-metastasico 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT04894370/combination-of-spartalizumab-mdcf-and-radiotherapy-in-patients-with-metastatic-squamous-cell-anal-carcinoma 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06590259/un-estudio-sobre-la-eficacia-y-la-seguridad-de-la-ablacion-multimodal-combinada-con-terapia-sistemica-en-el-tratamiento-de-la-crclm 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06590259/a-study-on-the-efficacy-and-safety-of-multi-mode-ablation-combined-with-systemic-therapy-in-the-treatment-of-crclm 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06974110/estudio-de-moma-341-administrado-por-via-oral-en-participantes-con-tumores-solidos-avanzados-o-metastasicos 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06974110/study-of-orally-administered-moma-341-in-participants-with-advanced-or-metastatic-solid-tumors 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06856187/tratamiento-estandar-de-segunda-linea-tratamiento-secuencial-con-tas-102-y-bevacizumab-combinado-con-tratamiento-local-en-cancer-colorrectal-avanzado 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06856187/second-line-standard-treatment-sequential-tas-102-and-bevacizumab-combined-with-local-treatment-in-advanced-colorectal-cancer 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06551207/cadonilimab-en-combinacion-con-fruquintinib-y-radioterapia-estereotactica-ablativa-sbrt-como-tratamiento-de-tercera-linea-y-en-lineas-posteriores-en-pacientes-con-crc-mss 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06551207/cadonilimab-combined-with-fruquintinib-and-sbrt-as-athird-line-and-posterior-line-treatment-in-patients-with-mss-crc 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT05870800/ensayo-de-fase-ii-abierto-y-no-aleatorizado-sobre-quimioinmunoterapia-neoadyuvante-para-el-cancer-colorrectal-no-metastasico-y-resecable-nicer 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT05870800/phase-ii-open-label-trial-of-neoadjuvant-immunochemotherapy-for-resectable-non-metastatic-colon-cancer-nicer 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07550088/bal-bot-agent-797-en-crc-con-pmmr-y-metastasis-hepaticas 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07550088/bal-bot-agent-797-in-pmmr-crc-with-liver-metastases 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06505551/estudio-de-fase-i-ii-de-celulas-t-con-receptores-de-celulas-t-autologas-scg142-en-pacientes-con-carcinoma-positivo-para-hpv16-52 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06505551/phase-1-2-study-of-autologous-scg142-tcr-t-cells-in-patients-with-hpv16-52-positive-carcinoma 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07261709/trifluridina-tipiracil-mas-fruquintinib-frente-a-trifluridina-tipiracil-mas-bevacizumab-en-cancer-colorrectal-metastasico-refractario-un-ensayo-aleatorizado-controlado-de-etiqueta-abierta-de-no 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07261709/trifluridine-tipiracil-plus-fruquintinib-vs-trifluridine-tipiracil-plus-bevacizumab-in-refractory-metastatic-colorectal-cancer-a-randomized-controlled-open-label-non-inferiority-trial 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT04587128/terapia-anti-egfr-en-lineas-tempranas-para-facilitar-el-retratamiento-en-pacientes-seleccionados-con-mcrc 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT04587128/early-line-anti-egfr-therapy-to-facilitate-retreatment-for-select-patients-with-mcrc 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06616259/tratamiento-de-primera-linea-con-mcapox-cetuximab-frente-a-mfolfox6-cetuximab-en-pacientes-con-cmmr-no-operable-del-lado-izquierdo-con-ras-braf-tipo-salvaje-y-mss-un-estudio-multicentrico 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06616259/first-line-treatment-of-mcapox-cetuximab-vs-mfolfox6-cetuximab-for-ras-braf-wild-type-mss-unresectable-left-sided-mcrc-a-multicenter-randomized-controlled-phase-iii-study 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07553572/aplicacion-digital-para-la-monitorizacion-remota-y-el-manejo-de-los-sintomas 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07553572/remote-monitoring-and-symptom-management-digital-application 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07364656/analisis-de-la-presencia-y-los-efectos-sobre-la-funcion-cardiaca-de-los-autoanticuerpos-anti-nav1-5-en-pacientes-con-tumores-metastasicos 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07364656/analysis-of-the-presence-and-cardiac-functional-effects-of-anti-nav1-5-autoantibodies-in-patients-with-metastatic-tumors 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT05985954/estudio-de-fase-1b-abierto-con-ulixertinib-y-cetuximab-o-ulixertinib-en-combinacion-con-cetuximab-y-encorafenib-en-pacientes-con-cancer-colorrectal-irresecable-o-metastasico-que-previamente-han 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT05985954/open-label-phase-1b-study-of-ulixertinib-and-cetuximab-or-ulixertinib-in-combination-with-cetuximab-and-encorafenib-in-patients-with-unresectable-or-metastatic-colorectal-cancer-who-have-previously 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT04845490/estudio-comparativo-de-mitomicina-y-lobaplatino-en-pacientes-con-cancer-colorrectal-avanzado-sometidos-a-cirugia-radical-combinada-con-quimioterapia-intraperitoneal-hiperermica 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT04845490/comparative-study-of-mitomycin-and-lobaplatin-in-advanced-colorectal-cancer-patients-with-radical-surgery-combined-with-hyperthermic-intraperitoneal-chemotherapy 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06858969/chidamida-en-combinacion-con-un-inhibidor-de-pd-1-bevacizumab-y-xelox-para-el-cancer-colorrectal-metastasico 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06858969/chidamide-in-combination-with-pd-1-inhibitor-bevacizumab-and-xelox-for-metastatic-colorectal-cancer 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06825624/artemis-102-combinaciones-con-hs-20093-en-pacientes-con-cancer-colorrectal-metastasico-avanzado 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06825624/artemis-102-hs-20093-combinations-in-patients-with-advanced-metastatic-colorectal-cancer 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT04612309/estudio-retrospectivo-sobre-el-uso-de-inmunoterapia-en-pacientes-con-cancer-colorrectal-metastasico-msi-h 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT04612309/retrospective-study-on-the-use-of-immunotherapy-in-patients-with-msi-h-metastatic-colorectal-cancer 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07011576/un-estudio-de-fruquintinib-mas-folfiri-como-tratamiento-de-segunda-linea-para-participantes-con-cancer-colorrectal-metastasico-mcrc 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07011576/a-study-of-fruquintinib-plus-folfiri-as-second-line-treatment-for-participants-with-metastatic-colorectal-cancer-fruitful 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT00722228/vacuna-contra-el-cancer-con-celulas-tumorales-completas-tanto-autologa-como-alogenica-para-tumores-metastasicos 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT00722228/autologous-and-allogeneic-whole-cell-cancer-vaccine-for-metastatic-tumors 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07389265/continuacion-del-tratamiento-con-cetuximab-tras-la-progresion-en-primera-linea-en-el-cancer-colorrectal-metastasico 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07389265/continuation-of-cetuximab-beyond-first-line-progression-in-metastatic-colorectal-cancer 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06008054/un-estudio-de-si-b003-bl-b01d1-si-b003-y-bl-b01d1-anticuerpo-monoclonal-anti-pd-1-en-pacientes-con-cancer-de-esofago-localmente-avanzado-o-metastasico-cancer-gastrico-cancer-colorrectal-y-otros 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06008054/a-study-of-si-b003-bl-b01d1-si-b003-and-bl-b01d1-pd-1-monoclonal-antibody-in-patients-with-locally-advanced-or-metastatic-esophageal-cancer-gastric-cancer-colorectal-cancer-and-other-gastrointestinal 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT05700656/galunisertib-en-combinacion-con-capecitabina-en-el-tratamiento-del-cancer-colorrectal-avanzado-con-microsatelites-estables-mss 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT05700656/galunisertib-combined-with-capecitabine-in-advanced-crc-with-pm 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06940778/biopsia-liquida-centrada-en-las-celulas-tumorales-circulantes-y-el-adn-tumoral-circulante-como-herramienta-de-medicina-de-precision-en-los-tumores-gastrointestinales 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06940778/liquid-biopsy-focusing-on-circulating-tumor-cells-and-circulating-tumor-dna-as-precision-medicine-in-gastrointestinal-tumors 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT05720559/estrategia-de-bloqueo-temprano-para-la-metastasis-hepatica-sincronica-del-cancer-colorrectal-basada-en-la-deteccion-prehepatica-de-ctc 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT05720559/early-blocking-strategy-for-metachronous-liver-metastasis-of-colorectal-cancer-based-on-pre-hepatic-ctc-detection 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07583381/un-estudio-prospectivo-sobre-una-tecnologia-de-estimacion-de-la-presion-asistida-por-subarmonicos-para-la-prediccion-temprana-de-la-respuesta-a-la-terapia-sistemica-en-metastasis-hepaticas-del-cancer 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07583381/a-prospective-study-of-a-subharmonic-aided-pressure-estimate-technology-for-early-prediction-of-response-to-systemic-therapy-in-colorectal-cancer-liver-metastases 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07177742/estudio-de-cohorte-prospectivo-sobre-la-relacion-entre-la-peroxiredoxina-1-exosomal-prdx1-y-la-metastasis-hepatica-postoperatoria 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07177742/prospective-cohort-study-on-the-relationship-between-exosomal-peroxiredoxin-1-prdx1-and-postoperative-liver-metastasis 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06999252/rimegepant-en-combinacion-con-un-inhibidor-de-pd-1-en-pacientes-con-cancer-colorrectal-con-metastasis-hepaticas 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06999252/rimegepant-combined-with-pd-1-in-liver-metastasis-colorectal-cancer-patients 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07410676/ebnk-001-celulas-nk-alogenicas-con-dosis-bajas-de-il-15-pembrolizumab-en-tumores-solidos-avanzados 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07410676/ebnk-001-allogeneic-nk-cells-with-low-dose-il-15-pembrolizumab-in-advanced-solid-tumors 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT01174121/inmunoterapia-con-linfocitos-infiltrantes-tumorales-para-pacientes-con-cancer-metastasico 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT01174121/immunotherapy-using-tumor-infiltrating-lymphocytes-for-patients-with-metastatic-cancer 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT05655780/el-papel-del-perfil-molecular-tumoral-cms-el-genotipo-ugt1a1-y-la-actividad-de-la-beta-glucuronidasa-de-la-microbiota-intestinal-en-la-eficacia-del-tratamiento-la-toxicidad-la-supervivencia-y-la 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT05655780/the-role-of-the-tumor-molecular-profile-cms-ugt1a1-genotype-and-beta-glucuronidase-activity-of-the-intestinal-microbiota-for-treatment-efficiency-toxicity-survival-and-quality-of-life-in-patients 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07193862/estudio-piloto-de-un-microdispositivo-implantable-para-la-evaluacion-in-situ-de-la-respuesta-a-farmacos-en-pacientes-con-metastasis-hepaticas-de-cancer-colorrectal 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07193862/pilot-study-of-an-implantable-microdevice-for-in-situ-evaluation-of-drug-response-in-patients-with-colorectal-liver-metastasis 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT02980510/comparacion-de-folfirinox-con-panitumumab-frente-a-mfolfox6-con-panitumumab-en-pacientes-con-cancer-colorrectal-metastasico-con-ras-b-raf-de-tipo-salvaje 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT02980510/comparison-folfirinox-panitumumab-vs-mfolfox6-panitumumab-in-ras-b-raf-wild-type-metastatic-colorectal-cancer-patients 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT01531595/estudio-de-bevacizumab-en-combinacion-con-esquemas-alternos-de-xeliri-y-xelox-en-cancer-colorrectal-metastasico 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT01531595/study-of-bevacizumab-in-combination-with-alternating-xeliri-and-xelox-in-metastatic-colorectal-cancer 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT05863195/evaluacion-de-la-quimioterapia-con-bomba-de-infusion-como-complemento-a-la-quimioterapia-estandar-en-comparacion-con-la-quimioterapia-estandar-sola-en-pacientes-con-metastasis-hepaticas-irresecables 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT05863195/testing-pump-chemotherapy-in-addition-to-standard-of-care-chemotherapy-versus-standard-of-care-chemotherapy-alone-for-patients-with-unresectable-colorectal-liver-metastases-the-pump-trial 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07656766/sintilimab-mas-acetato-de-gossipol-en-el-cancer-colorrectal-avanzado 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07656766/sintilimab-plus-gossypol-acetate-in-advanced-colorectal-cancer 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT05243862/seguridad-y-actividad-de-polypepi1018-en-combinacion-con-atezolizumab-en-el-cancer-colorrectal 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT05243862/safety-and-activity-of-polypepi1018-plus-atezolizumab-in-colorectal-cancer 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT04516681/combinacion-de-acido-ascorbico-intravenoso-y-adebrelimab-en-cancer-colorrectal-metastasico 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT04516681/combination-of-iv-ascorbic-acid-and-adebrelimab-in-metastatic-colorectal-cancer 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07430527/revision-del-protocolo-para-el-tratamiento-del-cancer-colorrectal-en-atencion-secundaria 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07430527/secondary-care-colorectal-cancer-pathway-review 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT05379595/un-estudio-de-amivantamab-en-monoterapia-y-en-combinacion-con-la-quimioterapia-estandar-en-participantes-con-cancer-colorrectal-avanzado-o-metastasico 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT05379595/a-study-of-amivantamab-monotherapy-and-in-addition-to-standard-of-care-chemotherapy-in-participants-with-advanced-or-metastatic-colorectal-cancer 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT05579340/ejercicio-fisico-postoperatorio-y-metastasis-hepatica-del-cancer-colorrectal 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT05579340/postoperative-exercise-training-and-colorectal-cancer-liver-metastasis 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT04579380/estudio-basket-con-tucatinib-y-trastuzumab-en-tumores-solidos-con-alteraciones-de-her2 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT04579380/basket-study-of-tucatinib-and-trastuzumab-in-solid-tumors-with-her2-alterations 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06714903/efecto-de-la-microbiota-intestinal-y-sus-metabolitos-en-la-eficacia-de-la-inmunoterapia-en-el-cancer-colorrectal-metastasico 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06714903/effect-of-gut-microbiota-and-its-metabolites-on-the-efficacy-of-immunotherapy-in-metastatic-colorectal-cancer 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT02888743/durvalumab-y-tremelimumab-con-o-sin-radioterapia-en-dosis-altas-o-bajas-en-el-tratamiento-de-pacientes-con-cancer-colorrectal-metastasico-o-cancer-de-pulmon-no-microcitico 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT02888743/durvalumab-and-tremelimumab-with-or-without-high-or-low-dose-radiation-therapy-in-treating-patients-with-metastatic-colorectal-or-non-small-cell-lung-cancer 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06562543/un-ensayo-para-evaluar-la-seguridad-y-la-actividad-del-fruquintinib-en-poblaciones-minoritarias-con-cancer-colorrectal-avanzado-previamente-tratado 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06562543/a-trial-to-evaluate-the-safety-and-activity-of-fruquintinib-in-minority-populations-with-advanced-previously-treated-colorectal-cancer 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07000305/un-estudio-de-cetuximab-combinado-con-envolimab-y-mfolfox6-en-sujetos-con-cancer-colorrectal-avanzado 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07000305/a-study-of-cetuximab-combined-with-envolimab-and-mfolfox6-in-subjects-with-advanced-colorectal-cancer 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06630624/determinacion-de-la-dosis-eficacia-y-respuesta-inmunologica-de-ip-001-tras-ablacion-por-microondas-mwa-o-ablacion-por-radiofrecuencia-irreversible-ire-en-pacientes-con-metastasis-hepaticas-de-cancer 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06630624/dose-finding-efficacy-and-immunological-response-of-ip-001-following-mwa-or-ire-for-crlm 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT05322590/bxq-350-en-pacientes-con-carcinoma-colorrectal-metastasico-de-diagnostico-reciente 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT05322590/bxq-350-in-newly-diagnosed-metastatic-colorectal-carcinoma 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT06275958/estudio-de-dosis-quimioterapia-con-dosis-reducidas-en-primera-linea-en-pacientes-de-edad-avanzada-con-cancer-colorrectal-metastasico 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06275958/dosage-study-upfront-dose-reduced-chemotherapy-in-older-patients-with-metastatic-colorectal-cancer 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06500052/un-estudio-de-bl-m17d1-en-pacientes-con-cancer-gastrointestinal-her2-positivo-de-baja-expresion-localmente-avanzado-o-metastasico-y-otros-tumores-solidos 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06500052/a-study-of-bl-m17d1-in-patients-with-locally-advanced-or-metastatic-her2-positive-lower-expression-gastrointestinal-cancer-and-other-solid-tumors 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07150403/quimioterapia-combinada-de-segunda-linea-folfox-o-folfiri-mas-fruquintinib-frente-a-quimioterapia-combinada-folfox-o-folfiri-mas-bevacizumab-en-cancer-colorrectal-metastasico 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07150403/second-line-doublet-chemotherapy-folfox-or-folfiri-plus-fruquintinib-versus-doublet-chemotherapy-folfox-or-folfiri-plus-bevacizumab-in-metastatic-colorectal-cancer 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT05248581/trasplante-hepatico-de-donante-vivo-para-metastasis-hepaticas-irresecables-de-cancer-colorrectal 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT05248581/living-donor-liver-transplant-for-unresectable-colorectal-liver-metastases 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06605430/cannabis-medicinal-en-pacientes-con-cancer-avanzado-de-pancreas-y-cancer-colorrectal 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06605430/medical-cannabis-in-patients-with-advanced-pancreatic-and-colorectal-cancer 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06462963/oligocare-twics-ensayos-dentro-de-cohortes-ensayo-comparativo-de-la-toxicidad-aguda-en-la-radioterapia-estereotactica-ablativa-sbrt-en-una-sola-fraccion-frente-a-multiples-fracciones-para-el 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT06462963/oligocare-twics-trials-within-cohorts-trial-comparing-acute-toxicity-in-single-fraction-vs-multiple-fraction-sbrt-for-metastasis-directed-treatment-sprint 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT03908788/deteccion-de-la-aparicion-de-mutaciones-en-el-gen-ras-homologo-del-oncogen-viral-del-sarcoma-de-rata-en-el-adn-circulante-acido-desoxirribonucleico-en-pacientes-con-ccrc-metastasico-cancer 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT03908788/detection-of-the-emergence-of-ras-rat-sarcoma-viral-oncogene-homolog-mutations-in-circulating-dna-deoxyribonucleic-acid-in-patients-with-mcrc-metastatic-colorectal-cancer-during-treatment-with-anti 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT07462143/un-ensayo-clinico-de-fase-ii-iii-con-rc148-mas-quimioterapia-como-terapia-de-primera-linea-para-el-cancer-colorrectal-irresecable-o-metastasico 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT07462143/a-phase-ii-iii-clinical-trial-of-rc148-plus-chemotherapy-as-1l-therapy-for-unresectable-or-metastatic-colorectal-cancer 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT03740503/investigacion-genomica-de-pacientes-con-respuestas-inusuales 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT03740503/genomic-investigation-of-unusual-responders 2026-08-07 weekly 0.7 https://crcwarriors.org/ensayo/NCT04444921/ea2176-ensayo-clinico-de-fase-iii-con-carboplatino-y-paclitaxel-nivolumab-en-pacientes-con-cancer-anal-metastasico 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT04444921/ea2176-phase-3-clinical-trial-of-carboplatin-and-paclitaxel-nivolumab-in-metastatic-anal-cancer-patients 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT03654131/ablacion-por-microondas-frente-a-radioterapia-estereotactica-para-metastasis-hepaticas-de-cancer-colorrectal-en-enfermedad-oligometastasica-un-ensayo-prospectivo-aleatorizado-de-fase-ii 2026-08-07 weekly 0.6 https://crcwarriors.org/ensayo/NCT03654131/microwave-ablation-versus-stereotactic-body-radiotherapy-for-colorectal-liver-metastases-in-oligometastatic-disease-a-prospective-randomised-phase-2-trial 2026-08-07 weekly 0.6 https://crcwarriors.org/medicamento/oxaliplatin 2026-08-07 weekly 0.7 https://crcwarriors.org/medicamento/oxaliplatin/ensayos 2026-08-07 weekly 0.6 https://crcwarriors.org/medicamento/uracil 2026-08-07 weekly 0.7 https://crcwarriors.org/medicamento/uracil/ensayos 2026-08-07 weekly 0.6 https://crcwarriors.org/medicamento/fluorouracil 2026-08-07 weekly 0.7 https://crcwarriors.org/medicamento/fluorouracil/ensayos 2026-08-07 weekly 0.6 https://crcwarriors.org/medicamento/5-fluorouracil 2026-08-07 weekly 0.7 https://crcwarriors.org/medicamento/5-fluorouracil/ensayos 2026-08-07 weekly 0.6 https://crcwarriors.org/medicamento/leucovorin 2026-08-07 weekly 0.7 https://crcwarriors.org/medicamento/leucovorin/ensayos 2026-08-07 weekly 0.6 https://crcwarriors.org/medicamento/bevacizumab 2026-08-07 weekly 0.7 https://crcwarriors.org/medicamento/bevacizumab/ensayos 2026-08-07 weekly 0.6 https://crcwarriors.org/medicamento/capecitabine 2026-07-31 weekly 0.7 https://crcwarriors.org/medicamento/capecitabine/ensayos 2026-07-31 weekly 0.6 https://crcwarriors.org/medicamento/irinotecan 2026-08-07 weekly 0.7 https://crcwarriors.org/medicamento/irinotecan/ensayos 2026-08-07 weekly 0.6 https://crcwarriors.org/medicamento/cetuximab 2026-07-25 weekly 0.7 https://crcwarriors.org/medicamento/cetuximab/ensayos 2026-07-25 weekly 0.6 https://crcwarriors.org/medicamento/pembrolizumab 2026-07-24 weekly 0.7 https://crcwarriors.org/medicamento/pembrolizumab/ensayos 2026-07-24 weekly 0.6 https://crcwarriors.org/medicamento/met 2026-07-24 weekly 0.7 https://crcwarriors.org/medicamento/met/ensayos 2026-07-24 weekly 0.6 https://crcwarriors.org/medicamento/panitumumab 2026-06-23 weekly 0.7 https://crcwarriors.org/medicamento/panitumumab/ensayos 2026-06-23 weekly 0.6 https://crcwarriors.org/medicamento/nivolumab 2026-07-16 weekly 0.7 https://crcwarriors.org/medicamento/nivolumab/ensayos 2026-07-16 weekly 0.6 https://crcwarriors.org/medicamento/regorafenib 2026-08-07 weekly 0.7 https://crcwarriors.org/medicamento/regorafenib/ensayos 2026-08-07 weekly 0.6 https://crcwarriors.org/medicamento/rego 2026-08-07 weekly 0.7 https://crcwarriors.org/medicamento/rego/ensayos 2026-08-07 weekly 0.6 https://crcwarriors.org/medicamento/tislelizumab 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/tislelizumab/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/fruquintinib 2026-07-30 weekly 0.7 https://crcwarriors.org/medicamento/fruquintinib/ensayos 2026-07-30 weekly 0.6 https://crcwarriors.org/medicamento/trastuzumab 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/trastuzumab/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/paclitaxel 2026-06-18 weekly 0.7 https://crcwarriors.org/medicamento/paclitaxel/ensayos 2026-06-18 weekly 0.6 https://crcwarriors.org/medicamento/trifluridine 2026-07-30 weekly 0.7 https://crcwarriors.org/medicamento/trifluridine/ensayos 2026-07-30 weekly 0.6 https://crcwarriors.org/medicamento/cyclophosphamid 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/cyclophosphamid/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/cyclophosphamide 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/cyclophosphamide/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/atezolizumab 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/atezolizumab/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/carboplatin 2026-07-24 weekly 0.7 https://crcwarriors.org/medicamento/carboplatin/ensayos 2026-07-24 weekly 0.6 https://crcwarriors.org/medicamento/cisplatin 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/cisplatin/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/sintilimab 2026-07-31 weekly 0.7 https://crcwarriors.org/medicamento/sintilimab/ensayos 2026-07-31 weekly 0.6 https://crcwarriors.org/medicamento/durvalumab 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/durvalumab/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/ipilimumab 2026-07-16 weekly 0.7 https://crcwarriors.org/medicamento/ipilimumab/ensayos 2026-07-16 weekly 0.6 https://crcwarriors.org/medicamento/gemcitabine 2026-06-18 weekly 0.7 https://crcwarriors.org/medicamento/gemcitabine/ensayos 2026-06-18 weekly 0.6 https://crcwarriors.org/medicamento/pemetrexed 2026-07-24 weekly 0.7 https://crcwarriors.org/medicamento/pemetrexed/ensayos 2026-07-24 weekly 0.6 https://crcwarriors.org/medicamento/celecoxib 2026-05-15 weekly 0.7 https://crcwarriors.org/medicamento/celecoxib/ensayos 2026-05-15 weekly 0.6 https://crcwarriors.org/medicamento/cele 2026-05-15 weekly 0.7 https://crcwarriors.org/medicamento/cele/ensayos 2026-05-15 weekly 0.6 https://crcwarriors.org/medicamento/s-1 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/s-1/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/aldesleukin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/aldesleukin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/fludarabine 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/fludarabine/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/aspirin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/aspirin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/fulvestrant 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/fulvestrant/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/encorafenib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/encorafenib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/docetaxel 2026-08-06 weekly 0.7 https://crcwarriors.org/medicamento/docetaxel/ensayos 2026-08-06 weekly 0.6 https://crcwarriors.org/medicamento/aflibercept 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/aflibercept/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/binimetinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/binimetinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/trametinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/trametinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/tori 2026-06-26 weekly 0.7 https://crcwarriors.org/medicamento/tori/ensayos 2026-06-26 weekly 0.6 https://crcwarriors.org/medicamento/palbociclib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/palbociclib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/toripalimab 2026-06-26 weekly 0.7 https://crcwarriors.org/medicamento/toripalimab/ensayos 2026-06-26 weekly 0.6 https://crcwarriors.org/medicamento/erlotinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/erlotinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/everolimus 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/everolimus/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/nab-paclitaxel 2026-06-18 weekly 0.7 https://crcwarriors.org/medicamento/nab-paclitaxel/ensayos 2026-06-18 weekly 0.6 https://crcwarriors.org/medicamento/balstilimab 2026-07-31 weekly 0.7 https://crcwarriors.org/medicamento/balstilimab/ensayos 2026-07-31 weekly 0.6 https://crcwarriors.org/medicamento/botensilimab 2026-07-31 weekly 0.7 https://crcwarriors.org/medicamento/botensilimab/ensayos 2026-07-31 weekly 0.6 https://crcwarriors.org/medicamento/cadonilimab 2026-04-24 weekly 0.7 https://crcwarriors.org/medicamento/cadonilimab/ensayos 2026-04-24 weekly 0.6 https://crcwarriors.org/medicamento/serplulimab 2026-07-10 weekly 0.7 https://crcwarriors.org/medicamento/serplulimab/ensayos 2026-07-10 weekly 0.6 https://crcwarriors.org/medicamento/vemurafenib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/vemurafenib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/avelumab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/avelumab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/cemiplimab 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/cemiplimab/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/sargramostim 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/sargramostim/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/metformin 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/metformin/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/olaparib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/olaparib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/temozolomide 2026-06-18 weekly 0.7 https://crcwarriors.org/medicamento/temozolomide/ensayos 2026-06-18 weekly 0.6 https://crcwarriors.org/medicamento/dostarlimab 2026-08-04 weekly 0.7 https://crcwarriors.org/medicamento/dostarlimab/ensayos 2026-08-04 weekly 0.6 https://crcwarriors.org/medicamento/adebrelimab 2026-07-23 weekly 0.7 https://crcwarriors.org/medicamento/adebrelimab/ensayos 2026-07-23 weekly 0.6 https://crcwarriors.org/medicamento/trastuzumab+deruxteca 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/trastuzumab+deruxteca/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/trastuzumab+deruxtecan 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/trastuzumab+deruxtecan/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/adagrasib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/adagrasib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/dexamethasone 2026-05-19 weekly 0.7 https://crcwarriors.org/medicamento/dexamethasone/ensayos 2026-05-19 weekly 0.6 https://crcwarriors.org/medicamento/tremelimumab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/tremelimumab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/apatinib 2026-07-09 weekly 0.7 https://crcwarriors.org/medicamento/apatinib/ensayos 2026-07-09 weekly 0.6 https://crcwarriors.org/medicamento/cabozantinib 2026-06-03 weekly 0.7 https://crcwarriors.org/medicamento/cabozantinib/ensayos 2026-06-03 weekly 0.6 https://crcwarriors.org/medicamento/peg 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/peg/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/mitomycin 2026-07-14 weekly 0.7 https://crcwarriors.org/medicamento/mitomycin/ensayos 2026-07-14 weekly 0.6 https://crcwarriors.org/medicamento/tucatinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/tucatinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/sorafenib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/sorafenib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/tipiracil 2026-07-24 weekly 0.7 https://crcwarriors.org/medicamento/tipiracil/ensayos 2026-07-24 weekly 0.6 https://crcwarriors.org/medicamento/lidocaine 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/lidocaine/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/abemaciclib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/abemaciclib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/camrelizumab 2026-04-16 weekly 0.7 https://crcwarriors.org/medicamento/camrelizumab/ensayos 2026-04-16 weekly 0.6 https://crcwarriors.org/medicamento/ivonescimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ivonescimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/metronidazole 2026-05-19 weekly 0.7 https://crcwarriors.org/medicamento/metronidazole/ensayos 2026-05-19 weekly 0.6 https://crcwarriors.org/medicamento/raltitrexed 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/raltitrexed/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/pertuzumab 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/pertuzumab/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/ramucirumab 2026-07-24 weekly 0.7 https://crcwarriors.org/medicamento/ramucirumab/ensayos 2026-07-24 weekly 0.6 https://crcwarriors.org/medicamento/ribociclib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/ribociclib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/amg 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/amg/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/ql1706 2026-07-28 weekly 0.7 https://crcwarriors.org/medicamento/ql1706/ensayos 2026-07-28 weekly 0.6 https://crcwarriors.org/medicamento/sirolimus 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/sirolimus/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/envafolimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/envafolimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/sotorasib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/sotorasib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/selumetinib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/selumetinib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/letrozole 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/letrozole/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/dabrafenib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/dabrafenib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/sunitinib 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/sunitinib/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/tas 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/tas/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/ak112 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/ak112/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/lenvatinib 2026-07-08 weekly 0.7 https://crcwarriors.org/medicamento/lenvatinib/ensayos 2026-07-08 weekly 0.6 https://crcwarriors.org/medicamento/hydroxychloroquine 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/hydroxychloroquine/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/osimertinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/osimertinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/gefitinib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/gefitinib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/bortezomib 2026-05-06 weekly 0.7 https://crcwarriors.org/medicamento/bortezomib/ensayos 2026-05-06 weekly 0.6 https://crcwarriors.org/medicamento/lapatinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/lapatinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/axitinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/axitinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/filgrastim 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/filgrastim/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/infliximab 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/infliximab/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/amivantamab 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/amivantamab/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/vandetanib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/vandetanib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/cediranib 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/cediranib/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/chidamide 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/chidamide/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/sulindac 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/sulindac/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/dasatinib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/dasatinib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/melphala 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/melphala/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/retifanlimab 2026-07-02 weekly 0.7 https://crcwarriors.org/medicamento/retifanlimab/ensayos 2026-07-02 weekly 0.6 https://crcwarriors.org/medicamento/vorinosta 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/vorinosta/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/vorinostat 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/vorinostat/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/melphalan 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/melphalan/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/midazolam 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/midazolam/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/iparomlimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/iparomlimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/afatinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/afatinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/tuvonralimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/tuvonralimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/cobimetinib 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/cobimetinib/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/doxorubicin 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/doxorubicin/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/indocyanine+green 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/indocyanine+green/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/tegafu 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/tegafu/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/sasanlimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/sasanlimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/temsirolimus 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/temsirolimus/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/zanidatamab 2026-06-09 weekly 0.7 https://crcwarriors.org/medicamento/zanidatamab/ensayos 2026-06-09 weekly 0.6 https://crcwarriors.org/medicamento/veliparib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/veliparib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/azacitidine 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/azacitidine/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/tegafur 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/tegafur/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/chemo 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/chemo/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/enzalutamide 2026-06-03 weekly 0.7 https://crcwarriors.org/medicamento/enzalutamide/ensayos 2026-06-03 weekly 0.6 https://crcwarriors.org/medicamento/pumitamig 2026-07-02 weekly 0.7 https://crcwarriors.org/medicamento/pumitamig/ensayos 2026-07-02 weekly 0.6 https://crcwarriors.org/medicamento/other 2026-05-16 weekly 0.7 https://crcwarriors.org/medicamento/other/ensayos 2026-05-16 weekly 0.6 https://crcwarriors.org/medicamento/g17dt 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/g17dt/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/eflornithine 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/eflornithine/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/decitabine 2026-07-10 weekly 0.7 https://crcwarriors.org/medicamento/decitabine/ensayos 2026-07-10 weekly 0.6 https://crcwarriors.org/medicamento/bkm120 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/bkm120/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/moviprep 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/moviprep/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/g17d 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/g17d/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/jab-21822 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/jab-21822/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/propofol 2026-08-01 weekly 0.7 https://crcwarriors.org/medicamento/propofol/ensayos 2026-08-01 weekly 0.6 https://crcwarriors.org/medicamento/trifluridine-tipiracil 2026-07-24 weekly 0.7 https://crcwarriors.org/medicamento/trifluridine-tipiracil/ensayos 2026-07-24 weekly 0.6 https://crcwarriors.org/medicamento/sol 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/sol/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/entinostat 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/entinostat/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/nw-301v 2026-06-19 weekly 0.7 https://crcwarriors.org/medicamento/nw-301v/ensayos 2026-06-19 weekly 0.6 https://crcwarriors.org/medicamento/adc 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/adc/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/pdr001 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/pdr001/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/tno155 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/tno155/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/hlx10 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/hlx10/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/pazopanib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/pazopanib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/t3011 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/t3011/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/anlotinib 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/anlotinib/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/hrs-4642 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/hrs-4642/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/nktr 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/nktr/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/omeprazole 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/omeprazole/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/rmc-6236 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/rmc-6236/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/crizotinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/crizotinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/dexmedetomidine 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/dexmedetomidine/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/tocilizumab 2026-05-19 weekly 0.7 https://crcwarriors.org/medicamento/tocilizumab/ensayos 2026-05-19 weekly 0.6 https://crcwarriors.org/medicamento/fianlimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/fianlimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/etrumadenant 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/etrumadenant/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/ropivacaine 2026-06-05 weekly 0.7 https://crcwarriors.org/medicamento/ropivacaine/ensayos 2026-06-05 weekly 0.6 https://crcwarriors.org/medicamento/ts-1 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/ts-1/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/shr-8068 2026-04-02 weekly 0.7 https://crcwarriors.org/medicamento/shr-8068/ensayos 2026-04-02 weekly 0.6 https://crcwarriors.org/medicamento/nintedanib 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/nintedanib/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/lenalidomide 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/lenalidomide/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/methotrexate 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/methotrexate/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/prednisone 2026-08-06 weekly 0.7 https://crcwarriors.org/medicamento/prednisone/ensayos 2026-08-06 weekly 0.6 https://crcwarriors.org/medicamento/itraconazole 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/itraconazole/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/sym004 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/sym004/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/penpulimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/penpulimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/ruxolitinib 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/ruxolitinib/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/lorigerlimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/lorigerlimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/spartalizumab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/spartalizumab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/nw-301d 2026-06-19 weekly 0.7 https://crcwarriors.org/medicamento/nw-301d/ensayos 2026-06-19 weekly 0.6 https://crcwarriors.org/medicamento/riluzole 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/riluzole/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/tiragolumab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/tiragolumab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/pegfilgrastim 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/pegfilgrastim/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/saline 2026-06-05 weekly 0.7 https://crcwarriors.org/medicamento/saline/ensayos 2026-06-05 weekly 0.6 https://crcwarriors.org/medicamento/nktr- 2026-05-16 weekly 0.7 https://crcwarriors.org/medicamento/nktr-/ensayos 2026-05-16 weekly 0.6 https://crcwarriors.org/medicamento/sevoflurane 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/sevoflurane/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/daraxonrasib 2026-06-18 weekly 0.7 https://crcwarriors.org/medicamento/daraxonrasib/ensayos 2026-06-18 weekly 0.6 https://crcwarriors.org/medicamento/epacadostat 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/epacadostat/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/imatinib 2026-05-27 weekly 0.7 https://crcwarriors.org/medicamento/imatinib/ensayos 2026-05-27 weekly 0.6 https://crcwarriors.org/medicamento/tivozanib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/tivozanib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/shr-a1811 2026-07-01 weekly 0.7 https://crcwarriors.org/medicamento/shr-a1811/ensayos 2026-07-01 weekly 0.6 https://crcwarriors.org/medicamento/sgm-101 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/sgm-101/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/bbi608 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/bbi608/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/bi-1701963 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/bi-1701963/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/bp102 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/bp102/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/pf-07220060 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/pf-07220060/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/imiquimod 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/imiquimod/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/naliri 2026-06-03 weekly 0.7 https://crcwarriors.org/medicamento/naliri/ensayos 2026-06-03 weekly 0.6 https://crcwarriors.org/medicamento/abbv-400 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/abbv-400/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/hmn14 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/hmn14/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/allostim 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/allostim/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/neratinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/neratinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/bibf 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/bibf/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/radiotherapy 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/radiotherapy/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/inavolisib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/inavolisib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/ganitumab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ganitumab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/e7386 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/e7386/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/semaxanib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/semaxanib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/ibi363 2026-07-28 weekly 0.7 https://crcwarriors.org/medicamento/ibi363/ensayos 2026-07-28 weekly 0.6 https://crcwarriors.org/medicamento/osi-906 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/osi-906/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/rmc-9805 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/rmc-9805/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/etbx-011 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/etbx-011/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/bupivacain 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/bupivacain/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/hdm201 2026-06-03 weekly 0.7 https://crcwarriors.org/medicamento/hdm201/ensayos 2026-06-03 weekly 0.6 https://crcwarriors.org/medicamento/thymalfasin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/thymalfasin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/hs-20093 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/hs-20093/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/tucidinosta 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/tucidinosta/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/indomethacin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/indomethacin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/tucidinostat 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/tucidinostat/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/doxycycline 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/doxycycline/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/enadenotucirev 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/enadenotucirev/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/regn7075 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/regn7075/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/defactinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/defactinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/romidepsi 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/romidepsi/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/calderasib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/calderasib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/amg-655 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/amg-655/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/mk-2206 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/mk-2206/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/eniluracil 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/eniluracil/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/vedolizumab 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/vedolizumab/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/indomethaci 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/indomethaci/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/fleet 2026-07-11 weekly 0.7 https://crcwarriors.org/medicamento/fleet/ensayos 2026-07-11 weekly 0.6 https://crcwarriors.org/medicamento/nilotinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/nilotinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/plenvu 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/plenvu/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/pucotenlimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/pucotenlimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/rosuvastati 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/rosuvastati/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/selpercatinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/selpercatinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/romidepsin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/romidepsin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/gvax 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/gvax/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/panobinosta 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/panobinosta/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/mangafodipir 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/mangafodipir/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/relatlimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/relatlimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/m9140 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/m9140/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/mcla-129 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/mcla-129/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/flucytosine 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/flucytosine/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/thymalfasi 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/thymalfasi/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/talazoparib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/talazoparib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/etrolizumab 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/etrolizumab/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/nimotuzumab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/nimotuzumab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/cs-1008 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/cs-1008/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/dalotuzumab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/dalotuzumab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/selinexo 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/selinexo/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/ulixertinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/ulixertinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/vismodegib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/vismodegib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/zanzalintinib 2026-07-02 weekly 0.7 https://crcwarriors.org/medicamento/zanzalintinib/ensayos 2026-07-02 weekly 0.6 https://crcwarriors.org/medicamento/zimberelimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/zimberelimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/egfr 2026-05-16 weekly 0.7 https://crcwarriors.org/medicamento/egfr/ensayos 2026-05-16 weekly 0.6 https://crcwarriors.org/medicamento/selinexor 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/selinexor/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/amg-479 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/amg-479/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/niraparib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/niraparib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/incb001158 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/incb001158/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/gv20-0251 2026-06-04 weekly 0.7 https://crcwarriors.org/medicamento/gv20-0251/ensayos 2026-06-04 weekly 0.6 https://crcwarriors.org/medicamento/bibf-1120 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/bibf-1120/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/n-803 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/n-803/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/e7820 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/e7820/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/abx-egf 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/abx-egf/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/onvansertib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/onvansertib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/pd-0325901 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/pd-0325901/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/chemoradiotherapy 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/chemoradiotherapy/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/brivanib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/brivanib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/sg001 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/sg001/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/cyclosporine 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/cyclosporine/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/rosuvastatin 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/rosuvastatin/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/ner1006 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/ner1006/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/alectinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/alectinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/panobinostat 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/panobinostat/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/mangafodipi 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/mangafodipi/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/hs-10370 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/hs-10370/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/mw4911 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/mw4911/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/neomyci 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/neomyci/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/maraviroc 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/maraviroc/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/eribulin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/eribulin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/magrolimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/magrolimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/bbo-10203 2026-06-03 weekly 0.7 https://crcwarriors.org/medicamento/bbo-10203/ensayos 2026-06-03 weekly 0.6 https://crcwarriors.org/medicamento/rnk08954 2026-06-19 weekly 0.7 https://crcwarriors.org/medicamento/rnk08954/ensayos 2026-06-19 weekly 0.6 https://crcwarriors.org/medicamento/ci-1040 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ci-1040/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/nis793 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/nis793/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/cv301 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/cv301/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/ivosidenib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/ivosidenib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/imc-a12 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/imc-a12/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/tinzaparin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/tinzaparin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/napabucasi 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/napabucasi/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/hs-10502 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/hs-10502/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/rimiducid 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/rimiducid/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/pralsetinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/pralsetinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/calmangafodipir 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/calmangafodipir/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/gdc-1971 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/gdc-1971/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/reolysi 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/reolysi/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/st316 2026-07-30 weekly 0.7 https://crcwarriors.org/medicamento/st316/ensayos 2026-07-30 weekly 0.6 https://crcwarriors.org/medicamento/conatumumab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/conatumumab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/s-531011 2026-07-23 weekly 0.7 https://crcwarriors.org/medicamento/s-531011/ensayos 2026-07-23 weekly 0.6 https://crcwarriors.org/medicamento/ceralasertib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/ceralasertib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/masitinib 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/masitinib/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/d-1553 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/d-1553/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/rec-4881 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/rec-4881/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/budigalimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/budigalimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/bms-986340 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/bms-986340/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/inc280 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/inc280/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/kd018 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/kd018/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/arfolitixorin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/arfolitixorin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/sgn1 2026-06-19 weekly 0.7 https://crcwarriors.org/medicamento/sgn1/ensayos 2026-06-19 weekly 0.6 https://crcwarriors.org/medicamento/ca102n 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ca102n/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/udenafil 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/udenafil/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/volrustomig 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/volrustomig/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/foxy-5 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/foxy-5/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/cmab009 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/cmab009/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/anastrozole 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/anastrozole/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/amt2003 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/amt2003/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/exemestane 2026-06-18 weekly 0.7 https://crcwarriors.org/medicamento/exemestane/ensayos 2026-06-18 weekly 0.6 https://crcwarriors.org/medicamento/alt-803 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/alt-803/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/imlunestrant 2026-06-19 weekly 0.7 https://crcwarriors.org/medicamento/imlunestrant/ensayos 2026-06-19 weekly 0.6 https://crcwarriors.org/medicamento/pro95780 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/pro95780/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/azd5305 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/azd5305/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/ak119 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/ak119/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/e7070 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/e7070/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/elimusertib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/elimusertib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/bevacizumab-irdye800cw 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/bevacizumab-irdye800cw/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/pirfenidone 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/pirfenidone/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/enzastaurin 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/enzastaurin/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/nv1020 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/nv1020/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/entrectinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/entrectinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/bibw-2992 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/bibw-2992/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/erdafitinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/erdafitinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/ssgj-612 2026-06-19 weekly 0.7 https://crcwarriors.org/medicamento/ssgj-612/ensayos 2026-06-19 weekly 0.6 https://crcwarriors.org/medicamento/dovitinib 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/dovitinib/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/enoxaparin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/enoxaparin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/denosumab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/denosumab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/vatalanib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/vatalanib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/fmt 2026-05-27 weekly 0.7 https://crcwarriors.org/medicamento/fmt/ensayos 2026-05-27 weekly 0.6 https://crcwarriors.org/medicamento/floxuridine 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/floxuridine/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/rivaroxaba 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/rivaroxaba/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/xilonix 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/xilonix/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/artesunate 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/artesunate/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/bms-986016 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/bms-986016/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/bli850 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/bli850/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/hs-20117 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/hs-20117/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/hlx208 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/hlx208/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/nns309 2026-06-06 weekly 0.7 https://crcwarriors.org/medicamento/nns309/ensayos 2026-06-06 weekly 0.6 https://crcwarriors.org/medicamento/fluzoparib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/fluzoparib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/capivasertib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/capivasertib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/copanlisib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/copanlisib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/rezatapop 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/rezatapop/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/leflunomide 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/leflunomide/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/ipatasertib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/ipatasertib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/camizestrant 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/camizestrant/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/larotrectinib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/larotrectinib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/dato-dxd 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/dato-dxd/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/rmc-4630 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/rmc-4630/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/bi-765049 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/bi-765049/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/dulanermin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/dulanermin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/cannabidiol 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/cannabidiol/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/ridaforolimus 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/ridaforolimus/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/ga-nns309 2026-06-06 weekly 0.7 https://crcwarriors.org/medicamento/ga-nns309/ensayos 2026-06-06 weekly 0.6 https://crcwarriors.org/medicamento/naproxen 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/naproxen/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/lubiprostone 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/lubiprostone/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/neomycin 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/neomycin/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/nalirifox 2026-06-03 weekly 0.7 https://crcwarriors.org/medicamento/nalirifox/ensayos 2026-06-03 weekly 0.6 https://crcwarriors.org/medicamento/bupivacaine 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/bupivacaine/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/ufox 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/ufox/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/mrg007 2026-07-31 weekly 0.7 https://crcwarriors.org/medicamento/mrg007/ensayos 2026-07-31 weekly 0.6 https://crcwarriors.org/medicamento/dsp107 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/dsp107/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/gi-4000 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/gi-4000/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/oleclumab 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/oleclumab/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/trk-950 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/trk-950/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/hua33 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/hua33/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/bisacodyl 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/bisacodyl/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/hf50 2026-06-19 weekly 0.7 https://crcwarriors.org/medicamento/hf50/ensayos 2026-06-19 weekly 0.6 https://crcwarriors.org/medicamento/jab-3312 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/jab-3312/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/bgb-43395 2026-06-19 weekly 0.7 https://crcwarriors.org/medicamento/bgb-43395/ensayos 2026-06-19 weekly 0.6 https://crcwarriors.org/medicamento/cb-839 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/cb-839/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/pm8002 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/pm8002/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/pemigatinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/pemigatinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/gastrografin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/gastrografin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/plerixafo 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/plerixafo/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/sgi-110 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/sgi-110/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/citrafleet 2026-07-11 weekly 0.7 https://crcwarriors.org/medicamento/citrafleet/ensayos 2026-07-11 weekly 0.6 https://crcwarriors.org/medicamento/mm-151 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/mm-151/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/carmustine 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/carmustine/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/abiraterone 2026-06-03 weekly 0.7 https://crcwarriors.org/medicamento/abiraterone/ensayos 2026-06-03 weekly 0.6 https://crcwarriors.org/medicamento/ompenaclid 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ompenaclid/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/mm-398 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/mm-398/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/rivaroxaban 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/rivaroxaban/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/js207 2026-05-06 weekly 0.7 https://crcwarriors.org/medicamento/js207/ensayos 2026-05-06 weekly 0.6 https://crcwarriors.org/medicamento/thalidomide 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/thalidomide/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/il2 2026-05-06 weekly 0.7 https://crcwarriors.org/medicamento/il2/ensayos 2026-05-06 weekly 0.6 https://crcwarriors.org/medicamento/hsk42360 2026-06-19 weekly 0.7 https://crcwarriors.org/medicamento/hsk42360/ensayos 2026-06-19 weekly 0.6 https://crcwarriors.org/medicamento/silymarin 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/silymarin/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/desflurane 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/desflurane/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/rapamyci 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/rapamyci/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/utidelone 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/utidelone/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/loperamide 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/loperamide/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/gh21 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/gh21/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/si-b003 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/si-b003/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/etbx-051 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/etbx-051/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/can04 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/can04/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/etbx-061 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/etbx-061/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/gi-6301 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/gi-6301/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/grt-c901 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/grt-c901/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/grt-r902 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/grt-r902/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/nc410 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/nc410/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/a166 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/a166/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/rifaximi 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/rifaximi/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/ly3214996 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/ly3214996/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/rapamycin 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/rapamycin/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/avzo-021 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/avzo-021/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/famitinib 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/famitinib/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/bmx-001 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/bmx-001/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/shr-1701 2026-04-02 weekly 0.7 https://crcwarriors.org/medicamento/shr-1701/ensayos 2026-04-02 weekly 0.6 https://crcwarriors.org/medicamento/prexasertib 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/prexasertib/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/tovorafenib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/tovorafenib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/flox 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/flox/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/sph5030 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/sph5030/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/plerixafor 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/plerixafor/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/simvastatin 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/simvastatin/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/resveratrol 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/resveratrol/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/cm-24 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/cm-24/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/cp-675 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/cp-675/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/g-csf 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/g-csf/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/gemnabp 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/gemnabp/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/rezatapopt 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/rezatapopt/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/ono-4578 2026-04-18 weekly 0.7 https://crcwarriors.org/medicamento/ono-4578/ensayos 2026-04-18 weekly 0.6 https://crcwarriors.org/medicamento/piritramid 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/piritramid/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/mm-121 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/mm-121/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/curcumin 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/curcumin/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/savolitinib 2026-07-07 weekly 0.7 https://crcwarriors.org/medicamento/savolitinib/ensayos 2026-07-07 weekly 0.6 https://crcwarriors.org/medicamento/bms-986504 2026-06-19 weekly 0.7 https://crcwarriors.org/medicamento/bms-986504/ensayos 2026-06-19 weekly 0.6 https://crcwarriors.org/medicamento/dtx 2026-03-29 weekly 0.7 https://crcwarriors.org/medicamento/dtx/ensayos 2026-03-29 weekly 0.6 https://crcwarriors.org/medicamento/pds0101 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/pds0101/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/acetaminophen 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/acetaminophen/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/m7824 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/m7824/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/silymari 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/silymari/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/simvastati 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/simvastati/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/golytely 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/golytely/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/bl-b01d1 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/bl-b01d1/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/byl719 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/byl719/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/aipalolitovorelizumab 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/aipalolitovorelizumab/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/mgd007 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/mgd007/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/vactosertib 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/vactosertib/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/sym021 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/sym021/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/xl092 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/xl092/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/adalimumab 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/adalimumab/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/incb106385 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/incb106385/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/interferon 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/interferon/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/ly3023414 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/ly3023414/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/tegavivint 2026-04-24 weekly 0.7 https://crcwarriors.org/medicamento/tegavivint/ensayos 2026-04-24 weekly 0.6 https://crcwarriors.org/medicamento/rp2 2026-05-27 weekly 0.7 https://crcwarriors.org/medicamento/rp2/ensayos 2026-05-27 weekly 0.6 https://crcwarriors.org/medicamento/levoleucovori 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/levoleucovori/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/mesalamine 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/mesalamine/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/tg6002 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/tg6002/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/jab-23e73 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/jab-23e73/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/yl-17231 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/yl-17231/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/alpelisib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/alpelisib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/ropidoxuridine 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ropidoxuridine/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/citraflee 2026-07-11 weekly 0.7 https://crcwarriors.org/medicamento/citraflee/ensayos 2026-07-11 weekly 0.6 https://crcwarriors.org/medicamento/cyad-101 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/cyad-101/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/glutamine 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/glutamine/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/kqb198 2026-05-27 weekly 0.7 https://crcwarriors.org/medicamento/kqb198/ensayos 2026-05-27 weekly 0.6 https://crcwarriors.org/medicamento/lazertinib 2026-06-18 weekly 0.7 https://crcwarriors.org/medicamento/lazertinib/ensayos 2026-06-18 weekly 0.6 https://crcwarriors.org/medicamento/ezabenlimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ezabenlimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/ngm438 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ngm438/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/isis 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/isis/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/vs-7375 2026-06-23 weekly 0.7 https://crcwarriors.org/medicamento/vs-7375/ensayos 2026-06-23 weekly 0.6 https://crcwarriors.org/medicamento/epinephrine 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/epinephrine/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/propranolol 2026-05-01 weekly 0.7 https://crcwarriors.org/medicamento/propranolol/ensayos 2026-05-01 weekly 0.6 https://crcwarriors.org/medicamento/naproxe 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/naproxe/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/nsaid 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/nsaid/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/sc-201 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/sc-201/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/tegavivi 2026-03-29 weekly 0.7 https://crcwarriors.org/medicamento/tegavivi/ensayos 2026-03-29 weekly 0.6 https://crcwarriors.org/medicamento/ethynyluracil 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/ethynyluracil/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/gsk5764227 2026-08-04 weekly 0.7 https://crcwarriors.org/medicamento/gsk5764227/ensayos 2026-08-04 weekly 0.6 https://crcwarriors.org/medicamento/avx701 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/avx701/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/tinzapari 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/tinzapari/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/hmbd-001 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/hmbd-001/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/surufatinib 2026-05-19 weekly 0.7 https://crcwarriors.org/medicamento/surufatinib/ensayos 2026-05-19 weekly 0.6 https://crcwarriors.org/medicamento/ixabepilone 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ixabepilone/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/selenium 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/selenium/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/hlx07 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/hlx07/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/jdq443 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/jdq443/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/tazemetostat 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/tazemetostat/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/pds01adc 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/pds01adc/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/krn330 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/krn330/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/inca33890 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/inca33890/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/ensartinib 2026-06-18 weekly 0.7 https://crcwarriors.org/medicamento/ensartinib/ensayos 2026-06-18 weekly 0.6 https://crcwarriors.org/medicamento/rmc-6291 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/rmc-6291/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/levoleucovorin 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/levoleucovorin/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/pf-07799933 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/pf-07799933/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/rifaximin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/rifaximin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/jx-594 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/jx-594/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/reolysin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/reolysin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/tas-102 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/tas-102/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/star0602 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/star0602/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/ferumoxytol 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ferumoxytol/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/jmt101 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/jmt101/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/bl-m17d1 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/bl-m17d1/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/b1962 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/b1962/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/cibisatamab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/cibisatamab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/elironrasib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/elironrasib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/obinutuzumab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/obinutuzumab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/regimen/folfox 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/folfiri 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/capox 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/folfoxiri 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/folfox-bevacizumab 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/folfiri-bevacizumab 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/folfiri-cetuximab 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/folfiri-panitumumab 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/folfoxiri-bevacizumab 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/capecitabine-mono 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/pembrolizumab-mono 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/encorafenib-cetuximab 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/trastuzumab-pertuzumab 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/trifluridine-tipiracil 2026-02-13 monthly 0.8 https://crcwarriors.org/articulo/2850/aspirina-para-la-prevencion-del-cancer-en-individuos-con-sindrome-de-lynch-primeros-resultados-del-ensayo-multicentrico-aleatorizado-doble-ciego-de-no-inferioridad-capp3 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2850/aspirin-for-cancer-prevention-in-individuals-with-lynch-syndrome-first-results-from-the-capp3-multicentre-randomised-double-blind-non-inferiority-trial 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2828/efectos-antitumorales-de-las-celulas-car-nk92mi-dirigidas-contra-cd133-en-el-cancer-colorrectal 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2828/anti-tumor-effects-of-cd133-targeted-car-nk92mi-cells-in-colorectal-cancer 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2826/estrategias-de-administracion-de-virus-oncoliticos-en-los-canceres-gastrointestinales-avances-mecanismos-y-traslacion-clinica 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2826/delivery-strategies-for-oncolytic-viruses-in-gastrointestinal-cancers-progress-mechanisms-and-clinical-translations 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2810/arid1a-regula-la-metastasis-del-cancer-colorrectal-a-traves-de-la-via-akt-mtor-p70s6k 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2810/arid1a-regulates-colorectal-cancer-metastasis-through-the-akt-mtor-p70s6k-pathway 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2802/factores-pronosticos-en-el-borde-de-invasion-y-en-el-area-peritumoral-del-cancer-colorrectal-perspectivas-actuales-y-consideraciones-futuras 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2802/invasive-front-and-peritumoral-prognostic-factors-in-colorectal-cancer-current-perspectives-and-future-considerations 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2783/dependencia-de-la-enzima-tipo-furina-en-el-cancer-colorrectal-con-mutacion-en-kras-como-diana-para-estrategias-de-tratamiento-personalizadas 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2783/furin-like-enzyme-dependency-in-kras-mutant-colorectal-cancer-as-a-target-for-personalized-treatment-strategies 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2687/dirigirse-a-lig1-para-superar-la-resistencia-al-oxaliplatino-mediante-la-induccion-de-la-panoptosis-en-el-cancer-colorrectal 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2687/targeting-lig1-to-overcome-oxaliplatin-resistance-by-inducing-panoptosis-in-colorectal-cancer 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2686/analisis-del-microambiente-inmunosupresor-en-el-cancer-colorrectal-resistente-a-la-quimioterapia-mediante-el-analisis-transcriptomico-de-celulas-individuales 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2686/dissecting-immunosuppressive-microenvironment-in-chemotherapy-resistant-colorectal-cancer-through-single-cell-transcriptomic-analysis 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2504/quien-rechaza-el-asesoramiento-genetico-evaluacion-del-rechazo-al-asesoramiento-genetico-entre-los-participantes-en-un-programa-de-cribado-genomico-a-nivel-poblacional 2026-08-03 monthly 0.5 https://crcwarriors.org/articulo/2504/who-declines-genetic-counseling-an-assessment-of-genetic-counseling-declination-among-individuals-participating-in-a-population-wide-genomic-screening-program 2026-08-03 monthly 0.5 https://crcwarriors.org/articulo/2483/identificacion-sistematica-de-biomarcadores-genomicos-de-falta-de-respuesta-a-los-tratamientos-contra-el-cancer 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2483/systematic-identification-of-genomic-nonresponse-biomarkers-to-cancer-therapies 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2479/mecanismos-y-avances-en-la-resistencia-a-los-farmacos-en-el-cancer-colorrectal-una-revision-sistematica-de-las-redes-reguladoras-multicapa 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2479/mechanisms-and-advances-of-drug-resistance-in-colorectal-cancer-a-systematic-overview-of-multi-layered-regulatory-networks 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2476/mecanismos-y-desafios-clinicos-de-la-remodelacion-del-microambiente-tumoral-mediada-por-la-inmunoterapia-con-inhibidores-de-puntos-de-control-en-el-carcinoma-nasofaringeo 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2476/mechanisms-and-clinical-challenges-of-icb-mediated-remodeling-of-the-tumor-microenvironment-in-nasopharyngeal-carcinoma 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2429/redes-regulatorias-multidimensionales-de-la-resistencia-a-los-farmacos-en-el-cancer-colorrectal-desde-los-mecanismos-moleculares-hasta-nuevas-estrategias-terapeuticas 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2429/multidimensional-regulatory-networks-of-drug-resistance-in-colorectal-cancer-from-molecular-mechanisms-to-novel-therapeutic-counterstrategies 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2415/adcs-para-el-carcinoma-colorrectal-analisis-de-la-evidencia-clinica-para-la-innovacion-en-el-diseno-molecular 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2415/adcs-for-colorectal-carcinoma-decoding-clinical-evidence-for-molecular-design-innovation 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2317/alteraciones-especificas-del-subtipo-en-el-transporte-de-cobre-asociadas-con-las-mutaciones-de-kras-en-lineas-celulares-isogenicas-de-cancer-colorrectal 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2317/subtype-specific-alterations-in-copper-trafficking-associated-with-kras-mutations-in-isogenic-colorectal-cancer-cell-lines 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2303/sintesis-y-evaluacion-preclinica-de-89-zr-dfo-atezolizumab-para-la-imagen-pet-inmunitaria-en-el-cancer-colorrectal 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2303/synthesis-and-preclinical-evaluation-of-89-zr-dfo-atezolizumab-for-immuno-pet-imaging-in-colorectal-cancer 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2237/la-arn-polimerasa-i-endotelial-que-esta-regulada-por-spen-es-un-objetivo-para-mejorar-la-inmunoterapia-anti-pd-1-en-el-tratamiento-del-cancer 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2237/endothelial-rna-polymerase-i-which-is-regulated-by-spen-is-a-target-for-improving-anti-pd-1-immunotherapy-of-cancer 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2130/evaluaciones-endoscopicas-y-radiologicas-de-la-inmunoterapia-neoadyuvante-en-pacientes-con-cancer-colorrectal-localmente-avanzado-con-dmmr-msi-h-o-mutacion-en-los-genes-pole-pold1 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2130/endoscopic-and-imaging-evaluations-of-neoadjuvant-immunotherapy-in-patients-with-locally-advanced-colorectal-cancer-with-dmmr-msi-h-or-pole-pold1-mutation 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/1783/virus-oncoliticos-recubiertos-basados-en-una-estrategia-de-doble-ataque-que-desencadena-la-terapia-car-t-dirigida-a-cd19-en-tumores-gastrointestinales 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/1783/coated-oncolytic-viruses-based-double-strike-strategy-triggering-cd19-car-t-therapy-in-gastrointestinal-tumors 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2861/modulacion-de-la-microbiota-intestinal-en-los-canceres-gastrointestinales-desde-las-caracteristicas-de-la-disbiosis-hasta-las-intervenciones-terapeuticas 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2861/gut-microbiota-modulation-of-gastrointestinal-cancers-from-dysbiosis-signatures-to-therapeutic-interventions 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2859/relacion-entre-los-sitios-de-mutacion-del-gen-kras-y-las-caracteristicas-clinicas-en-el-cancer-colorrectal 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2859/relationship-between-kras-gene-mutation-sites-and-clinical-characteristics-in-colorectal-cancer 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2858/panorama-genomico-e-implicaciones-terapeuticas-del-cancer-colorrectal-con-fusion-de-alk 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2858/genomic-landscape-and-therapeutic-implications-of-alk-fusion-positive-colorectal-cancer 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2857/predictores-genomicos-transcriptomicos-y-moleculares-de-la-respuesta-a-la-terapia-neoadyuvante-en-el-cancer-colorrectal-localmente-avanzado-una-revision-narrativa 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2857/genomic-transcriptomic-and-molecular-predictors-of-response-to-neoadjuvant-therapy-in-locally-advanced-rectal-cancer-a-narrative-review 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2852/un-modelo-de-radiomica-predice-la-eficacia-de-un-inhibidor-de-cdk4-6-en-primera-linea-combinado-con-terapia-endocrina-en-el-cancer-de-mama-avanzado-hr-her2 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2852/radiomics-model-predicts-efficacy-of-first-line-cdk4-6-inhibitor-combined-with-endocrine-therapy-in-hr-her2-advanced-breast-cancer 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2851/un-ensayo-de-fase-ii-de-un-solo-brazo-para-evaluar-la-reintroduccion-de-irinotecan-a-dosis-altas-guiada-por-el-genotipo-ugt1a1-en-pacientes-con-cancer-colorrectal-metastasico-refractario 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2851/a-single-arm-phase-ii-trial-of-ugt1a1-genotype-guided-high-dose-irinotecan-rechallenge-in-refractory-metastatic-colorectal-cancer 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2849/dirigirse-a-la-enfermedad-residual-molecular-y-a-la-evasion-inmune-en-la-recurrencia-del-cancer-colorrectal-inmunoterapia-y-terapias-celulares-guiadas-por-biomarcadores 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2849/targeting-molecular-residual-disease-and-immune-escape-in-colorectal-cancer-recurrence-biomarker-guided-immunotherapy-and-cell-therapies 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2847/fototerapia-inmunoterapia-del-carcinoma-de-colon-mediante-un-complejo-de-nanoparticulas-de-carbono-y-fe-ii-con-un-inmunoadyuvante 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2847/photothermal-immunotherapy-of-colon-carcinoma-by-carbon-nanoparticle-fe-ii-complex-with-immunoadjuvant 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2846/prediccion-multimodelo-del-pronostico-especifico-por-estadio-del-cancer-colorrectal-mediante-el-aprendizaje-profundo-en-conjunto-basado-en-la-atencion-aplicado-a-datos-de-perfiles-genomicos 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2846/a-multi-model-prediction-of-a-stage-specific-prognosis-for-colorectal-cancer-using-attention-driven-deep-ensemble-learning-on-genomic-profiling-data 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2845/descubrimiento-de-derivados-de-hidrazona-como-nuevos-antagonistas-de-stat3-para-el-tratamiento-del-cancer-de-pancreas-y-de-colon 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2845/discovery-of-hydrazone-derivatives-as-novel-stat3-antagonists-against-pancreatic-and-colorectal-cancers 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2840/linfoma-de-hodgkin-clasico-una-revision 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2840/classic-hodgkin-lymphoma-a-review 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2839/adicion-de-altas-dosis-de-vitamina-d3-al-tratamiento-estandar-en-pacientes-con-cancer-colorrectal-metastasico-el-ensayo-clinico-aleatorizado-solaris-alliance-a021703 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2839/addition-of-high-dose-vitamin-d3-to-standard-treatment-in-patients-with-metastatic-colorectal-cancer-the-solaris-randomized-clinical-trial-alliance-a021703 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2838/el-analisis-especifico-de-variantes-del-fenomeno-de-exclusion-mutua-entre-los-oncogenes-braf-egfr-y-kras-revela-una-superposicion-con-pares-de-mutantes-funcionalmente-antagonicos 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2838/variant-specific-landscape-of-mutual-exclusivity-among-braf-egfr-and-kras-oncogenes-reveals-overlap-with-functionally-antagonistic-mutant-pairs 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2835/el-foretinib-induce-la-muerte-celular-inmunogenica-y-potencia-la-eficacia-de-la-inmunoterapia-anti-cd47-en-el-cancer-colorrectal 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2835/foretinib-triggers-immunogenic-cell-death-and-enhances-efficacy-of-anti-cd47-immunotherapy-in-colorectal-cancer 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2834/asociacion-de-los-macrofagos-intratumorales-cd68-cd163-de-tipo-m2-con-la-supervivencia-en-el-cancer-colorrectal-metastasico-tratado-con-quimioterapia-mas-bevacizumab 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2834/association-of-intratumoral-cd68-cd163-m2-like-macrophages-with-survival-in-metastatic-colorectal-cancer-treated-with-chemotherapy-plus-bevacizumab 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2833/nanoformulaciones-de-resveratrol-para-el-tratamiento-del-cancer-una-revision-exhaustiva-de-las-estrategias-especificas-para-cada-enfermedad-y-las-barreras-clinicas-y-traslacionales 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2833/resveratrol-nanoformulations-for-cancer-management-a-comprehensive-review-of-disease-specific-strategies-and-clinical-translational-barriers 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2829/la-optimizacion-del-proceso-de-fabricacion-y-de-la-superficie-electrostatica-de-las-celulas-car-t-mejora-la-eficacia-terapeutica-en-las-neoplasias-hepaticas 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2829/manufacturing-and-electrostatic-surface-optimization-of-car-t-cells-improve-therapeutic-efficacy-in-liver-malignancies 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2825/organizacion-europea-para-la-prevencion-del-cancer-sobre-la-deteccion-precoz-del-cancer-un-documento-de-posicion-elaborado-por-un-panel-de-expertos 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2825/european-cancer-prevention-organization-on-cancer-screening-an-expert-panel-position-paper 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2824/perfil-genomico-y-caracteristicas-clinicas-de-los-canceres-colorrectales-con-mutaciones-en-erbb2-her2 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2824/genomic-landscape-and-clinical-characteristics-of-erbb2-her2-mutated-colorectal-cancers 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2823/respuesta-prolongada-a-la-inhibicion-combinada-de-braf-y-mek-en-cancer-colorrectal-con-mutacion-braf-un-caso-clinico 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2823/prolonged-response-to-combined-braf-and-mek-inhibition-in-braf-mutant-colorectal-cancer-a-case-report 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2820/quimioterapia-neoadyuvante-y-bevacizumab-para-metastasis-peritoneales-de-cancer-colorrectal-resultados-clinicos-y-traslacionales-del-ensayo-de-fase-ii-bev-ip 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2820/neoadjuvant-chemotherapy-and-bevacizumab-for-colorectal-peritoneal-metastases-clinical-and-translational-outcomes-of-the-phase-ii-bev-ip-trial 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2819/administracion-de-sirna-mediante-coacervados-peptidicos-para-el-bloqueo-dual-de-pd-1-pd-l1-con-el-fin-de-mejorar-la-inmunoterapia-del-cancer-colorrectal 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2819/peptide-coacervate-mediated-sirna-delivery-for-dual-pd-1-pd-l1-blockade-to-enhance-colorectal-cancer-immunotherapy 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2818/evaluacion-del-rendimiento-de-un-ensayo-de-genotipado-de-regiones-criticas-basado-en-massarray-para-el-diagnostico-de-cancer-colorrectal-que-analiza-los-genes-kras-nras-braf-y-pik3ca-utilizando 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2818/performance-evaluation-of-a-colorectal-cancer-associated-massarray-based-hotspot-genotyping-assay-for-kras-nras-braf-and-pik3ca-using-solid-tumor-specimens 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2817/dependencias-distintas-de-erk-y-pi3k-median-una-respuesta-heterogenea-a-la-inhibicion-de-ras-on-en-el-cancer-colorrectal-con-mutacion-en-kras 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2817/distinct-erk-and-pi3k-dependencies-mediate-a-heterogeneous-response-to-ras-on-inhibition-in-kras-mutant-colorectal-cancer 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2809/diferencias-en-la-transcriptomica-espacial-de-los-patrones-de-crecimiento-histopatologico-en-metastasis-hepaticas-del-cancer-colorrectal 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2809/spatial-transcriptomics-differences-of-histopathological-growth-patterns-in-colorectal-cancer-liver-metastases 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2808/el-papel-multifacetico-de-socs3-en-el-cancer-colorrectal-mecanismos-moleculares-e-implicaciones-clinicas 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2808/the-multifaceted-role-of-socs3-in-colorectal-cancer-molecular-mechanisms-and-clinical-implications 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2807/commit-estudio-aleatorizado-de-mfolfox6-bevacizumab-atezolizumab-frente-a-atezolizumab-en-monoterapia-como-tratamiento-de-primera-linea-del-cancer-colorrectal-metastasico-con-deficiencia-en-la 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2807/commit-a-randomized-study-of-mfolfox6-bevacizumab-atezolizumab-or-atezolizumab-alone-as-first-line-treatment-of-deficient-dna-mismatch-repair-metastatic-colorectal-cancer 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2806/las-mutaciones-del-gen-kras-reprograman-las-modificaciones-m6a-del-arn-para-impulsar-la-evasion-inmunitaria-dependiente-de-cd73-en-el-cancer-colorrectal 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2806/kras-mutations-reprogram-rna-m6a-modifications-to-drive-cd73-dependent-immune-evasion-in-colorectal-cancer 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2804/afinacion-y-caracterizacion-de-la-maduracion-del-nuevo-anticuerpo-monoclonal-mab-pb-223-dirigido-contra-los-o-glicanos-especificos-del-cancer-que-terminan-en-2-6-acidos-sialicos 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2804/affinity-maturation-and-characterization-of-the-novel-monoclonal-antibody-mab-pb-223-targeting-cancer-specific-o-glycans-terminating-with-2-6-sialic-acids 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2803/comparacion-de-la-eficacia-y-la-seguridad-de-las-diferentes-opciones-de-tratamiento-en-tercera-linea-para-pacientes-con-cancer-colorrectal-metastasico-una-revision-sistematica-y-un-metaanalisis-de 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2803/comparing-the-effectiveness-and-safety-of-different-third-line-management-options-for-patients-with-metastatic-colorectal-cancer-a-systematic-review-and-reconstructed-individual-patient-data-meta 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2799/los-analisis-transcriptomicos-a-nivel-de-celula-unica-y-espacial-revelan-que-pigt-es-un-regulador-clave-del-remodelado-inmunometabolico-en-las-metastasis-hepaticas-del-cancer-colorrectal 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2799/single-cell-and-spatial-transcriptomic-landscapes-reveal-pigt-as-a-pivotal-regulator-of-immunometabolic-remodeling-in-colorectal-cancer-liver-metastasis 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2798/superar-la-resistencia-a-los-tratamientos-anti-egfr-mecanismos-de-resistencia-al-cetuximab-y-al-panitumumab-y-nuevas-estrategias-de-combinacion 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2798/overcoming-resistance-to-anti-egfr-therapies-mechanisms-of-cetuximab-and-panitumumab-resistance-and-emerging-combination-strategies 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2797/la-actividad-citolitica-inmune-se-correlaciona-con-las-alteraciones-del-microambiente-tumoral-en-el-cancer-colorrectal 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2797/immune-cytolytic-activity-correlates-with-tumor-microenvironmental-aberrations-in-colorectal-cancer 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2796/oncofertilidad-femenina-en-el-cancer-colorrectal-incertidumbres-reproductivas-y-posibles-beneficios-de-la-inmunoterapia 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2796/female-oncofertility-in-colorectal-cancer-reproductive-uncertainties-and-potential-benefits-of-immunotherapy 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2793/plasticidad-molecular-de-lama3-a-lo-largo-del-espectro-de-la-enfermedad-mecanismos-patogenicos-y-traslacion-clinica 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2793/molecular-plasticity-of-lama3-across-the-disease-spectrum-pathogenic-mechanisms-and-clinical-translation 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2792/analisis-de-la-incidencia-y-los-resultados-perioperatorios-de-las-reacciones-adversas-relacionadas-con-el-sistema-inmunitario-en-la-inmunoterapia-preoperatoria-para-el-cancer-colorrectal-basado-en 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2792/analysis-on-the-incidence-and-perioperative-outcomes-of-immune-related-adverse-events-in-preoperative-immunotherapy-for-colorectal-cancer-based-on-multicenter-real-world-data 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2791/informe-de-la-27-a-conferencia-anual-de-consenso-sobre-el-cancer-gastrointestinal-del-oeste-de-canada-dedicada-al-cancer-colorrectal-celebrada-en-calgary-alberta-los-dias-26-y-27-de-septiembre-de 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2791/report-from-the-27th-annual-western-canadian-gastrointestinal-cancer-consensus-conference-on-colorectal-cancer-calgary-alberta-26-27-september-2025-advances-in-colon-and-rectal-cancer 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2790/sobreexpresion-amplificacion-de-her2-en-el-cancer-colorrectal-la-heterogeneidad-espacial-intratumoral-como-factor-clave-de-la-discordancia-en-la-deteccion-y-la-respuesta-al-tratamiento 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2790/her2-overexpression-amplification-in-colorectal-cancer-spatial-intratumoral-heterogeneity-as-a-key-determinant-of-detection-discordance-and-therapy-response 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2789/avances-recientes-en-la-investigacion-clinica-y-de-biologia-molecular-sobre-las-lesiones-serriladas-rectales 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2789/recent-progress-in-clinical-and-molecular-biological-research-in-rectal-serrated-lesions 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2784/dirigirse-a-las-vias-moleculares-y-geneticas-que-impulsan-la-tumorigenesis-para-lograr-una-terapia-de-precision-en-el-cancer-colorrectal 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2784/targeting-molecular-and-genetic-pathways-driving-tumorigenesis-for-precision-therapy-in-colorectal-cancer 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2779/impacto-en-la-supervivencia-de-los-eventos-adversos-graves-relacionados-con-la-inmunoterapia-en-los-canceres-digestivos-con-deficiencia-en-la-reparacion-del-desajuste-y-alta-inestabilidad-de 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2779/impact-on-survival-of-severe-immuno-related-adverse-events-in-deficient-mismatch-repair-microsatellite-instable-high-digestive-cancers-treated-with-immunotherapy 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2774/las-celulas-t-derivadas-de-ipsc-alogenicas-demuestran-eficacia-antitumoral-frente-a-tejidos-derivados-de-pacientes 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2774/allogeneic-ipsc-derived-t-cells-demonstrate-antitumor-efficacy-against-patient-derived-tissues 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2773/un-nuevo-anticuerpo-monoclonal-anti-caderina-17-ca-17-mab-5-para-multiples-aplicaciones 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2773/a-novel-anti-cadherin-17-monoclonal-antibody-ca-17-mab-5-for-multiple-applications 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2771/inmunoterapia-en-el-cancer-colorrectal-asociado-a-la-deficiencia-constitucional-del-sistema-de-reparacion-de-errores-de-emparejamiento-cmmrd-en-pacientes-pediatricos-informe-de-un-caso-de-una 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2771/immunotherapy-in-pediatric-constitutional-mismatch-repair-deficiency-cmmrd-associated-colorectal-cancer-report-of-a-rare-variant-and-recommendations-for-screening 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2770/terapia-neoadyuvante-total-basada-en-radioterapia-de-corta-duracion-mas-tislelizumab-para-el-cancer-colorrectal-localmente-avanzado-neo-star-resultados-preliminares-de-un-ensayo-aleatorizado-de-fase 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2770/short-course-radiotherapy-based-total-neoadjuvant-therapy-plus-tislelizumab-for-locally-advanced-rectal-cancer-neo-star-early-outcomes-of-a-randomized-phase-ii-trial 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2768/copanlisib-en-combinacion-con-nivolumab-para-el-tratamiento-del-cancer-colorrectal-con-microsatelites-estables-un-ensayo-de-fase-1-2 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2768/copanlisib-in-combination-with-nivolumab-formicrosatellite-stable-colorectal-cancer-a-phase-1-2-trial 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2767/dhodh-es-un-objetivo-sintal-letal-en-el-cancer-colorrectal-con-mutacion-en-pik3ca 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2767/dhodh-is-a-synthetic-lethal-target-in-pik3ca-mutant-colorectal-cancer 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2766/panorama-genomico-y-molecular-del-cancer-colorrectal-de-inicio-temprano-nuevos-conocimientos-e-implicaciones-clinicas-una-revision-sistematica 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2766/genomic-and-molecular-landscape-of-early-onset-colorectal-cancer-emerging-insights-and-clinical-implications-a-systematic-review 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2765/remodelacion-inmune-sistemica-tras-la-reseccion-curativa-r0-de-metastasis-hepaticas-de-cancer-colorrectal 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2765/systemic-immune-remodeling-following-curative-r0-resection-of-colorectal-liver-metastases 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2762/sirexatamab-en-combinacion-con-bevacizumab-y-quimioterapia-como-terapia-de-segunda-linea-para-el-adenocarcinoma-colorrectal-avanzado-el-ensayo-de-fase-ii-defiance 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2762/sirexatamab-in-combination-with-bevacizumab-and-chemotherapy-as-second-line-therapy-for-advanced-colorectal-adenocarcinoma-the-phase-ii-defiance-trial 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2761/resultados-de-supervivencia-y-factores-pronosticos-en-pacientes-con-cancer-colorrectal-metastasico-tratados-en-primera-linea-con-mfolfoxiri-mas-bevacizumab-un-estudio-observacional-en-vietnam 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2761/survival-outcomes-and-prognostic-factors-in-patients-with-metastatic-colorectal-cancer-treated-first-line-mfolfoxiri-plus-bevacizumab-a-real-world-study-in-vietnam 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2759/nueva-estrategia-de-tratamiento-y-lineas-de-investigacion-futuras-para-el-cancer-con-mutacion-en-el-gen-braf 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2759/new-treatment-strategy-and-future-research-direction-for-braf-mutated-cancer 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2758/la-inhibicion-de-kras-g12d-reprograma-el-microambiente-inmunosupresor-inducido-por-el-tumor-y-potencia-la-inmunidad-antitumoral-mediada-por-las-celulas-nk 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2758/kras-g12d-inhibition-reprograms-the-tumor-induced-immunosuppressive-environment-and-enhances-nk-cell-mediated-antitumor-immunity 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2757/el-potencial-terapeutico-de-los-conjugados-anticuerpo-farmaco-en-el-cancer-colorrectal-avanzado-una-revision-sistematica-y-metaanalisis 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2757/the-therapeutic-potential-of-antibody-drug-conjugates-in-advanced-colorectal-cancer-a-systematic-review-and-meta-analysis 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2756/revision-sistematica-y-comparacion-indirecta-ajustada-de-los-inhibidores-de-los-puntos-de-control-inmunitario-en-primera-linea-para-el-cancer-colorrectal-metastasico 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2756/systematic-review-and-adjusted-indirect-comparison-of-first-line-immune-checkpoint-inhibitors-in-metastatic-colorectal-cancer 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2755/un-dihidrofenantreno-derivado-de-pholidota-chinensis-actua-como-un-componente-bioactivo-que-induce-la-ferroptosis-mediada-por-gpx4-en-el-cancer-colorrectal 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2755/a-pholidota-chinensis-derived-dihydrophenanthrene-acts-as-a-bioactive-constituent-to-trigger-gpx4-mediated-ferroptosis-in-colorectal-cancer 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2753/vactosertib-mas-pembrolizumab-en-pacientes-con-cancer-colorrectal-o-gastrico-metastasico-con-inestabilidad-microsatelital-no-alta-un-estudio-multicentrico-de-fase-ib-iia 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2753/vactosertib-plus-pembrolizumab-in-patients-with-non-microsatellite-instability-high-metastatic-colorectal-or-gastric-cancer-a-multicenter-phase-ib-iia-study 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2751/evaluacion-in-vitro-e-in-silico-del-potencial-antitumoral-del-extracto-etanolico-de-las-semillas-de-bryonia-laciniosa-contra-el-cancer-colorrectal-y-el-cancer-hepatocelular 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2751/in-vitro-and-in-silico-evaluation-of-the-anticancer-potential-of-ethanolic-seed-extract-of-bryonia-laciniosa-against-colorectal-and-hepatocellular-cancer 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2750/el-contexto-tisular-determina-diferentes-resultados-premalignos-en-un-modelo-transgenico-de-raton-pik3ca-mutante-hpv16-e6-e7 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2750/tissue-context-shapes-distinct-premalignant-outcomes-in-an-hpv16-e6-e7-mutant-pik3ca-transgenic-mouse-model 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2749/conjugados-anticuerpo-farmaco-en-el-cancer-colorrectal-avances-desafios-y-perspectivas 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2749/antibody-drug-conjugates-in-colorectal-cancer-advances-challenges-and-prospectives 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2745/aspirina-como-terapia-adyuvante-para-el-cancer-colorrectal-con-tumores-con-mutacion-en-pik3ca-y-sobreexpresion-de-cox-2-el-estudio-de-investigacion-traslacional-ascolt-y-metaanalisis 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2745/adjuvant-aspirin-for-colorectal-cancer-with-pik3ca-mutated-and-cox-2-overexpressed-tumours-the-ascolt-translational-research-study-and-meta-analysis 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2744/eficacia-y-seguridad-a-corto-plazo-de-la-inmunoterapia-neoadyuvante-en-el-cancer-colorrectal-localmente-avanzado-con-deficiencia-en-la-reparacion-del-desajuste 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2744/short-term-efficacy-and-safety-of-neoadjuvant-immunotherapy-for-locally-advanced-colon-cancer-with-deficient-mismatch-repair 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2743/cancer-colorrectal-metastasico-diagnosticado-antes-de-los-35-anos-un-subgrupo-distinto-de-enfermedad-de-inicio-temprano 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2743/metastatic-colorectal-cancer-diagnosed-before-age-35-a-distinct-subset-of-early-onset-disease 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2739/tratamiento-del-cancer-de-recto-localizado-en-los-paises-nordicos-comparacion-de-las-guias-nordicas-con-las-guias-holandesas-de-la-esmo-y-de-la-nccn 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2739/treatment-of-localized-rectal-cancer-in-the-nordic-countries-comparison-of-nordic-to-dutch-esmo-and-nccn-guidelines 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2737/primer-caso-descrito-de-mutaciones-duales-de-resistencia-kras-y96c-y96s-detectadas-mediante-biopsia-liquida-en-un-cancer-colorrectal-metastasico-con-mutacion-kras-g12c 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2737/first-report-of-dual-kras-y96c-y96s-resistance-mutations-detected-by-liquid-biopsy-in-kras-g12c-mutant-metastatic-colorectal-cancer 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2736/inmunoterapia-de-primera-linea-frente-a-quimioterapia-en-el-cancer-colorrectal-metastasico-con-msi-h-dmmr-una-revision-sistematica-y-un-metaanalisis-de-estudios-de-fase-iii 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2736/first-line-immunotherapy-versus-chemotherapy-in-msi-h-dmmr-metastatic-colorectal-cancer-a-systematic-review-and-meta-analysis-of-phase-iii-studies 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2723/evolucion-de-la-resistencia-a-la-inmunoterapia-mediada-por-macrofagos-de-la-cavidad-spp1-en-la-metastasis-peritoneal-del-cancer-colorrectal 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2723/evolution-of-spp1-cavity-macrophage-mediated-immunotherapy-resistance-in-peritoneal-metastasis-of-colorectal-cancer 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2722/estudio-de-fase-i-de-escalada-de-dosis-que-combina-la-quimioembolizacion-con-microesferas-de-irinotecan-y-la-radioembolizacion-con-microesferas-de-vidrio-de-itrio-90-en-metastasis-hepaticas-de-cancer 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2722/phase-i-dose-escalation-study-combining-irinotecan-loaded-drug-eluting-bead-chemoembolization-with-yttrium-90-glass-microspheres-radioembolization-in-colorectal-liver-metastases-debir-90-y 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2721/la-terapia-con-celulas-car-t-dirigidas-contra-gcc-no-protegidas-demuestra-una-eficacia-significativa-en-pacientes-con-cancer-colorrectal-avanzado 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2721/non-armored-gcc-targeting-car-t-cell-therapy-demonstrates-significant-efficacy-in-patients-with-advanced-colorectal-cancer 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2719/prediccion-temprana-de-la-enfermedad-residual-minima-en-el-cancer-colorrectal-mediante-el-analisis-del-estado-de-metilacion-de-septin9-en-el-adn-tumoral-circulante 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2719/early-prediction-of-minimal-residual-disease-in-colorectal-cancer-via-septin9-methylation-status-in-circulating-tumor-dna 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2718/desde-la-fermentacion-hasta-los-farmabioticos-ingenieria-de-lactobacillus-derivado-del-kefir-para-una-inmunoterapia-intratumoral-dirigida-en-el-cancer-colorrectal 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2718/from-fermentation-to-pharmabiotics-engineering-kefir-derived-lactobacillus-for-targeted-intratumoral-immunotherapy-in-colorectal-cancer 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2717/dirigirse-al-ecosistema-espacial-metabolico-inmune-en-las-metastasis-hepaticas-del-cancer-colorrectal-estrategias-farmacologicas-y-el-paradigma-de-interrumpir-normalizar-restablecer 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2717/targeting-the-spatial-metabolic-immune-ecosystem-in-colorectal-cancer-liver-metastasis-pharmacological-strategies-and-the-break-normalize-reset-paradigm 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2714/el-adn-tumoral-circulante-para-predecir-el-riesgo-de-tromboembolia-venosa-en-el-cancer-de-recto-localmente-avanzado 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2714/circulating-tumor-dna-to-predict-the-risk-of-venous-thromboembolism-in-locally-advanced-rectal-cancer 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2710/quimiocirugia-neoadyuvante-con-dosis-escaladas-frente-a-la-quimiocirugia-neoadyuvante-estandar-para-el-cancer-colorrectal-localmente-avanzado-resultados-a-9-anos-de-un-ensayo-aleatorizado-de-fase-2 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2710/dose-escalated-versus-standard-neoadjuvant-chemoradiation-therapy-for-locally-advanced-rectal-cancer-nine-year-results-of-a-randomized-phase-2-trial 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2708/alteraciones-del-genoma-mitocondrial-en-el-cancer-desde-mutaciones-y-epigenetica-hasta-terapias-dirigidas 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2708/mitochondrial-genome-alterations-in-cancer-from-mutations-and-epigenetics-to-targeted-therapiesack 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2707/imagenes-multimodales-y-caracterizacion-tisular-mediante-ecografia-mejorada-con-inteligencia-artificial-para-predecir-la-eficacia-de-la-inmunoterapia-en-el-cancer-de-recto 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2707/artificial-intelligence-enhanced-ultrasound-multimodal-imaging-and-tissue-characterization-for-predicting-immunotherapy-efficacy-in-rectal-cancer 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2705/oncologia-de-precision-de-ultima-generacion-en-el-cancer-colorrectal-con-estabilidad-en-los-microsatelites-enfoque-integrado-que-va-mas-alla-de-ras-y-raf 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2705/next-generation-precision-oncology-in-microsatellite-stable-colorectal-cancer-integrated-targeting-beyond-ras-and-raf 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2703/impacto-pronostico-de-la-diseminacion-a-traves-de-los-espacios-aereos-y-su-asociacion-con-la-mutacion-kras-y-los-factores-histopatologicos-en-metastasis-pulmonares-de-cancer-colorrectal-resecadas 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2703/prognostic-impact-of-spread-through-air-spaces-and-its-association-with-kras-mutation-and-histopathologic-factors-in-resected-colorectal-lung-metastases 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2702/respuesta-clinica-completa-a-serplulimab-mas-bevacizumab-y-quimioterapia-en-adenocarcinoma-sigmoide-metastasico-mss-kras-mutado-informe-de-un-caso-y-revision-de-la-literatura 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2702/clinical-complete-response-to-serplulimab-plus-bevacizumab-and-chemotherapy-in-mss-kras-mutant-metastatic-sigmoid-colon-adenocarcinoma-a-case-report-and-literature-review 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2699/trasplante-de-higado-de-donante-fallecido-y-supervivencia-postoperatoria-en-pacientes-con-metastasis-hepaticas-irresecables-de-cancer-colorrectal-un-estudio-multicentrico-retrospectivo 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2699/deceased-donor-liver-transplantation-and-postoperative-survival-in-patients-with-unresectable-colorectal-liver-metastases-a-retrospective-multicenter-study 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2698/los-carcinomas-colorectales-enteroblasticos-y-hepatoides-son-canceres-agresivos-con-un-inmunofenotipo-distintivo-mientras-que-el-carcinoma-de-celulas-claras-parece-representar-una-transformacion-de 2026-08-08 monthly 0.5 https://crcwarriors.org/articulo/2698/enteroblastic-and-hepatoid-colorectal-carcinomas-are-aggressive-cancers-with-a-distinctive-immunophenotype-while-clear-cell-carcinoma-appears-to-represent-clear-cell-change-in-conventional-colorectal 2026-08-08 monthly 0.5 https://crcwarriors.org/news-detail.php?id=nuevas-funcionalidades-en-el-buscador-de-ensayos-clinicos-mapa-interactivo-filtros-avanzados-y-mas 2026-08-06 monthly 0.5 https://crcwarriors.org/news-detail.php?id=nueva-experiencia-de-noticias-cientificas-ia-personalizada-traduccion-en-tiempo-real-y-mucho-mas 2026-08-07 monthly 0.5 https://crcwarriors.org/news-detail.php?id=lanzamos-la-beta-de-crc-warriors-buscamos-testers 2026-08-06 monthly 0.5 https://crcwarriors.org/news-detail.php?id=glosario-de-farmacos-2-0-mas-inteligente-mas-completo-mas-potente 2026-08-08 monthly 0.5 https://crcwarriors.org/combinaciones/63 2025-12-21 monthly 0.5 https://crcwarriors.org/combinaciones/62 2025-12-21 monthly 0.5 https://crcwarriors.org/combinaciones/33 2025-12-20 monthly 0.5 https://crcwarriors.org/combinaciones/34 2025-12-20 monthly 0.5 https://crcwarriors.org/combinaciones/36 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/52 2025-12-20 monthly 0.5 https://crcwarriors.org/combinaciones/11 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/45 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/42 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/1 2025-12-21 monthly 0.5 https://crcwarriors.org/combinaciones/12 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/48 2025-12-21 monthly 0.5 https://crcwarriors.org/combinaciones/13 2025-12-21 monthly 0.5 https://crcwarriors.org/combinaciones/30 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/53 2025-12-20 monthly 0.5 https://crcwarriors.org/combinaciones/3 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/5 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/50 2025-12-21 monthly 0.5 https://crcwarriors.org/combinaciones/15 2025-12-21 monthly 0.5 https://crcwarriors.org/combinaciones/39 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/59 2025-12-20 monthly 0.5 https://crcwarriors.org/combinaciones/2 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/49 2025-12-20 monthly 0.5 https://crcwarriors.org/combinaciones/56 2025-12-20 monthly 0.5 https://crcwarriors.org/combinaciones/64 2025-12-21 monthly 0.5 https://crcwarriors.org/combinaciones/38 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/4 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/16 2025-12-21 monthly 0.5 https://crcwarriors.org/combinaciones/19 2025-12-20 monthly 0.5 https://crcwarriors.org/combinaciones/54 2025-12-20 monthly 0.5 https://crcwarriors.org/combinaciones/51 2025-12-20 monthly 0.5 https://crcwarriors.org/combinaciones/40 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/55 2025-12-20 monthly 0.5 https://crcwarriors.org/combinaciones/18 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/61 2025-12-21 monthly 0.5 https://crcwarriors.org/combinaciones/41 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/20 2025-12-20 monthly 0.5 https://crcwarriors.org/combinaciones/21 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/22 2025-12-07 monthly 0.5 https://crcwarriors.org/help/getting-started.php 2026-08-01 monthly 0.4 https://crcwarriors.org/help/clinical-trials-guide.php 2026-08-01 monthly 0.4 https://crcwarriors.org/help/understanding-mutations.php 2026-08-01 monthly 0.4 https://crcwarriors.org/help/medication-database.php 2026-08-01 monthly 0.4 https://crcwarriors.org/help/privacy-security.php 2026-08-01 monthly 0.4 https://crcwarriors.org/help/faq.php 2026-08-01 monthly 0.4